PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34360703-7	2021	Some (poly)phenolics such as caffeic acid, hydroxytyrosol, resveratrol, curcumin, nordihydroguaiaretic acid (NDGA), and quercetin have been reported to reduce the formation of 5-LOX eicosanoids in vitro.	Masoprocol	82-107	arachidonate 5-lipoxygenase	Homo sapiens	176-181
34360703-7	2021	Some (poly)phenolics such as caffeic acid, hydroxytyrosol, resveratrol, curcumin, nordihydroguaiaretic acid (NDGA), and quercetin have been reported to reduce the formation of 5-LOX eicosanoids in vitro.	Masoprocol	109-113	arachidonate 5-lipoxygenase	Homo sapiens	176-181
2478607-6	1989	BW 755C and nordihydroguaiaretic acid, but not indomethacin, inhibited RGC release by PAF.	Masoprocol	12-37	PCNA clamp associated factor	Homo sapiens	86-89
2512249-6	1989	Unlike the other compounds, the phenolic drugs nordihydroguaiaretic acid (NDGA) and butylated hydroxyanisole (BHA), which block lipid peroxidation, affect both signals triggered by the binding of lectin to its receptors: they suppress the rise of intracellular free calcium concentration and inhibit some of the events, depending on the sole protein kinase C activation, namely IL-2 receptor expression and phorbol myristate acetate (PMA)-induced pH change.	Masoprocol	47-72	interleukin 2	Mus musculus	378-382
2512249-6	1989	Unlike the other compounds, the phenolic drugs nordihydroguaiaretic acid (NDGA) and butylated hydroxyanisole (BHA), which block lipid peroxidation, affect both signals triggered by the binding of lectin to its receptors: they suppress the rise of intracellular free calcium concentration and inhibit some of the events, depending on the sole protein kinase C activation, namely IL-2 receptor expression and phorbol myristate acetate (PMA)-induced pH change.	Masoprocol	74-78	interleukin 2	Mus musculus	378-382
35222431-10	2022	We also revealed that supplementation with ARA or nordihydroguaiaretic acid (NDGA) could suppress the function of CD8+ T cells.	Masoprocol	50-75	CD8a molecule	Homo sapiens	114-117
35222431-10	2022	We also revealed that supplementation with ARA or nordihydroguaiaretic acid (NDGA) could suppress the function of CD8+ T cells.	Masoprocol	77-81	CD8a molecule	Homo sapiens	114-117
2695506-8	1989	LHRH-A-induced steroidogenesis was inhibited by 5, 8, 11, 14 Eicosatetraynoic acid (ETYA), an inhibitor of all the three known pathways of arachidonic acid metabolism, and by nordihydroguaiaretic acid, and inhibitory of the lipoxygenase pathway of arachidonic acid metabolism.	Masoprocol	175-200	gonadotropin releasing hormone 1	Rattus norvegicus	0-4
2557901-2	1989	Recent studies showed that soybean lipoxygenase inhibitors like phenidone and nordihydroguaiaretic acid (NDGA) reduce the catalytically active ferric lipoxygenase to its inactive ferrous form.	Masoprocol	78-103	linoleate 9S-lipoxygenase-4	Glycine max	35-47
2557901-2	1989	Recent studies showed that soybean lipoxygenase inhibitors like phenidone and nordihydroguaiaretic acid (NDGA) reduce the catalytically active ferric lipoxygenase to its inactive ferrous form.	Masoprocol	78-103	linoleate 9S-lipoxygenase-4	Glycine max	150-162
2557901-2	1989	Recent studies showed that soybean lipoxygenase inhibitors like phenidone and nordihydroguaiaretic acid (NDGA) reduce the catalytically active ferric lipoxygenase to its inactive ferrous form.	Masoprocol	105-109	linoleate 9S-lipoxygenase-4	Glycine max	35-47
2557901-2	1989	Recent studies showed that soybean lipoxygenase inhibitors like phenidone and nordihydroguaiaretic acid (NDGA) reduce the catalytically active ferric lipoxygenase to its inactive ferrous form.	Masoprocol	105-109	linoleate 9S-lipoxygenase-4	Glycine max	150-162
2557901-5	1989	Incubation of soybean lipoxygenase and linoleic acid with p-aminophenol, catechol, hydroquinone, NDGA, or phenidone resulted in the formation of the one-electron oxidation products of these compounds.	Masoprocol	97-101	linoleate 9S-lipoxygenase-4	Glycine max	22-34
2761761-1	1989	Bath application of the inhibitors of phospholipases, nordihydroguaiaretic acid (NDGA) and p-bromo-phenacyl bromide (BPB), to the rat hippocampal slices suppressed long-term potentiation (LTP) in Schaffer/commissural-CA1 pyramidal synapses.	Masoprocol	54-79	carbonic anhydrase 1	Rattus norvegicus	217-220
2545780-9	1989	Inhibition of 5-lipoxygenase by nordihydro-guaiaretic acid or AA-861 blocked the PAF-induced augmentation of both TNF and LTB4 production.	Masoprocol	32-58	arachidonate 5-lipoxygenase	Rattus norvegicus	14-28
2545780-9	1989	Inhibition of 5-lipoxygenase by nordihydro-guaiaretic acid or AA-861 blocked the PAF-induced augmentation of both TNF and LTB4 production.	Masoprocol	32-58	PCNA clamp associated factor	Rattus norvegicus	81-84
2545780-9	1989	Inhibition of 5-lipoxygenase by nordihydro-guaiaretic acid or AA-861 blocked the PAF-induced augmentation of both TNF and LTB4 production.	Masoprocol	32-58	tumor necrosis factor	Rattus norvegicus	114-117
2545840-7	1989	Inhibition of AA metabolites of the lipoxygenase pathway by nordihydroguaiaretic acid, 5,8,11,14-eicosatetranoic acid, and caffeic acid results in a concentration-dependent inhibition of VIP release evoked by 4-AP.	Masoprocol	60-85	vasoactive intestinal polypeptide	Mus musculus	187-190
2549806-4	1989	Blood is collected into the 5-lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA) to suppress ex vivo formation.	Masoprocol	53-78	arachidonate 5-lipoxygenase	Homo sapiens	28-42
2549806-4	1989	Blood is collected into the 5-lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA) to suppress ex vivo formation.	Masoprocol	80-84	arachidonate 5-lipoxygenase	Homo sapiens	28-42
2777805-9	1989	Pretreatment of endothelial cells with nordihydroguaiaretic acid blunted the thrombin-induced cell retraction.	Masoprocol	39-64	coagulation factor II, thrombin	Homo sapiens	77-85
2514267-8	1989	Nordihydroguaiaretic acid (NDGA), the most potent lipoxygenase inhibitor, was a competitive inhibitor with Ki = 0.29 microM.	Masoprocol	0-25	linoleate 9S-lipoxygenase-4	Glycine max	50-62
2514267-8	1989	Nordihydroguaiaretic acid (NDGA), the most potent lipoxygenase inhibitor, was a competitive inhibitor with Ki = 0.29 microM.	Masoprocol	27-31	linoleate 9S-lipoxygenase-4	Glycine max	50-62
2682268-8	1989	Concomitant blockade of both lipoxygenase and cyclooxygenase activity by nordihydroguaiaretic acid (NDGA 10-30 mumol/l) nearly abolished the contractile response thereby enhancing the relaxant component of the bradykinin effect.	Masoprocol	73-98	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	46-60
2682268-8	1989	Concomitant blockade of both lipoxygenase and cyclooxygenase activity by nordihydroguaiaretic acid (NDGA 10-30 mumol/l) nearly abolished the contractile response thereby enhancing the relaxant component of the bradykinin effect.	Masoprocol	73-98	kininogen 1	Canis lupus familiaris	210-220
2682268-8	1989	Concomitant blockade of both lipoxygenase and cyclooxygenase activity by nordihydroguaiaretic acid (NDGA 10-30 mumol/l) nearly abolished the contractile response thereby enhancing the relaxant component of the bradykinin effect.	Masoprocol	100-104	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	46-60
2682268-8	1989	Concomitant blockade of both lipoxygenase and cyclooxygenase activity by nordihydroguaiaretic acid (NDGA 10-30 mumol/l) nearly abolished the contractile response thereby enhancing the relaxant component of the bradykinin effect.	Masoprocol	100-104	kininogen 1	Canis lupus familiaris	210-220
2682268-10	1989	Concomitant blockade of both lipoxygenase and cyclooxygenase by NDGA (10 mumol/l) again attenuated the contractile component of the angiotensin effect thereby unmasking the venodilator activity which could be inhibited by the angiotensin II receptor blocker saralasin (0.01-1 mumol/l).	Masoprocol	64-68	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	46-60
2761761-1	1989	Bath application of the inhibitors of phospholipases, nordihydroguaiaretic acid (NDGA) and p-bromo-phenacyl bromide (BPB), to the rat hippocampal slices suppressed long-term potentiation (LTP) in Schaffer/commissural-CA1 pyramidal synapses.	Masoprocol	81-85	carbonic anhydrase 1	Rattus norvegicus	217-220
2540688-7	1989	The lipoxygenase inhibitors nordihydroguaiaretic acid (NDGA) and AA861 used at 1 to 50 micrograms/ml reduced in a concentration-dependent fashion asbestos- or silica-stimulated TNF release.	Masoprocol	28-53	tumor necrosis factor-like	Rattus norvegicus	177-180
2540688-7	1989	The lipoxygenase inhibitors nordihydroguaiaretic acid (NDGA) and AA861 used at 1 to 50 micrograms/ml reduced in a concentration-dependent fashion asbestos- or silica-stimulated TNF release.	Masoprocol	55-59	tumor necrosis factor-like	Rattus norvegicus	177-180
2492639-4	1989	Here, we report that the 5-lipoxygenase metabolites of arachidonic acid activate the pertussis toxin-sensitive G protein-gated muscarinic K+ channel (IK.ACh): arachidonic acid activation of IK.ACh was prevented by the lipoxygenase inhibitors, nordihydroguaiaretic acid and AA-861; leukotriene A4 and C4 activated IK.ACh.	Masoprocol	243-268	arachidonate 5-lipoxygenase	Homo sapiens	25-39
2537155-10	1989	Methylene blue, nordihydroguaiaretic acid, and the phospholipase A2 inhibitor, parabromophenacyl bromide, inhibited melittin-induced relaxations, while the cyclo-oxygenase inhibitor, indomethacin, was without effect.	Masoprocol	16-41	melittin	Apis mellifera	116-124
2629896-7	1989	However, de-endothelialization of rat thoracic aortic rings or treatment of aortic rings with the 5-lipoxygenase inhibitor nordihydroguaiaretic acid abolished the relaxant effect of LTD4.	Masoprocol	123-148	arachidonate 5-lipoxygenase	Rattus norvegicus	98-112
2513175-11	1989	Nordihydroguaiaretic acid inhibited the level of the secreted form of IL-1 beta, but tended to increase the cell-associated level.	Masoprocol	0-25	interleukin 1 beta	Homo sapiens	70-79
2908862-4	1989	Piriprost, a specific inhibitor of 5-lipoxygenase, inhibits proliferation of these cell lines up to 95% with 50% cell inhibition at approximately 3 x 10(-5) M. Other less specific lipoxygenase inhibitors such as caffeic acid, nordihydroguaiaretic acid, and BW755C have similar activity in a [3H]-thymidine incorporation assay.	Masoprocol	226-251	arachidonate 5-lipoxygenase	Homo sapiens	35-49
3144281-1	1988	Soybean lipoxygenase is rapidly inactivated when incubated with arachidonic acid and any of several lipoxygenase inhibitors, including NDGA, the aminopyrazolines BW 755C and BW 540C, and the acetohydroxamic acid derivatives BW A4C and BW A137C.	Masoprocol	135-139	linoleate 9S-lipoxygenase-4	Glycine max	8-20
2488013-8	1989	However, the induction of SOD was prevented by the phospholipase A2 inhibitor, quinacrine, and the lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA).	Masoprocol	123-148	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	99-111
2488013-8	1989	However, the induction of SOD was prevented by the phospholipase A2 inhibitor, quinacrine, and the lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA).	Masoprocol	150-154	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	99-111
2570372-8	1989	The lipoxygenase and phospholipase A2 inhibitor nordihydroguaiaretic acid, when added to the perfusate 30 min before the tetanus, abolished both long-term potentiation of the population excitatory postsynaptic potential and the tetanus-induced increase in glutamate release.	Masoprocol	48-73	phospholipase A2 group IB	Rattus norvegicus	21-37
3138407-8	1988	Nordihydroguaiaretic acid, an inhibitor of the lipoxygenase pathway, blocked completely the release of prolactin induced by ethanol.	Masoprocol	0-25	prolactin	Rattus norvegicus	103-112
3138991-3	1988	Tetramethylbenzidine oxidation was completely inhibited by the classical lipoxygenase inhibitor nordihydroguaiaretic acid.	Masoprocol	96-121	linoleate 9S-lipoxygenase-4	Glycine max	73-85
2855591-6	1988	Separate experiments showed that inhibitors of arachidonic acid release and metabolism (bromophenacyl bromide, nordihydroguaiaretic acid, caffeic acid or esculetin) blocked corticosterone production in fasciculata cells stimulated with ACTH, suggesting that arachidonic acid could be the common intermediate in the actions of AII and ACTH on steroid synthesis.	Masoprocol	111-136	angiotensinogen	Rattus norvegicus	326-329
3207972-17	1988	Nordihydroguaiaretic acid (an antioxidant; 5-lipoxygenase inhibitor) and BW 755C (an antioxidant; a dual inhibitor of cyclo-oxygenase and 5-lipoxygenase) significantly attenuated PLA2-induced AH to cooling.	Masoprocol	0-25	phospholipase A2 group IB	Rattus norvegicus	179-183
2840081-4	1988	This was equipotent in our system with the known lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA).	Masoprocol	72-97	linoleate 9S-lipoxygenase-4	Glycine max	49-61
2840081-4	1988	This was equipotent in our system with the known lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA).	Masoprocol	99-103	linoleate 9S-lipoxygenase-4	Glycine max	49-61
3401534-7	1988	hCG enhanced the uptake of both iodinated proteins, with peak uptake values at 6 and 9 h. Intra-bursal injections of an ovulation inhibiting dose (0.5 mg/bursa) of indomethacin-a cycooxygenase inhibitor-and nordihydroguaiaretic acid (NDGA), esculetin, or caffeic acid--inhibitors of lipoxygenase--concomitantly with hCG attenuated the action of the hormone on 125I-BSA uptake.	Masoprocol	207-232	chorionic gonadotropin subunit beta 5	Homo sapiens	0-3
2840609-0	1988	Induction but not maintenance of calcium-induced long-term potentiation in dentate gyrus and area CA1 of the hippocampal slice is blocked by nordihydroguaiaretic acid.	Masoprocol	141-166	carbonic anhydrase 1	Homo sapiens	98-101
2453577-6	1988	The lipoxygenase inhibitor, nordihydroguaiaretic acid, however, totally abolished A23187-induced [3H]arachidonic acid release from both diluent- and GM-CSF-treated neutrophils.	Masoprocol	28-53	colony stimulating factor 2	Homo sapiens	149-155
3238311-6	1988	Moreover, the phospholipase A2 inhibitor, nordihydroguaiaretic acid significantly inhibited PC degradation, lysoPC formation, and NAG release, whereas the lipoxygenase inhibitor, BW 755C had little effect on these parameters.	Masoprocol	42-67	phospholipase A2 group IB	Homo sapiens	14-30
3238311-6	1988	Moreover, the phospholipase A2 inhibitor, nordihydroguaiaretic acid significantly inhibited PC degradation, lysoPC formation, and NAG release, whereas the lipoxygenase inhibitor, BW 755C had little effect on these parameters.	Masoprocol	42-67	O-GlcNAcase	Homo sapiens	130-133
3401534-7	1988	hCG enhanced the uptake of both iodinated proteins, with peak uptake values at 6 and 9 h. Intra-bursal injections of an ovulation inhibiting dose (0.5 mg/bursa) of indomethacin-a cycooxygenase inhibitor-and nordihydroguaiaretic acid (NDGA), esculetin, or caffeic acid--inhibitors of lipoxygenase--concomitantly with hCG attenuated the action of the hormone on 125I-BSA uptake.	Masoprocol	234-238	chorionic gonadotropin subunit beta 5	Homo sapiens	0-3
3128168-4	1988	Nordihydroguaiaretic acid (NDGA), eicosatetraynoic acid (ETYA), and indomethacin, extensively utilized inhibitors of the cyclooxygenase and lipoxygenase branches of the arachidonate cascade, also inhibit cytochrome P-450-dependent arachidonic acid metabolism.	Masoprocol	0-25	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	204-220
3260875-5	1988	Nordihydroguaiaretic acid and chloroquine suppressed the stimulatory effect of EGF in a dose-dependent manner.	Masoprocol	0-25	epidermal growth factor like 1	Rattus norvegicus	79-82
3139810-7	1988	NDGA was the most potent inhibitor of lipoxygenase reactions, but was not selective.	Masoprocol	0-4	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	38-50
3131692-4	1988	Nordihydroguaiaretic acid (NDGA), which reduces the production of arachidonate metabolites via the lipoxygenase pathway, also reduced basal and TRH or arachidonic-acid-stimulated-PRL release.	Masoprocol	0-25	prolactin	Rattus norvegicus	179-182
3131692-4	1988	Nordihydroguaiaretic acid (NDGA), which reduces the production of arachidonate metabolites via the lipoxygenase pathway, also reduced basal and TRH or arachidonic-acid-stimulated-PRL release.	Masoprocol	27-31	prolactin	Rattus norvegicus	179-182
3131692-5	1988	The inhibitory effect of NDGA on PRL release could be overcome by the addition of 15-HETE.	Masoprocol	25-29	prolactin	Rattus norvegicus	33-36
3395165-8	1988	The lipoxygenase-inhibitor nordihydroguaiaretic acid (NDGA), inhibited the responses to ACh and A23187, but did not reduce the responses to PGI2.	Masoprocol	27-52	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	4-16
3395165-8	1988	The lipoxygenase-inhibitor nordihydroguaiaretic acid (NDGA), inhibited the responses to ACh and A23187, but did not reduce the responses to PGI2.	Masoprocol	54-58	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	4-16
3394583-3	1988	NDGA (0.5 microM) caused potentiation of PIA-induced relaxation.	Masoprocol	0-4	RPTOR independent companion of MTOR complex 2	Homo sapiens	41-44
2836275-5	1988	All these effects were inhibited by the phospholipase A2 inhibitors, quinacrine and nordihydroguaiaretic acid (NDGA), while the lipoxygenase inhibitor, BW755C, had no influence and the cyclooxygenase inhibitor, indomethacin, potentiated the increases in mucosal permeability and N-acetyl-glucosaminidase release.	Masoprocol	84-109	phospholipase A2 group IB	Rattus norvegicus	40-56
2836275-5	1988	All these effects were inhibited by the phospholipase A2 inhibitors, quinacrine and nordihydroguaiaretic acid (NDGA), while the lipoxygenase inhibitor, BW755C, had no influence and the cyclooxygenase inhibitor, indomethacin, potentiated the increases in mucosal permeability and N-acetyl-glucosaminidase release.	Masoprocol	111-115	phospholipase A2 group IB	Rattus norvegicus	40-56
3125041-7	1988	Nordihydroguaiaretic acid, which inhibits 5-lipoxygenase, however, totally abolished arachidonic acid- and reduced PLA2-stimulated oxytocin secretion.	Masoprocol	0-25	arachidonate 5-lipoxygenase	Homo sapiens	42-56
3125041-7	1988	Nordihydroguaiaretic acid, which inhibits 5-lipoxygenase, however, totally abolished arachidonic acid- and reduced PLA2-stimulated oxytocin secretion.	Masoprocol	0-25	phospholipase A2 group IB	Homo sapiens	115-119
3125041-7	1988	Nordihydroguaiaretic acid, which inhibits 5-lipoxygenase, however, totally abolished arachidonic acid- and reduced PLA2-stimulated oxytocin secretion.	Masoprocol	0-25	oxytocin/neurophysin I prepropeptide	Homo sapiens	131-139
3125044-9	1988	On the other hand, addition of nordihydroguaiaretic acid (but not indomethacin) reduces LHRH-stimulated P levels by about 50%.	Masoprocol	31-56	gonadotropin releasing hormone 1	Rattus norvegicus	88-92
3125044-10	1988	Nordihydroguaiaretic acid, as well, markedly attenuates the P response due to combined treatment with LHRH and AA.	Masoprocol	0-25	gonadotropin releasing hormone 1	Rattus norvegicus	102-106
3138902-3	1988	Lipoxygenase inhibitors (5,8,11,14-eicosatetraynoic acid, nordihydroguaiaretic acid) strongly inhibit the lipoxin formation.	Masoprocol	58-83	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	0-12
2834771-6	1988	Ten microM NdgA (nordihydroguaiaretic acid) an inhibitor of lipoxygenase pathway, inhibited LTB4 and LTC4 production, increased basal level of casein secretion and inhibited PRL-stimulated casein secretion.	Masoprocol	11-15	prolactin	Oryctolagus cuniculus	174-177
2834771-6	1988	Ten microM NdgA (nordihydroguaiaretic acid) an inhibitor of lipoxygenase pathway, inhibited LTB4 and LTC4 production, increased basal level of casein secretion and inhibited PRL-stimulated casein secretion.	Masoprocol	17-42	prolactin	Oryctolagus cuniculus	174-177
3304843-21	1987	The classical soybean lipoxygenase inhibitors are antioxidants, such as nordihydroguaiaretic acid (NDGA) and others, and the substrate analog 5,8,11,14 eicosatetraynoic acid (ETYA), which also inhibit cyclooxygenase (g).	Masoprocol	72-97	linoleate 9S-lipoxygenase-4	Glycine max	22-34
2452609-4	1988	Nordihydroguaiaretic acid (NDGA), an inhibitor of lipoxygenase, significantly reduced the dilator responses to ACh, A23187 and SP, but did not reduce the responses to sodium nitrite.	Masoprocol	0-25	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	50-62
2452609-4	1988	Nordihydroguaiaretic acid (NDGA), an inhibitor of lipoxygenase, significantly reduced the dilator responses to ACh, A23187 and SP, but did not reduce the responses to sodium nitrite.	Masoprocol	27-31	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	50-62
2834428-2	1988	The cytotoxicity of TNF on L-M cells was clearly reduced by lysosomotropic agents, DMSO (hydroxyl radical scavenger), NDGA (lipoxygenase inhibitor), and sodium azide (mitochondrial respiration inhibitor).	Masoprocol	118-122	tumor necrosis factor	Homo sapiens	20-23
2836681-2	1988	The reaction was dependent on lipoxygenation, was potentiated by indomethacin (IM) and was inhibited by nordihidro-guairetic acid (NDGA), (iii) both 14C-arachidonic acid (14C-AA) release and leukotriene B4 (LTB4) synthesis of ME-treated PMNLs were elevated as compared to those of FMLP triggered cells.	Masoprocol	131-135	formyl peptide receptor 1	Homo sapiens	281-285
2821856-5	1987	In the presence of 2 structurally unrelated lipoxygenase inhibitors (nordihydroguaiaretic acid and AA-861), the leukotriene release was nearly completely inhibited and the AA-induced severe increase in vascular permeability was significantly reduced (2.5- to 3-fold rise in Kf,c, compared to a greater than 10-fold increase in Kf,c in the absence of lipoxygenase inhibition).	Masoprocol	69-94	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	44-56
2821856-5	1987	In the presence of 2 structurally unrelated lipoxygenase inhibitors (nordihydroguaiaretic acid and AA-861), the leukotriene release was nearly completely inhibited and the AA-induced severe increase in vascular permeability was significantly reduced (2.5- to 3-fold rise in Kf,c, compared to a greater than 10-fold increase in Kf,c in the absence of lipoxygenase inhibition).	Masoprocol	69-94	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	350-362
3113998-2	1987	The metabolic effects of nerve stimulation but not those of ATP and noradrenaline were inhibited strongly by the phospholipase A2 inhibitor bromophenacyl bromide (BPB, 20 microM) and the cyclooxygenase inhibitor indomethacin (Indo, 20 microM) and only slightly by the lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA, 20 microM).	Masoprocol	291-316	phospholipase A2 group IB	Rattus norvegicus	113-129
3113998-2	1987	The metabolic effects of nerve stimulation but not those of ATP and noradrenaline were inhibited strongly by the phospholipase A2 inhibitor bromophenacyl bromide (BPB, 20 microM) and the cyclooxygenase inhibitor indomethacin (Indo, 20 microM) and only slightly by the lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA, 20 microM).	Masoprocol	318-322	phospholipase A2 group IB	Rattus norvegicus	113-129
3037070-4	1987	Hypoxia-induced neutrophil uptake was prevented by nordihydroguaiaretic acid (NDGA) or diethylcarbamazine (DEC), two structurally different inhibitors of lipoxygenase.	Masoprocol	51-76	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	154-166
3037070-4	1987	Hypoxia-induced neutrophil uptake was prevented by nordihydroguaiaretic acid (NDGA) or diethylcarbamazine (DEC), two structurally different inhibitors of lipoxygenase.	Masoprocol	78-82	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	154-166
3122742-2	1987	The addition of either hydrocortisone or nordihydroguaiaretic acid (NDGA) decreased the cytotoxic effect of TNF-alpha but exogenously added arachidonate or linoleate, indomethacin and eicosatetraynoic acid (ETYA) were without effect.	Masoprocol	41-66	tumor necrosis factor	Mus musculus	108-117
3122742-2	1987	The addition of either hydrocortisone or nordihydroguaiaretic acid (NDGA) decreased the cytotoxic effect of TNF-alpha but exogenously added arachidonate or linoleate, indomethacin and eicosatetraynoic acid (ETYA) were without effect.	Masoprocol	68-72	tumor necrosis factor	Mus musculus	108-117
3122826-1	1987	Nordihydroguaiaretic acid (NDGA), one of the most efficient inhibitors of lipoxygenases, is shown, by electron paramagnetic resonance, circular dichroism, and fluorescence studies, to reduce the catalytically active ferric soybean lipoxygenase 1 (Eox) to the inactive ferrous form (Ered).	Masoprocol	0-25	seed linoleate 13S-lipoxygenase-1	Glycine max	231-245
3122826-1	1987	Nordihydroguaiaretic acid (NDGA), one of the most efficient inhibitors of lipoxygenases, is shown, by electron paramagnetic resonance, circular dichroism, and fluorescence studies, to reduce the catalytically active ferric soybean lipoxygenase 1 (Eox) to the inactive ferrous form (Ered).	Masoprocol	27-31	seed linoleate 13S-lipoxygenase-1	Glycine max	231-245
3122826-7	1987	Because the catalytically inactive Ered is oxidized by fatty acid hydroperoxides (e.g., LOOH) to give the active Eox, reducing agents such as NDGA are most effective as lipoxygenase inhibitors at low hydroperoxide concentrations.	Masoprocol	142-146	linoleate 9S-lipoxygenase-4	Glycine max	169-181
3110530-6	1987	5, 8, 11, 14 Eicosatetraynoic acid (ETYA), a general inhibitor of AA metabolism, and Nordihydroguaiaretic acid (NDGA), an inhibitor of the lipoxygenase pathway of AA metabolism, inhibited hCG induced T secretion while indomethacin, an inhibitor of cyclo-oxygenase pathway, had no effect on hCG induced T secretion.	Masoprocol	85-110	hypertrichosis 2 (generalised, congenital)	Homo sapiens	188-191
3304843-21	1987	The classical soybean lipoxygenase inhibitors are antioxidants, such as nordihydroguaiaretic acid (NDGA) and others, and the substrate analog 5,8,11,14 eicosatetraynoic acid (ETYA), which also inhibit cyclooxygenase (g).	Masoprocol	99-103	linoleate 9S-lipoxygenase-4	Glycine max	22-34
3102978-7	1986	Endothelium-dependent relaxations induced by larger concentrations of thimerosal, as well as relaxations produced by acetylcholine, were inhibited by the antioxidant and lipoxygenase inhibitor nordihydroguaiaretic acid, by haemoglobin, and by the inhibitor of soluble guanylate cyclase methylene blue.	Masoprocol	193-218	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	170-182
3653044-5	1987	The stimulatory effect of PAF on mucin secretion is blocked by equimolar concentrations of nordihydroguiaretic acid (NDGA) a "mixed" inhibitor of both cyclo- and lipoxygenase pathways of arachidonic acid metabolism.	Masoprocol	91-115	PCNA clamp associated factor	Rattus norvegicus	26-29
3653044-5	1987	The stimulatory effect of PAF on mucin secretion is blocked by equimolar concentrations of nordihydroguiaretic acid (NDGA) a "mixed" inhibitor of both cyclo- and lipoxygenase pathways of arachidonic acid metabolism.	Masoprocol	91-115	solute carrier family 13 member 2	Rattus norvegicus	33-38
3653044-5	1987	The stimulatory effect of PAF on mucin secretion is blocked by equimolar concentrations of nordihydroguiaretic acid (NDGA) a "mixed" inhibitor of both cyclo- and lipoxygenase pathways of arachidonic acid metabolism.	Masoprocol	117-121	PCNA clamp associated factor	Rattus norvegicus	26-29
3653044-5	1987	The stimulatory effect of PAF on mucin secretion is blocked by equimolar concentrations of nordihydroguiaretic acid (NDGA) a "mixed" inhibitor of both cyclo- and lipoxygenase pathways of arachidonic acid metabolism.	Masoprocol	117-121	solute carrier family 13 member 2	Rattus norvegicus	33-38
3131638-5	1987	The IL-2-induced DNA synthesis was also inhibited by AA861, a specific inhibitor of arachidonate 5-lipoxygenase, and by other lipoxygenase inhibitors such as nordihydroguaiaretic acid and esculetin.	Masoprocol	158-183	interleukin 2	Mus musculus	4-8
2431915-4	1986	Nordihydroguaiaretic acid abolished the relaxation produced by substance P and A23187.	Masoprocol	0-25	tachykinin precursor 1	Homo sapiens	63-74
3094518-1	1986	The synthetic antioxidants butylated hydroxytoluene (BHT), nordihydroguaiaretic acid and the one-electron donor 1,1"-dimethylferrocene, inhibit cytosolic Ca++ increase, shape change, aggregation and ATP secretion in aspirinated washed human platelets stimulated by thrombin, vasopressin and platelet-activating factor.	Masoprocol	59-84	coagulation factor II, thrombin	Homo sapiens	265-273
3094518-1	1986	The synthetic antioxidants butylated hydroxytoluene (BHT), nordihydroguaiaretic acid and the one-electron donor 1,1"-dimethylferrocene, inhibit cytosolic Ca++ increase, shape change, aggregation and ATP secretion in aspirinated washed human platelets stimulated by thrombin, vasopressin and platelet-activating factor.	Masoprocol	59-84	arginine vasopressin	Homo sapiens	275-286
3087803-7	1986	The stimulatory effect of lyso-PAF is largely independent of any toxic or lytic effect, being biphasic, reversible, unassociated with impairment of the subsequent physiologic functioning of treated islets, and inhibitable (by Ni2+, La3+, or nordihydroguaiaretic acid but not by other lipoxygenase inhibitors).	Masoprocol	241-266	PCNA clamp associated factor	Rattus norvegicus	31-34
3091592-4	1986	With phorbol diesters as stimuli, the following inhibitors of phospholipase A2 and lipoxygenase suppressed release of H2O2 at nontoxic concentrations (microM range): p-bromophenacyl bromide, quinacrine, eicosatetraenoic acid, nordihydroguaiaretic acid, and phenidone.	Masoprocol	226-251	phospholipase A2, group IB, pancreas	Mus musculus	62-78
3091387-3	1986	Nordihydroguaiaretic acid (NDGA) and 3-amino-1-[m(trifluoromethyl)-phenyl]-2-pyrazoline (BW 755C), compounds that inhibit both the cyclooxygenase and lipoxygenase pathways, cause dose-dependent inhibition of CSF-induced human granulocyte-monocyte colony formation in vitro, with complete inhibition at 20 and 50 microM, respectively.	Masoprocol	0-25	colony stimulating factor 2	Homo sapiens	208-211
3086125-2	1986	Lipoxygenase is inhibited by nordihydroguaiaretic acid (NDGA), 3-amino-1-(m-(trifluoromethyl)phenyl)-2-pyrazoline (BW755C), 5,8,11,14-eicosatetraynoic acid (ETYA), salicylhydroxamate (SHAM) or hemin.	Masoprocol	29-54	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	0-12
3086125-2	1986	Lipoxygenase is inhibited by nordihydroguaiaretic acid (NDGA), 3-amino-1-(m-(trifluoromethyl)phenyl)-2-pyrazoline (BW755C), 5,8,11,14-eicosatetraynoic acid (ETYA), salicylhydroxamate (SHAM) or hemin.	Masoprocol	56-60	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	0-12
3002157-6	1985	The lipoxygenase inhibitor NDGA, indomethacin at high doses (50 microM), diethylcarbamazine and the phospholipase inhibitor dibromoacetophenone, inhibited the MCM dependent synthesis of collagenase in chondrocytes.	Masoprocol	27-31	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	4-16
3019576-7	1986	Hydrocortisone and nordihydroguairetic acid (NDGA), drugs which block endogenous LTB4 production in cell cultures inhibited [3H]thymidine incorporation of HT-2 cells stimulated by suboptimal but not optimal levels of IL-2.	Masoprocol	45-49	interleukin 2	Mus musculus	217-221
3080984-5	1986	The lipoxygenase inhibitors, 5,8,11,14-eicosatetraynoic acid and nordihydroguaiaretic acid, partially inhibited GnRH- and arachidonic acid-stimulated, but not phorbol-induced, LH secretion.	Masoprocol	65-90	gonadotropin releasing hormone 1	Rattus norvegicus	112-116
3012392-9	1986	However, NDGA or ETYA inhibited phospholipase A2-induced beta-End-IR release.	Masoprocol	9-13	phospholipase A2 group IB	Rattus norvegicus	32-48
3012392-11	1986	These data are consistent with the view that phospholipase A2 releases endogenous arachidonic acid which is transformed into products which stimulate ACTH and beta-endorphin release from the corticotrophs; the metabolizing enzyme (possibly a lipoxygenase or epoxygenase) is sensitive to NDGA and especially to ETYA.	Masoprocol	287-291	phospholipase A2 group IB	Rattus norvegicus	45-61
3088690-6	1986	Nor-dihydroguaiaretic acid (10 microM), an inhibitor of lipoxygenases, increased PGF2 alpha synthesis in the presence of prolactin.	Masoprocol	0-26	prolactin	Oryctolagus cuniculus	121-130
3934160-7	1985	When arachidonic acid metabolism via the 5-lipoxygenase route was inhibited by nordihydroguaiaretic acid, previously ineffective concentrations of exogenous 12-HETE were now able to stimulate the polymorphonuclear leukocyte 15-lipoxygenase.	Masoprocol	79-104	arachidonate 5-lipoxygenase	Homo sapiens	41-55
3934160-7	1985	When arachidonic acid metabolism via the 5-lipoxygenase route was inhibited by nordihydroguaiaretic acid, previously ineffective concentrations of exogenous 12-HETE were now able to stimulate the polymorphonuclear leukocyte 15-lipoxygenase.	Masoprocol	79-104	arachidonate 15-lipoxygenase	Homo sapiens	224-239
2856828-4	1985	Nordihydroguaretic acid (NDGA), methylene blue and haemoglobin reverse the effect of the EDRF.	Masoprocol	0-23	alpha hemoglobin stabilizing protein	Homo sapiens	89-93
2856828-4	1985	Nordihydroguaretic acid (NDGA), methylene blue and haemoglobin reverse the effect of the EDRF.	Masoprocol	25-29	alpha hemoglobin stabilizing protein	Homo sapiens	89-93
3935569-6	1985	Nordihydroguaiaretic acid (NDGA), an antioxidant, inhibited chymase-mediated exocytosis dose-dependently (ID50 less than or equal to 13.3 microM) while decreasing anti-IgE-mediated exocytosis by only 30% at 2.5-20 microM; net PGD2 release induced by both stimuli was inhibited dose-dependently.	Masoprocol	0-25	chymase 1	Rattus norvegicus	60-67
3935569-6	1985	Nordihydroguaiaretic acid (NDGA), an antioxidant, inhibited chymase-mediated exocytosis dose-dependently (ID50 less than or equal to 13.3 microM) while decreasing anti-IgE-mediated exocytosis by only 30% at 2.5-20 microM; net PGD2 release induced by both stimuli was inhibited dose-dependently.	Masoprocol	27-31	chymase 1	Rattus norvegicus	60-67
3017277-5	1986	The ESR signal was, however, inhibited by the lipoxygenase inhibitors nordihydroguaiaretic acid and N-ethylmaleimide.	Masoprocol	70-95	linoleate 9S-lipoxygenase-4	Glycine max	46-58
3910172-6	1985	Release of LHRH, however, was clearly stimulated when the lipoxygenase inhibitor nordihydroguaiaretic acid was added to the medium, suggesting that some arachidonic acid metabolites are inhibitory to LHRH secretion.	Masoprocol	81-106	gonadotropin releasing hormone 1	Homo sapiens	11-15
3910172-6	1985	Release of LHRH, however, was clearly stimulated when the lipoxygenase inhibitor nordihydroguaiaretic acid was added to the medium, suggesting that some arachidonic acid metabolites are inhibitory to LHRH secretion.	Masoprocol	81-106	gonadotropin releasing hormone 1	Homo sapiens	200-204
3924104-5	1985	NADPH-dependent synthesis of both EETs and DHETs from arachidonate by hepatic microsomal cytochrome P-450-mono-oxygenase activity was demonstrable with these methods and was significantly suppressed by the compound BW755C (500 microM), but not by eicosa-5,8,11,14-tetraynoic acid (ETYA, 20 microM) or by nordihydroguaiaretic acid (NDGA, 50 microM).	Masoprocol	304-329	cytochrome P450 family 20 subfamily A member 1	Homo sapiens	89-120
3929783-3	1985	Two well-known inhibitors of 5-lipoxygenase, nordihydroguaiaretic acid and phenidone, blocked LTB4 synthesis without affecting ATP production.	Masoprocol	45-70	arachidonate 5-lipoxygenase	Rattus norvegicus	29-43
3924104-5	1985	NADPH-dependent synthesis of both EETs and DHETs from arachidonate by hepatic microsomal cytochrome P-450-mono-oxygenase activity was demonstrable with these methods and was significantly suppressed by the compound BW755C (500 microM), but not by eicosa-5,8,11,14-tetraynoic acid (ETYA, 20 microM) or by nordihydroguaiaretic acid (NDGA, 50 microM).	Masoprocol	331-335	cytochrome P450 family 20 subfamily A member 1	Homo sapiens	89-120
2988756-2	1985	The reduction was inhibited by phospholipase A2 inhibitors, such as dibromoacetophenone, the lipoxygenase inhibitor nordihydroguaiaretic acid, an NADH-dehydrogenase inhibitor, the microfilament inhibitor cytochalasin B, oxygen radical scavengers such as superoxide dismutase, antioxidants such as butyl hydroxyanisole and non-specific inhibitors such as retinoic acid.	Masoprocol	116-141	phospholipase A2, group IB, pancreas	Mus musculus	31-47
2986647-5	1985	Degranulation induced by A23187 and FMLP was inhibited by 50% by ETYA (16 and 11 microM respectively) and by NDGA (1.5 and 6.5 microM respectively).	Masoprocol	109-113	formyl peptide receptor 1	Homo sapiens	36-40
3972457-0	1985	Inhibition of neutrophil phospholipase A2 by p-bromophenylacyl bromide, nordihydroguaiaretic acid, 5,8,11,14-eicosatetraynoic acid and quercetin.	Masoprocol	72-97	phospholipase A2 group IB	Homo sapiens	25-41
2981665-13	1985	Indomethacin (inhibitor of cyclooxygenase) and nordihydroguaiaretic acid (inhibitor of lipoxygenase) blocked ovulation and inhibited hCG-induced ovarian collagenolysis.	Masoprocol	47-72	hypertrichosis 2 (generalised, congenital)	Homo sapiens	133-136
3924036-3	1985	The antimycin A-resistant oxygen uptake was further inhibited by the lipoxygenase inhibitors salicylhydroxamic acid, 5,8,11,14-eicosatetraynoic acid, nordihydroguaiaretic acid, 4-nitrocatechol or propylgallate by about 20-30% corresponding to 5-7% of the total oxygen uptake.	Masoprocol	150-175	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	69-81
2578053-7	1985	Nordihydroguaiaretic acid, an inhibitor of LPX, decreased HR induced by anti-IgE (greater than or equal to 3.3 X 10(-6) M, p less than 0.01) and allergens, but reduced C5a-initiated HR only at a higher concentration (greater than or equal to 7 X 10(-5) M, p less than 0.01).	Masoprocol	0-25	immunoglobulin heavy constant epsilon	Homo sapiens	77-80
2578053-7	1985	Nordihydroguaiaretic acid, an inhibitor of LPX, decreased HR induced by anti-IgE (greater than or equal to 3.3 X 10(-6) M, p less than 0.01) and allergens, but reduced C5a-initiated HR only at a higher concentration (greater than or equal to 7 X 10(-5) M, p less than 0.01).	Masoprocol	0-25	complement C5a receptor 1	Homo sapiens	168-171
6086621-4	1984	Preincubation of cells with quinacrine, an inhibitor of phospholipase A2, or with the lipoxygenase inhibitors 5,8,11,14-eicosatetraynoic acid or nordihydroguaiaretic acid prior to thrombin challenge resulted in a concentration-dependent attenuation of the response.	Masoprocol	145-170	coagulation factor II	Mus musculus	180-188
6149270-4	1984	In addition, this event was inhibited by quinacrine, 5,8,11,14-eicosatetraynoic acid, and nordi-hydroguaiaretic acid, suggesting involvement of phospholipase A2 with subsequent formation of lipoxygenase metabolities of arachidonic acid.	Masoprocol	90-116	phospholipase A2, group IB, pancreas	Mus musculus	144-160
6088878-10	1984	Eicosatetraenoic acid and nordihydroguaiaretic acid, cyclo-oxygenase-lipoxygenase pathway inhibitors, also markedly antagonized LTB4-, C5a des arg-, and FMLP-triggered LAI.	Masoprocol	26-51	complement C5a receptor 1	Homo sapiens	135-138
6088878-10	1984	Eicosatetraenoic acid and nordihydroguaiaretic acid, cyclo-oxygenase-lipoxygenase pathway inhibitors, also markedly antagonized LTB4-, C5a des arg-, and FMLP-triggered LAI.	Masoprocol	26-51	formyl peptide receptor 1	Homo sapiens	153-157
6413878-4	1983	The involvement in prolactin secretion of arachidonic acid metabolic products produced via the lipoxygenase pathway was investigated indirectly using nordihydroguaiaretic acid (NDGA), a specific inhibitor of this enzyme.	Masoprocol	150-175	prolactin	Homo sapiens	19-28
6425068-7	1984	Moreover, 50 microM NDGA antagonized the stimulatory effect of thyrotropin releasing hormone (TRH), phospholipase A2 and PMA on TSH release.	Masoprocol	20-24	thyrotropin releasing hormone	Homo sapiens	63-92
6425068-7	1984	Moreover, 50 microM NDGA antagonized the stimulatory effect of thyrotropin releasing hormone (TRH), phospholipase A2 and PMA on TSH release.	Masoprocol	20-24	thyrotropin releasing hormone	Homo sapiens	94-97
6425068-7	1984	Moreover, 50 microM NDGA antagonized the stimulatory effect of thyrotropin releasing hormone (TRH), phospholipase A2 and PMA on TSH release.	Masoprocol	20-24	phospholipase A2 group IB	Homo sapiens	100-116
6327541-0	1984	Differential effects of nordihydroguaiaretic acid (NDGA) on B-cell subsets: reversal of NDGA-induced antibody suppression by cyclic GMP is subset specific.	Masoprocol	24-49	5'-nucleotidase, cytosolic II	Mus musculus	132-135
6311844-2	1983	This pump activation, measured by ouabain-sensitive 86Rb+ uptake, appeared susceptible to the phospholipid-interacting drugs tetracaine and quinacrine, to the antioxydant nordihydroguaiaretic acid (NDGA), and to the calmodulin antagonist trifluoperazine, while much less susceptible to the methylation inhibitor-3-deazaadenosine.	Masoprocol	198-202	calmodulin 1	Homo sapiens	216-226
6411897-6	1983	The combined lipoxygenase/cyclooxygenase inhibitors BW 755 and eicosa-5,8,11,14-tetraynoic acid and the lipoxygenase inhibitor nordihydroguaiaretic acid also blocked the stimulation of PG synthesis by lys-bradykinin.	Masoprocol	127-152	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	104-116
6086344-12	1984	The stimulated release of prostaglandin E2 was inhibited in a dose-dependent manner by nordihydroguaiaretic acid, an inhibitor of 5-lipoxygenase and by FPL 55712, known as a receptor antagonist for some leukotrienes.	Masoprocol	87-112	arachidonate 5-lipoxygenase	Rattus norvegicus	130-144
6098611-5	1984	Nordihydroguaiaretic acid (NDGA), an inhibitor of the lipoxygenase enzyme, suppressed chemiluminescence, superoxide generation, oxygen consumption, and beta-glucuronidase release.	Masoprocol	0-25	glucuronidase beta	Homo sapiens	152-170
6098611-5	1984	Nordihydroguaiaretic acid (NDGA), an inhibitor of the lipoxygenase enzyme, suppressed chemiluminescence, superoxide generation, oxygen consumption, and beta-glucuronidase release.	Masoprocol	27-31	glucuronidase beta	Homo sapiens	152-170
6413878-4	1983	The involvement in prolactin secretion of arachidonic acid metabolic products produced via the lipoxygenase pathway was investigated indirectly using nordihydroguaiaretic acid (NDGA), a specific inhibitor of this enzyme.	Masoprocol	177-181	prolactin	Homo sapiens	19-28
6309177-2	1983	This action of the ionophore was inhibited by bromophenacyl bromide and nordihydroguaiaretic acid, inhibitors of the phospholipase A2 and lipoxygenase enzymes, respectively.	Masoprocol	72-97	phospholipase A2 group IB	Rattus norvegicus	117-150
6306770-3	1983	Thrombin-stimulated cyclic GMP formation was inhibited by mepacrine and nordihydroguaiaretic acid but unaffected by indomethacin, suggesting that lipoxygenase metabolites of arachidonic acid are involved in the response.	Masoprocol	72-97	coagulation factor II	Mus musculus	0-8
6306770-3	1983	Thrombin-stimulated cyclic GMP formation was inhibited by mepacrine and nordihydroguaiaretic acid but unaffected by indomethacin, suggesting that lipoxygenase metabolites of arachidonic acid are involved in the response.	Masoprocol	72-97	5'-nucleotidase, cytosolic II	Mus musculus	27-30
6814899-3	1982	In the current study, we examined the effects of two known lipoxygenase inhibitors, BW755c and nordihydroguaiaretic acid, on the augmentation of insulin release evoked by three pharmacologically distinct classes of insulin secretagogues--one which augments cyclic AMP accumulation (exemplified by theophylline), one which inhibits prostaglandin synthesis (sodium salicylate), and one which is independent of changes in cyclic AMP or prostaglandin availability (tolbutamide).	Masoprocol	95-120	insulin	Homo sapiens	145-152
6871537-3	1983	3 Nordihydroguaiaretic acid, a lipoxygenase inhibitor, totally abolished the uterine response to either oxytocin or angiotensin II.	Masoprocol	2-27	angiotensinogen	Rattus norvegicus	116-130
6819152-3	1982	The insulinotropic effect of phospholipase A2 was inhibited by nordihydroguaiaretic acid (NDGA) and 1-phenyl-3-pyrazolidinone (Phenidone) but not by indomethacin.	Masoprocol	63-88	phospholipase A2 group IB	Rattus norvegicus	29-45
6819152-3	1982	The insulinotropic effect of phospholipase A2 was inhibited by nordihydroguaiaretic acid (NDGA) and 1-phenyl-3-pyrazolidinone (Phenidone) but not by indomethacin.	Masoprocol	90-94	phospholipase A2 group IB	Rattus norvegicus	29-45
6814899-3	1982	In the current study, we examined the effects of two known lipoxygenase inhibitors, BW755c and nordihydroguaiaretic acid, on the augmentation of insulin release evoked by three pharmacologically distinct classes of insulin secretagogues--one which augments cyclic AMP accumulation (exemplified by theophylline), one which inhibits prostaglandin synthesis (sodium salicylate), and one which is independent of changes in cyclic AMP or prostaglandin availability (tolbutamide).	Masoprocol	95-120	insulin	Homo sapiens	215-222
6289942-8	1982	Inhibition of the lipoxygenase pathway with eicosatetraynoic acid (ETYA) or nordihydroguaiaretic acid (NDGA) did not affect the inhibition caused by arachidonic acid, so it is unlikely that a product of this pathway is responsible for the inhibition.	Masoprocol	103-107	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	18-30
5348405-0	1969	Effect of the antioxidant nordihydroguaiaretic acid on the in vitro activity of catechol-o-methyl transferase.	Masoprocol	26-51	catechol-O-methyltransferase	Homo sapiens	80-109
6805948-9	1982	Treatment of mice with nordihydroguaiaretic acid (10 to 90 mumol/mouse), a lipoxygenase inhibitor, also inhibited the induction of ODC by TPA.	Masoprocol	23-48	ornithine decarboxylase, structural 1	Mus musculus	131-134
6817941-5	1982	ODC activity which was suppressed by nordihydroguaiaretic acid or phenidone at a dose of 180 mumol/mouse was not further inhibited by indomethacin (1.12 mumol/mouse).	Masoprocol	37-62	ornithine decarboxylase, structural 1	Mus musculus	0-3
6817941-7	1982	Thus, the suppressive effect of nordihydroguaiaretic acid or phenidone on the ODC induction by TPA would be due to the inhibition of lipoxygenase.	Masoprocol	32-57	ornithine decarboxylase, structural 1	Mus musculus	78-81
6800960-4	1982	Arachidonic acid antagonists, nordihydroguaiaretic acid and quercetin caused dose-dependent inhibition of release induced by C3a plus cytochalasin B, however, lysozyme release induced by C3a in the absence of cytochalasin B was minimally affected.	Masoprocol	30-55	complement C3	Homo sapiens	125-128
1022139-1	1976	Nordihydroguaiaretic acid inhibits prostaglandin (PG) biosynthesis in vitro (ID50=228 muM), with a slope of dose-response curve high (b=209) as compared with indomethacin (ID50=0.1 muM, b=72.1).	Masoprocol	0-25	CD86 molecule	Rattus norvegicus	186-190
33662683-8	2021	For instance, three drugs Benserazide, Dobutamine and Masoprocol showed a superior consensus enrichment against the PLpro conformations.	Masoprocol	54-64	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	116-121
33916785-0	2021	Nordihydroguaiaretic Acid as a Novel Substrate and Inhibitor of Catechol O-Methyltransferase Modulates 4-Hydroxyestradiol-Induced Cyto- and Genotoxicity in MCF-7 Cells.	Masoprocol	0-25	catechol-O-methyltransferase	Homo sapiens	64-92
33916785-4	2021	The present study investigated the novel biological activities of NDGA in relation to COMT and the effects of COMT inhibition by NDGA on 4-OHE2-induced cyto- and genotoxicity in MCF-7 human breast cancer cells.	Masoprocol	66-70	catechol-O-methyltransferase	Homo sapiens	86-90
33916785-7	2021	The COMT-catalyzed methylation of 4-OHE2 was inhibited by NDGA at an IC50 of 22.4 microM in a mixed-type mode of inhibition by double reciprocal plot analysis.	Masoprocol	58-62	catechol-O-methyltransferase	Homo sapiens	4-8
34022265-8	2021	However, central pretreatment with a nonselective LOX inhibitor, nordihydroguaiaretic acid, partially attenuated the cardiovascular responses induced by nesfatin-1.	Masoprocol	65-90	nucleobindin 2	Rattus norvegicus	153-163
33916785-10	2021	Comet and apurinic/apyrimidinic site quantitation assays, cell death, and apoptosis in MCF-7 cells showed that NDGA decreased COMT-mediated formation of 4-MeOE2 and increased 4-OHE2-induced DNA damage and cytotoxicity.	Masoprocol	111-115	catechol-O-methyltransferase	Homo sapiens	126-130
33662683-9	2021	Further MD simulations for these drugs complexed with PLpro suggested the superior stability and binding of dobutamine and masoprocol inside the binding site compared to Benserazide.	Masoprocol	123-133	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	54-59
31743355-9	2019	Compound 18 (Masoprocol) showed a significant TP inhibitory activity (IC50 = 44.0 +- 0.5 muM).	Masoprocol	13-23	thymidine phosphorylase	Mus musculus	46-48
33131275-5	2021	Nordihydroguaiaretic acid (NDGA) regulated LXA4 expression and inflammation levels by affecting LOX.	Masoprocol	0-25	lysyl oxidase	Rattus norvegicus	96-99
33131275-5	2021	Nordihydroguaiaretic acid (NDGA) regulated LXA4 expression and inflammation levels by affecting LOX.	Masoprocol	27-31	lysyl oxidase	Rattus norvegicus	96-99
33041789-0	2020	Design and Synthesis of Novel Nordihydroguaiaretic Acid (NDGA) Analogues as Potential FGFR1 Kinase Inhibitors With Anti-Gastric Activity and Chemosensitizing Effect.	Masoprocol	30-55	fibroblast growth factor receptor 1	Homo sapiens	86-91
33041789-0	2020	Design and Synthesis of Novel Nordihydroguaiaretic Acid (NDGA) Analogues as Potential FGFR1 Kinase Inhibitors With Anti-Gastric Activity and Chemosensitizing Effect.	Masoprocol	57-61	fibroblast growth factor receptor 1	Homo sapiens	86-91
32393899-4	2020	The redox-type inhibitor nordihydroguaiaretic acid (NDGA) is lodged in the 5-LOX active site, now fully exposed by disordering of the helix that caps it in the apo-enzyme.	Masoprocol	25-50	arachidonate 5-lipoxygenase	Homo sapiens	75-80
32393899-4	2020	The redox-type inhibitor nordihydroguaiaretic acid (NDGA) is lodged in the 5-LOX active site, now fully exposed by disordering of the helix that caps it in the apo-enzyme.	Masoprocol	52-56	arachidonate 5-lipoxygenase	Homo sapiens	75-80
31234537-0	2019	Lipoprotein Lipase Inhibitor, Nordihydroguaiaretic Acid, Aggravates Metabolic Phenotypes and Alters HDL Particle Size in the Western Diet-Fed db/db Mice.	Masoprocol	30-55	lipoprotein lipase	Mus musculus	0-18
31602311-0	2019	Lifespan-increasing drug nordihydroguaiaretic acid inhibits p300 and activates autophagy.	Masoprocol	25-50	E1A binding protein p300	Mus musculus	60-64
31602311-4	2019	Here, we report that NDGA is an inhibitor of the epigenetic regulator p300.	Masoprocol	21-25	E1A binding protein p300	Mus musculus	70-74
31602311-5	2019	We find that NDGA inhibits p300 acetyltransferase activity in vitro and suppresses acetylation of a key p300 target in histones (i.e., H3K27) in cells.	Masoprocol	13-17	E1A binding protein p300	Mus musculus	27-31
31602311-5	2019	We find that NDGA inhibits p300 acetyltransferase activity in vitro and suppresses acetylation of a key p300 target in histones (i.e., H3K27) in cells.	Masoprocol	13-17	E1A binding protein p300	Mus musculus	104-108
31602311-6	2019	We use the cellular thermal shift assay to uniquely demonstrate NDGA binding to p300 in cells.	Masoprocol	64-68	E1A binding protein p300	Mus musculus	80-84
31602311-7	2019	Finally, in agreement with recent findings indicating that p300 is a potent blocker of autophagy, we show that NDGA treatment induces autophagy.	Masoprocol	111-115	E1A binding protein p300	Mus musculus	59-63
31602311-8	2019	These findings identify p300 as a target of NDGA and provide mechanistic insight into its role in longevity.	Masoprocol	44-48	E1A binding protein p300	Mus musculus	24-28
31234537-2	2019	Nordihydroguaiaretic acid (NDGA) has been recently reported to inhibit LPL secretion by endoplasmic reticulum (ER)-Golgi redistribution.	Masoprocol	0-25	lipoprotein lipase	Mus musculus	71-74
31234537-2	2019	Nordihydroguaiaretic acid (NDGA) has been recently reported to inhibit LPL secretion by endoplasmic reticulum (ER)-Golgi redistribution.	Masoprocol	27-31	lipoprotein lipase	Mus musculus	71-74
31234537-7	2019	We investigated whether the LPL inhibition by NDGA alters the metabolic phenotypes.	Masoprocol	46-50	lipoprotein lipase	Mus musculus	28-31
31234537-11	2019	Taken together, these findings demonstrated that LPL inhibition by NDGA aggravates metabolic parameters and alters HDL particle size.	Masoprocol	67-71	lipoprotein lipase	Mus musculus	49-52
23533689-0	2013	Nordihydroguaiaretic acid attenuates the oxidative stress-induced decrease of CD33 expression in human monocytes.	Masoprocol	0-25	CD33 molecule	Homo sapiens	78-82
29765501-5	2018	This view is consistent with known physiological role of ACOX1 in yielding precursors of specialized proresolving mediators (SPM) and with characteristics of aging and related disorders including reduced PGC1-alpha function and improvement by strategies rising ACOX1 (via hormonal gut FGF19 and nordihydroguaiaretic acid in metabolic syndrome and diabetes conditions) and SPM (neurodegenerative disorders, atherosclerosis, and stroke).	Masoprocol	295-320	acyl-CoA oxidase 1	Homo sapiens	57-62
29765501-5	2018	This view is consistent with known physiological role of ACOX1 in yielding precursors of specialized proresolving mediators (SPM) and with characteristics of aging and related disorders including reduced PGC1-alpha function and improvement by strategies rising ACOX1 (via hormonal gut FGF19 and nordihydroguaiaretic acid in metabolic syndrome and diabetes conditions) and SPM (neurodegenerative disorders, atherosclerosis, and stroke).	Masoprocol	295-320	acyl-CoA oxidase 1	Homo sapiens	261-266
25505619-0	2014	Nordihydroguaiaretic acid activates hTRPA1 and modulates behavioral responses to noxious cold in mice.	Masoprocol	0-25	transient receptor potential cation channel subfamily A member 1	Homo sapiens	36-42
25505619-11	2014	NDGA and terameprocol are efficacious activators of TRPA1.	Masoprocol	0-4	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	52-57
24743022-1	2014	We have previously described that arachidonic acid (AA)-5-lipoxygenase (5-LO) metabolism inhibitors such as NDGA and MK886, inhibit cell death by apoptosis, but not by necrosis, induced by extracellular ATP (ATPe) binding to P2X7 receptors in macrophages.	Masoprocol	108-112	arachidonate 5-lipoxygenase	Mus musculus	56-70
24743022-1	2014	We have previously described that arachidonic acid (AA)-5-lipoxygenase (5-LO) metabolism inhibitors such as NDGA and MK886, inhibit cell death by apoptosis, but not by necrosis, induced by extracellular ATP (ATPe) binding to P2X7 receptors in macrophages.	Masoprocol	108-112	ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit	Mus musculus	208-212
24743022-1	2014	We have previously described that arachidonic acid (AA)-5-lipoxygenase (5-LO) metabolism inhibitors such as NDGA and MK886, inhibit cell death by apoptosis, but not by necrosis, induced by extracellular ATP (ATPe) binding to P2X7 receptors in macrophages.	Masoprocol	108-112	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	225-229
23643094-0	2013	Nordihydroguaiaretic acid induces Nrf2 nuclear translocation in vivo and attenuates renal damage and apoptosis in the ischemia and reperfusion model.	Masoprocol	0-25	NFE2 like bZIP transcription factor 2	Rattus norvegicus	34-38
23627840-9	2013	PD 98059, quinacrine dihydrochloride, nordihydroguaiaretic acid, AA-861, phenidone, and indomethacin attenuated mepivacaine-induced ERK phosphorylation.	Masoprocol	38-63	Eph receptor B1	Rattus norvegicus	132-135
23229229-0	2013	In vitro inhibitory profile of NDGA against AChE and its in silico structural modifications based on ADME profile.	Masoprocol	31-35	acetylcholinesterase (Cartwright blood group)	Homo sapiens	44-48
23104557-0	2013	Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARalpha-dependent and -independent pathways.	Masoprocol	0-25	peroxisome proliferator activated receptor alpha	Mus musculus	113-122
23066085-4	2013	Pan-LOX inhibitor (nordihydroguaiaretic acid), 15-LOX inhibitor (luteolin) or 15/12-LOX inhibitor (baicalein) blocked the induced effect of DHA on SDC-1 expression and apoptosis in human prostate cancer cells, whereas 5-LOX inhibitor, AA861, was ineffective.	Masoprocol	19-44	syndecan 1	Homo sapiens	147-152
23044922-0	2012	Nordihydroguaiaretic acid inhibition of NFATc1 suppresses osteoclastogenesis and arthritis bone destruction in rats.	Masoprocol	0-25	nuclear factor of activated T-cells 1	Rattus norvegicus	40-46
23044922-1	2012	Nordihydroguaiaretic acid (NDGA) is known to have prominent anticancer activity against several cancers, and is also known to be an inhibitor of 5-lipoxygenase (5-LO).	Masoprocol	0-25	arachidonate 5-lipoxygenase	Rattus norvegicus	145-159
23044922-1	2012	Nordihydroguaiaretic acid (NDGA) is known to have prominent anticancer activity against several cancers, and is also known to be an inhibitor of 5-lipoxygenase (5-LO).	Masoprocol	27-31	arachidonate 5-lipoxygenase	Rattus norvegicus	145-159
30130298-7	2018	Finally, spinal 12/15-lipoxygenase inhibition by nordihydroguaiaretic acid (NDGA) both prevents phase II formalin flinching and reverses formalin-induced persistent tactile allodynia.	Masoprocol	49-74	arachidonate 15-lipoxygenase	Rattus norvegicus	16-34
30130298-7	2018	Finally, spinal 12/15-lipoxygenase inhibition by nordihydroguaiaretic acid (NDGA) both prevents phase II formalin flinching and reverses formalin-induced persistent tactile allodynia.	Masoprocol	76-80	arachidonate 15-lipoxygenase	Rattus norvegicus	16-34
28723868-9	2017	Of these, four phytochemicals including epigallocatechin gallate, alvaradoin M, alvaradoin E and nordihydroguaiaretic acid were found to be potential inhibitors of p53-MDM2 interaction.	Masoprocol	97-122	transformation related protein 53, pseudogene	Mus musculus	164-167
28723868-9	2017	Of these, four phytochemicals including epigallocatechin gallate, alvaradoin M, alvaradoin E and nordihydroguaiaretic acid were found to be potential inhibitors of p53-MDM2 interaction.	Masoprocol	97-122	transformed mouse 3T3 cell double minute 2	Mus musculus	168-172
27845352-5	2016	Neutralizing ROS with nordihydroguaiaretic acid (NDGA) abrogated cell death induced by AF-TUSC2-erlotinib, indicating a regulatory role for ROS in the efficacy of the three drug combination.	Masoprocol	22-47	tumor suppressor 2, mitochondrial calcium regulator	Homo sapiens	90-95
27845352-5	2016	Neutralizing ROS with nordihydroguaiaretic acid (NDGA) abrogated cell death induced by AF-TUSC2-erlotinib, indicating a regulatory role for ROS in the efficacy of the three drug combination.	Masoprocol	49-53	tumor suppressor 2, mitochondrial calcium regulator	Homo sapiens	90-95
27657032-12	2016	Prostaglandin E1 and NDGA could be regarded as promising candidates for CDK2 allosteric inhibitors.	Masoprocol	21-25	cyclin dependent kinase 2	Homo sapiens	72-76
26247680-6	2015	The protective effect of NDGA against cisplatin induced nephrotoxicity in the rats was further confirmed by significant restoration of antioxidant enzymes like SOD (86.28% inhibition), inflammatory markers like TNF-alpha (34.6 pg/ml) and histopathological examination.	Masoprocol	25-29	tumor necrosis factor	Rattus norvegicus	211-220
26155826-3	2015	The compound inhibited a soybean LOX to the same extent as the known inhibitor nordihydroguaiaretic acid.	Masoprocol	79-104	linoleate 9S-lipoxygenase-4	Glycine max	33-36
25224579-9	2014	SP600125, rauwolscine, quinacrine dihydrochloride, nordihydroguaiaretic acid, AA-861, phenidone and GF 109203X attenuated dexmedetomidine-induced JNK phosphorylation.	Masoprocol	51-76	mitogen-activated protein kinase 8	Rattus norvegicus	146-149
24853029-4	2014	Our results identified that NFATc3 was mainly localized in rat PASMCs and was upregulated in PAs during hypoxia-induced rat pulmonary hypertension (PH), while this effect was inhibited by administration of nordihydroguaiaretic acid (NDGA), a 15-lipoxygenase (15-LO) inhibitor.	Masoprocol	206-231	nuclear factor of activated T-cells 3	Rattus norvegicus	28-34
24853029-4	2014	Our results identified that NFATc3 was mainly localized in rat PASMCs and was upregulated in PAs during hypoxia-induced rat pulmonary hypertension (PH), while this effect was inhibited by administration of nordihydroguaiaretic acid (NDGA), a 15-lipoxygenase (15-LO) inhibitor.	Masoprocol	233-237	nuclear factor of activated T-cells 3	Rattus norvegicus	28-34
25419525-6	2014	All but nordihydroguaiaretic acid (NDGA) are VDR ligands, which inhibited the interaction between VDR and coactivator peptide SRC2-3 with an IC50 value of 15.8 microM.	Masoprocol	8-33	vitamin D receptor	Homo sapiens	45-48
25419525-6	2014	All but nordihydroguaiaretic acid (NDGA) are VDR ligands, which inhibited the interaction between VDR and coactivator peptide SRC2-3 with an IC50 value of 15.8 microM.	Masoprocol	8-33	vitamin D receptor	Homo sapiens	98-101
25419525-6	2014	All but nordihydroguaiaretic acid (NDGA) are VDR ligands, which inhibited the interaction between VDR and coactivator peptide SRC2-3 with an IC50 value of 15.8 microM.	Masoprocol	8-33	nuclear receptor coactivator 2	Homo sapiens	126-130
25419525-6	2014	All but nordihydroguaiaretic acid (NDGA) are VDR ligands, which inhibited the interaction between VDR and coactivator peptide SRC2-3 with an IC50 value of 15.8 microM.	Masoprocol	35-39	vitamin D receptor	Homo sapiens	45-48
25419525-6	2014	All but nordihydroguaiaretic acid (NDGA) are VDR ligands, which inhibited the interaction between VDR and coactivator peptide SRC2-3 with an IC50 value of 15.8 microM.	Masoprocol	35-39	vitamin D receptor	Homo sapiens	98-101
25419525-6	2014	All but nordihydroguaiaretic acid (NDGA) are VDR ligands, which inhibited the interaction between VDR and coactivator peptide SRC2-3 with an IC50 value of 15.8 microM.	Masoprocol	35-39	nuclear receptor coactivator 2	Homo sapiens	126-130
23603407-9	2013	NDGA treatment significantly decreased the MPO level and the number of macrophages/microglia.	Masoprocol	0-4	myeloperoxidase	Rattus norvegicus	43-46
23053656-0	2012	mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo.	Masoprocol	22-47	CREB regulated transcription coactivator 1	Mus musculus	0-6
23053656-5	2012	NDGA effectively inhibited basal level of mTORC1 but not mTORC2 activity in breast cancer cell lines.	Masoprocol	0-4	CREB regulated transcription coactivator 1	Mus musculus	42-48
24009835-0	2012	Impact on inflammation and recovery of skin barrier by nordihydroguaiaretic Acid as a protease-activated receptor 2 antagonist.	Masoprocol	55-80	F2R like trypsin receptor 1	Homo sapiens	86-115
24009835-5	2012	In this study, we show that nordihydroguaiaretic acid (NDGA) inhibits the PAR2-mediated signal pathway and plays a role in skin barrier recovery in atopic dermatitis.	Masoprocol	28-53	F2R like trypsin receptor 1	Homo sapiens	74-78
24009835-5	2012	In this study, we show that nordihydroguaiaretic acid (NDGA) inhibits the PAR2-mediated signal pathway and plays a role in skin barrier recovery in atopic dermatitis.	Masoprocol	55-59	F2R like trypsin receptor 1	Homo sapiens	74-78
22493235-4	2012	In the current work, we found that intrathecal (IT) delivery of the LOX inhibitor nordihydroguaiaretic acid prevented the carrageenan-evoked increase in spinal HXB(3) at doses that attenuated the associated hyperalgesia.	Masoprocol	82-107	lysyl oxidase	Rattus norvegicus	68-71
22497768-4	2012	The IC(50) values of three well-known 15-LOX-1 inhibitors, nordihydroguaiaretic acid, quercetin, and fisetin, were evaluated in 96- and 384-well formats, and they conform to previously reported data.	Masoprocol	59-84	arachidonate 15-lipoxygenase	Homo sapiens	38-46
22620965-2	2012	We found that epigallocatechin-3-gallate (EGCG), curcumin and nordihydroguaiaretic acid (NDGA) bind to TTR and modulate its amyloidogenicity, in vitro, although through different mechanisms of action.	Masoprocol	62-87	transthyretin	Mus musculus	103-106
22620965-2	2012	We found that epigallocatechin-3-gallate (EGCG), curcumin and nordihydroguaiaretic acid (NDGA) bind to TTR and modulate its amyloidogenicity, in vitro, although through different mechanisms of action.	Masoprocol	89-93	transthyretin	Mus musculus	103-106
22428532-6	2012	NDGA, described as a lipoxygenase inhibitor, exerted a significantly higher antioxidant activity than vitamin E and abrogated 4-HPR-mediated ROS.	Masoprocol	0-4	haptoglobin-related protein	Homo sapiens	128-131
22832115-6	2012	A c-fos/lipoxygenase pathway inhibitor and antioxidant, nordihydroguaiaretic acid (NDGA) significantly suppressed ADAMTS-4 mRNA induction and activity.	Masoprocol	56-81	ADAM metallopeptidase with thrombospondin type 1 motif 4	Homo sapiens	114-122
22432798-5	2012	In the present study, the effect of Nordihydroguaiaretic acid (NDGA) was studied on the climbing ability of the PD model Drosophila expressing normal human alpha synuclein (h-alphaS) in the neurons.	Masoprocol	63-67	synuclein alpha	Homo sapiens	156-171
22142471-0	2012	Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: Role of glycogen synthase kinase-3.	Masoprocol	50-75	kelch like ECH associated protein 1	Homo sapiens	92-97
22142471-0	2012	Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: Role of glycogen synthase kinase-3.	Masoprocol	50-75	NFE2 like bZIP transcription factor 2	Homo sapiens	124-128
22142471-4	2012	In this study, the cancer-chemopreventive agent nordihydroguaiaretic acid (NDGA) increased the level of Nrf2 protein and expression of heme oxygenase-1 (HO-1) in kidney-derived LLC-PK1 and HEK293T cells and in wild-type mouse embryo fibroblasts (MEFs).	Masoprocol	48-73	NFE2 like bZIP transcription factor 2	Homo sapiens	104-108
22142471-4	2012	In this study, the cancer-chemopreventive agent nordihydroguaiaretic acid (NDGA) increased the level of Nrf2 protein and expression of heme oxygenase-1 (HO-1) in kidney-derived LLC-PK1 and HEK293T cells and in wild-type mouse embryo fibroblasts (MEFs).	Masoprocol	48-73	heme oxygenase 1	Sus scrofa	135-151
22142471-4	2012	In this study, the cancer-chemopreventive agent nordihydroguaiaretic acid (NDGA) increased the level of Nrf2 protein and expression of heme oxygenase-1 (HO-1) in kidney-derived LLC-PK1 and HEK293T cells and in wild-type mouse embryo fibroblasts (MEFs).	Masoprocol	48-73	heme oxygenase 1	Homo sapiens	153-157
22142471-4	2012	In this study, the cancer-chemopreventive agent nordihydroguaiaretic acid (NDGA) increased the level of Nrf2 protein and expression of heme oxygenase-1 (HO-1) in kidney-derived LLC-PK1 and HEK293T cells and in wild-type mouse embryo fibroblasts (MEFs).	Masoprocol	75-79	NFE2 like bZIP transcription factor 2	Homo sapiens	104-108
22142471-4	2012	In this study, the cancer-chemopreventive agent nordihydroguaiaretic acid (NDGA) increased the level of Nrf2 protein and expression of heme oxygenase-1 (HO-1) in kidney-derived LLC-PK1 and HEK293T cells and in wild-type mouse embryo fibroblasts (MEFs).	Masoprocol	75-79	heme oxygenase 1	Sus scrofa	135-151
22142471-4	2012	In this study, the cancer-chemopreventive agent nordihydroguaiaretic acid (NDGA) increased the level of Nrf2 protein and expression of heme oxygenase-1 (HO-1) in kidney-derived LLC-PK1 and HEK293T cells and in wild-type mouse embryo fibroblasts (MEFs).	Masoprocol	75-79	heme oxygenase 1	Homo sapiens	153-157
22142471-12	2012	Importantly, NDGA caused inhibitory phosphorylation of GSK-3beta at Ser9 and at Thr390, and this was associated with a substantial reduction in Neh6 phosphorylation.	Masoprocol	13-17	glycogen synthase kinase 3 beta	Homo sapiens	55-64
22467300-5	2012	The LO inhibitor nordihydroguaiaretic acid attenuated the ACh relaxations by 35% in arteries from both WT and Alox15(-/-) mice.	Masoprocol	17-42	arachidonate 15-lipoxygenase	Mus musculus	110-116
22325100-0	2012	The protective effect of nordihydroguaiaretic acid on cerebral ischemia/reperfusion injury is mediated by the JNK pathway.	Masoprocol	25-50	mitogen-activated protein kinase 8	Rattus norvegicus	110-113
22209705-7	2012	Exposure of the distal axons to nordihydroguaiaretic acid (NDGA), a ROS scavenger, mitigated the reduction in the rate of axon elongation observed after knock-down of ATP5G1.	Masoprocol	32-57	ATP synthase membrane subunit c locus 1	Rattus norvegicus	167-173
22209705-7	2012	Exposure of the distal axons to nordihydroguaiaretic acid (NDGA), a ROS scavenger, mitigated the reduction in the rate of axon elongation observed after knock-down of ATP5G1.	Masoprocol	59-63	ATP synthase membrane subunit c locus 1	Rattus norvegicus	167-173
22832115-6	2012	A c-fos/lipoxygenase pathway inhibitor and antioxidant, nordihydroguaiaretic acid (NDGA) significantly suppressed ADAMTS-4 mRNA induction and activity.	Masoprocol	83-87	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	2-7
22832115-6	2012	A c-fos/lipoxygenase pathway inhibitor and antioxidant, nordihydroguaiaretic acid (NDGA) significantly suppressed ADAMTS-4 mRNA induction and activity.	Masoprocol	83-87	ADAM metallopeptidase with thrombospondin type 1 motif 4	Homo sapiens	114-122
22204798-10	2011	Reduction of all followed-up contractions caused by nordihydroguaiaretic acid, indicate that 5-lipoxygenase metabolites unselectively reduce contractions.	Masoprocol	52-77	arachidonate 5-lipoxygenase	Rattus norvegicus	93-107
21740906-3	2011	We demonstrate that both curcumin and nordihydroguaiaretic acid (NDGA) bind to TTR and stabilize the TTR tetramer.	Masoprocol	38-63	transthyretin	Homo sapiens	79-82
21740906-3	2011	We demonstrate that both curcumin and nordihydroguaiaretic acid (NDGA) bind to TTR and stabilize the TTR tetramer.	Masoprocol	38-63	transthyretin	Homo sapiens	101-104
21740906-3	2011	We demonstrate that both curcumin and nordihydroguaiaretic acid (NDGA) bind to TTR and stabilize the TTR tetramer.	Masoprocol	65-69	transthyretin	Homo sapiens	79-82
21740906-3	2011	We demonstrate that both curcumin and nordihydroguaiaretic acid (NDGA) bind to TTR and stabilize the TTR tetramer.	Masoprocol	65-69	transthyretin	Homo sapiens	101-104
20946124-9	2011	BK-induced release of IL-6, but not of IL-8, was partially inhibited by indomethacin (10 microM) and nordihydroguaiaretic acid (10 microM).	Masoprocol	101-126	kininogen 1	Homo sapiens	0-2
21643005-9	2011	Treatment of LM-MCF-7 cells with ERK1/2 inhibitor PD98059 (30-50 mumol/L) or LOX inhibitor NDGA (25 mumol/L) abolished the activation of FASN.	Masoprocol	91-95	lysyl oxidase	Homo sapiens	77-80
21643005-9	2011	Treatment of LM-MCF-7 cells with ERK1/2 inhibitor PD98059 (30-50 mumol/L) or LOX inhibitor NDGA (25 mumol/L) abolished the activation of FASN.	Masoprocol	91-95	fatty acid synthase	Homo sapiens	137-141
21700211-6	2011	The most robust and yet nontoxic Nrf2 activators found--nordihydroguaiaretic acid, fisetin, and gedunin--induced astrocyte-dependent neuroprotection from oxidative stress via an Nrf2-dependent mechanism.	Masoprocol	56-81	NFE2 like bZIP transcription factor 2	Homo sapiens	33-37
21700211-6	2011	The most robust and yet nontoxic Nrf2 activators found--nordihydroguaiaretic acid, fisetin, and gedunin--induced astrocyte-dependent neuroprotection from oxidative stress via an Nrf2-dependent mechanism.	Masoprocol	56-81	NFE2 like bZIP transcription factor 2	Homo sapiens	178-182
21211511-8	2011	Role of NOX-mediated ROS production was reaffirmed by the observation that the antioxidants, trolox, nordihydroguaiaretic acid (NDGA), quercetin and resveratrol downregulated cytokine-induced MMP-13 mRNA and protein expression.	Masoprocol	101-126	matrix metallopeptidase 13	Homo sapiens	192-198
21211511-8	2011	Role of NOX-mediated ROS production was reaffirmed by the observation that the antioxidants, trolox, nordihydroguaiaretic acid (NDGA), quercetin and resveratrol downregulated cytokine-induced MMP-13 mRNA and protein expression.	Masoprocol	128-132	matrix metallopeptidase 13	Homo sapiens	192-198
20946124-9	2011	BK-induced release of IL-6, but not of IL-8, was partially inhibited by indomethacin (10 microM) and nordihydroguaiaretic acid (10 microM).	Masoprocol	101-126	interleukin 6	Homo sapiens	22-26
21130735-4	2011	We have recently demonstrated in vitro that polyphenolic phytochemicals, curcumin and masoprocol, can rescue S-nitroso-PDI formation by scavenging NOx.	Masoprocol	86-96	protein disulfide isomerase family A member 2	Homo sapiens	119-122
21305043-4	2011	A recent study suggested that Nordihydroguaiaretic acid (NDGA) stimulates dynein/dynactin-mediated transport of its cargo including ZW10 (Zeste White 10).	Masoprocol	30-55	zw10 kinetochore protein	Homo sapiens	132-136
21305043-4	2011	A recent study suggested that Nordihydroguaiaretic acid (NDGA) stimulates dynein/dynactin-mediated transport of its cargo including ZW10 (Zeste White 10).	Masoprocol	30-55	zw10 kinetochore protein	Homo sapiens	138-152
21305043-4	2011	A recent study suggested that Nordihydroguaiaretic acid (NDGA) stimulates dynein/dynactin-mediated transport of its cargo including ZW10 (Zeste White 10).	Masoprocol	57-61	zw10 kinetochore protein	Homo sapiens	132-136
21305043-4	2011	A recent study suggested that Nordihydroguaiaretic acid (NDGA) stimulates dynein/dynactin-mediated transport of its cargo including ZW10 (Zeste White 10).	Masoprocol	57-61	zw10 kinetochore protein	Homo sapiens	138-152
20674562-0	2010	Hepatoma-derived growth factor promotes the resistance to anti-tumor effects of nordihydroguaiaretic acid in colorectal cancer cells.	Masoprocol	80-105	heparin binding growth factor	Homo sapiens	0-30
21264886-0	2011	Inhibitory effect of nordihydroguaiaretic acid on beta-catenin/Tcf signalling in beta-catenin-activated cells.	Masoprocol	21-46	catenin beta 1	Homo sapiens	50-62
21264886-0	2011	Inhibitory effect of nordihydroguaiaretic acid on beta-catenin/Tcf signalling in beta-catenin-activated cells.	Masoprocol	21-46	hepatocyte nuclear factor 4 alpha	Homo sapiens	63-66
21264886-0	2011	Inhibitory effect of nordihydroguaiaretic acid on beta-catenin/Tcf signalling in beta-catenin-activated cells.	Masoprocol	21-46	catenin beta 1	Homo sapiens	81-93
21264886-2	2011	We identified the inhibitory effect of nordihydroguaiaretic acid (NDGA) against beta-catenin/Tcf signalling in beta-catenin activated cells.	Masoprocol	39-64	catenin beta 1	Homo sapiens	80-92
21264886-2	2011	We identified the inhibitory effect of nordihydroguaiaretic acid (NDGA) against beta-catenin/Tcf signalling in beta-catenin activated cells.	Masoprocol	39-64	hepatocyte nuclear factor 4 alpha	Homo sapiens	93-96
21264886-2	2011	We identified the inhibitory effect of nordihydroguaiaretic acid (NDGA) against beta-catenin/Tcf signalling in beta-catenin activated cells.	Masoprocol	39-64	catenin beta 1	Homo sapiens	111-123
21264886-2	2011	We identified the inhibitory effect of nordihydroguaiaretic acid (NDGA) against beta-catenin/Tcf signalling in beta-catenin activated cells.	Masoprocol	66-70	catenin beta 1	Homo sapiens	80-92
21264886-2	2011	We identified the inhibitory effect of nordihydroguaiaretic acid (NDGA) against beta-catenin/Tcf signalling in beta-catenin activated cells.	Masoprocol	66-70	hepatocyte nuclear factor 4 alpha	Homo sapiens	93-96
21264886-2	2011	We identified the inhibitory effect of nordihydroguaiaretic acid (NDGA) against beta-catenin/Tcf signalling in beta-catenin activated cells.	Masoprocol	66-70	catenin beta 1	Homo sapiens	111-123
22870140-0	2011	Nordihydroguaiaretic acid inhibits growth of cervical cancer SiHa cells by up-regulating p21.	Masoprocol	0-25	H3 histone pseudogene 16	Homo sapiens	89-92
20615477-5	2010	However, the alteration was significantly reversed by nordihydroguairetic acid (NDGA), a 15-LOX inhibitor which blocked the formation of endogenous 15-HETE.	Masoprocol	80-84	arachidonate 15-lipoxygenase	Rattus norvegicus	89-95
20674562-3	2010	This study demonstrated that over-expression of HDGF could confer the resistance of human colorectal cancer (CRC) cells to nordihydroguaiaretic acid (NDGA) toxicity.	Masoprocol	123-148	heparin binding growth factor	Homo sapiens	48-52
20674562-3	2010	This study demonstrated that over-expression of HDGF could confer the resistance of human colorectal cancer (CRC) cells to nordihydroguaiaretic acid (NDGA) toxicity.	Masoprocol	150-154	heparin binding growth factor	Homo sapiens	48-52
20097158-3	2010	We demonstrate that the polyphenolic phytochemicals curcumin and masoprocol can rescue PDI from becoming S-nitrosylated and maintain its catalytic function under conditions mimicking nitrosative stress by forming stable NOx adducts.	Masoprocol	65-75	prolyl 4-hydroxylase subunit beta	Homo sapiens	87-90
20668019-7	2010	Inhibition of 15-LOX with nordihydroguaiaretic acid (NGDA), as well as caffeic acid, abrogated WTE-induced PPAR-gamma activation and upregulation of PPAR-gamma mRNA expression in A549 cells.	Masoprocol	26-51	arachidonate 15-lipoxygenase	Homo sapiens	14-20
20668019-7	2010	Inhibition of 15-LOX with nordihydroguaiaretic acid (NGDA), as well as caffeic acid, abrogated WTE-induced PPAR-gamma activation and upregulation of PPAR-gamma mRNA expression in A549 cells.	Masoprocol	26-51	peroxisome proliferator activated receptor gamma	Homo sapiens	107-117
20668019-7	2010	Inhibition of 15-LOX with nordihydroguaiaretic acid (NGDA), as well as caffeic acid, abrogated WTE-induced PPAR-gamma activation and upregulation of PPAR-gamma mRNA expression in A549 cells.	Masoprocol	26-51	peroxisome proliferator activated receptor gamma	Homo sapiens	149-159
20036014-9	2010	The LOX inhibitor nordihydroguaiaretic acid (NDGA) prevented LTB4/LTC4 release and BMBMC degranulation.	Masoprocol	18-43	lysyl oxidase	Canis lupus familiaris	4-7
20036014-9	2010	The LOX inhibitor nordihydroguaiaretic acid (NDGA) prevented LTB4/LTC4 release and BMBMC degranulation.	Masoprocol	45-49	lysyl oxidase	Canis lupus familiaris	4-7
20398386-10	2010	Moreover, the NSC-741909-induced ROS generation could be blocked by pretreatment with antioxidants, such as nordihydroguaiaretic acid, aesculetin, baicalein, and caffeic acid, which in turn, inhibited the NSC-741909-induced JNK activation and apoptosis.	Masoprocol	108-133	mitogen-activated protein kinase 8	Homo sapiens	224-227
20371994-10	2010	Furthermore, nordihydroguaiaretic acid was found to effectively inhibit the ganglioside-induced amyloidogenesis by preventing the binding of Abeta to the membrane.	Masoprocol	13-38	amyloid beta precursor protein	Rattus norvegicus	141-146
20492349-6	2010	Systemic treatment with the mu opioid agonist morphine, the COX inhibitor ketorolac, or the LOX inhibitor nordihydroguaiaretic acid significantly reduced tactile allodynia, while their effects on the lipid metabolites were different.	Masoprocol	106-131	lysyl oxidase	Rattus norvegicus	92-95
20492349-9	2010	Nordihydroguaiaretic acid-treated animals also displayed reduced basal levels of COX and 12-LOX metabolites, but only 12-LOX metabolites remained decreased after carrageenan treatment.	Masoprocol	0-25	lysyl oxidase	Rattus norvegicus	92-95
20567598-3	2010	Here, we report the identification of the 5-lipoxygenase inhibitors, NDGA, AA861, and MK886, as potent blockers of the TRPM7 channel.	Masoprocol	69-73	arachidonate 5-lipoxygenase	Homo sapiens	42-56
20567598-3	2010	Here, we report the identification of the 5-lipoxygenase inhibitors, NDGA, AA861, and MK886, as potent blockers of the TRPM7 channel.	Masoprocol	69-73	transient receptor potential cation channel subfamily M member 7	Homo sapiens	119-124
20097158-5	2010	Our study suggests that curcumin and masoprocol can serve as lead-candidate prophylactics for reactive oxygen species induced chaperone damage, protein misfolding and neurodegenerative disease; importantly, they can play a vital role in sustaining traffic along the ER"s secretory pathway by preserving functional integrity of PDI.	Masoprocol	37-47	prolyl 4-hydroxylase subunit beta	Homo sapiens	327-330
19938896-8	2010	Further, we found that the 5-LO inhibitor nordihydrogualaretic acid (NDGA) significantly reduced both MEHP-induced TNF-alpha release and MEHP-induced formation of reactive oxygen species (ROS), supporting an involvement of the 5-LO pathway in MEHP induced inflammatory reactions.	Masoprocol	69-73	tumor necrosis factor	Rattus norvegicus	115-124
19503098-3	2009	The use of the LOX inhibitor nordihydroguaiaretic acid (NDGA) and of the anti-oxidant N-acetylcysteine (NAC) demonstrated that ROS are important in maintaining the ALK kinase active.	Masoprocol	29-54	ALK receptor tyrosine kinase	Homo sapiens	164-167
20023240-0	2009	Chemosensitizing effect of nordihydroguaiaretic acid and its tetra-acetylated derivative on parental and multiresistant TA3 mouse mammary adenocarcinoma cells.	Masoprocol	27-52	RIKEN cDNA 2700049A03 gene	Mus musculus	120-123
20023240-2	2009	MATERIALS AND METHODS: The action of nordihydroguaiaretic acid (NDGA) and its tetra-acetylated derivative (NDGATA) on TA3 mouse mammary adenocarcinoma cells and their ability to restore doxorubicin (DOX), cisplatin (CPT) and methotrexate (MTX) sensitivity of the multiresistant variant TA3-MTX-R was examined.	Masoprocol	37-62	RIKEN cDNA 2700049A03 gene	Mus musculus	118-121
20023240-2	2009	MATERIALS AND METHODS: The action of nordihydroguaiaretic acid (NDGA) and its tetra-acetylated derivative (NDGATA) on TA3 mouse mammary adenocarcinoma cells and their ability to restore doxorubicin (DOX), cisplatin (CPT) and methotrexate (MTX) sensitivity of the multiresistant variant TA3-MTX-R was examined.	Masoprocol	64-68	RIKEN cDNA 2700049A03 gene	Mus musculus	118-121
19887452-5	2010	The ROS inhibitors, nordihydroguaiaretic acid and GSH, suppress phosphorylation of p38 and cell numbers positive for SA-beta-gal following irradiation.	Masoprocol	20-45	mitogen-activated protein kinase 14	Homo sapiens	83-86
19887452-5	2010	The ROS inhibitors, nordihydroguaiaretic acid and GSH, suppress phosphorylation of p38 and cell numbers positive for SA-beta-gal following irradiation.	Masoprocol	20-45	SH3 domain binding protein 5	Homo sapiens	117-124
19503098-3	2009	The use of the LOX inhibitor nordihydroguaiaretic acid (NDGA) and of the anti-oxidant N-acetylcysteine (NAC) demonstrated that ROS are important in maintaining the ALK kinase active.	Masoprocol	56-60	ALK receptor tyrosine kinase	Homo sapiens	164-167
18930721-0	2008	Cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate and nordihydroguaiaretic acid inhibit human Kv1.5 currents independently of lipoxygenase.	Masoprocol	48-73	potassium voltage-gated channel subfamily A member 5	Homo sapiens	88-93
19121070-7	2009	RESULTS: The results showed that A. actinomycetemcomitans lipopolysaccharide stimulated both iNOS activity and nitrite production by HOS cells; this was reduced by l-NIL, anti-CD14, or anti-TLR4 antibody, SQ22536, KT5720, genistein, bisindolylmaleimde, BPB, and NDGA, but was enhanced by db-cAMP, IBMX, and forskolin.	Masoprocol	262-266	nitric oxide synthase 2	Homo sapiens	93-97
18930721-3	2008	CDC and NDGA, but not gossypol, a structurally dissimilar inhibitor, reversibly inhibited hKv1.5 current in a concentration-dependent manner with IC(50) of 5.7 microM and 16.4 microM, respectively.	Masoprocol	8-12	potassium voltage-gated channel subfamily A member 5	Homo sapiens	90-96
18852027-0	2008	Nordihydroguaiaretic acid activates the antioxidant pathway Nrf2/HO-1 and protects cerebellar granule neurons against oxidative stress.	Masoprocol	0-25	NFE2 like bZIP transcription factor 2	Homo sapiens	60-64
18852027-0	2008	Nordihydroguaiaretic acid activates the antioxidant pathway Nrf2/HO-1 and protects cerebellar granule neurons against oxidative stress.	Masoprocol	0-25	heme oxygenase 1	Homo sapiens	65-69
18852027-2	2008	We found that nordihydroguaiaretic acid (NDGA), a powerful antioxidant from Larrea tridentate, activates the antioxidant pathway Nrf2/heme oxygenase-1 (HO-1) in cerebellar granule neurons and protects them against H(2)O(2) or 3-nitropropionic acid-induced neurotoxicity.	Masoprocol	14-39	heme oxygenase 1	Homo sapiens	129-150
18852027-2	2008	We found that nordihydroguaiaretic acid (NDGA), a powerful antioxidant from Larrea tridentate, activates the antioxidant pathway Nrf2/heme oxygenase-1 (HO-1) in cerebellar granule neurons and protects them against H(2)O(2) or 3-nitropropionic acid-induced neurotoxicity.	Masoprocol	14-39	heme oxygenase 1	Homo sapiens	152-156
18852027-2	2008	We found that nordihydroguaiaretic acid (NDGA), a powerful antioxidant from Larrea tridentate, activates the antioxidant pathway Nrf2/heme oxygenase-1 (HO-1) in cerebellar granule neurons and protects them against H(2)O(2) or 3-nitropropionic acid-induced neurotoxicity.	Masoprocol	41-45	heme oxygenase 1	Homo sapiens	129-150
18852027-2	2008	We found that nordihydroguaiaretic acid (NDGA), a powerful antioxidant from Larrea tridentate, activates the antioxidant pathway Nrf2/heme oxygenase-1 (HO-1) in cerebellar granule neurons and protects them against H(2)O(2) or 3-nitropropionic acid-induced neurotoxicity.	Masoprocol	41-45	heme oxygenase 1	Homo sapiens	152-156
18491370-0	2008	Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells.	Masoprocol	22-47	insulin like growth factor 1 receptor	Homo sapiens	62-76
18719338-10	2008	Treatment of mice with either indomethacin or nordihydroguaiaretic acid decreased the ABR threshold shifts after overexposure, indicating that COX-1 and LOX inhibitors exhibited protective effects against acoustic injury.	Masoprocol	46-71	cytochrome c oxidase I, mitochondrial	Mus musculus	143-148
18779659-6	2008	Both intraperitoneal and intravenous NDGA administration attenuated ovalbumin (OVA)-induced influx into the lungs of total leukocytes, as well as IL-4, IL-5, IL-13, and TNF-alpha levels.	Masoprocol	37-41	interleukin 4	Homo sapiens	146-150
18779659-6	2008	Both intraperitoneal and intravenous NDGA administration attenuated ovalbumin (OVA)-induced influx into the lungs of total leukocytes, as well as IL-4, IL-5, IL-13, and TNF-alpha levels.	Masoprocol	37-41	interleukin 5	Homo sapiens	152-156
18779659-6	2008	Both intraperitoneal and intravenous NDGA administration attenuated ovalbumin (OVA)-induced influx into the lungs of total leukocytes, as well as IL-4, IL-5, IL-13, and TNF-alpha levels.	Masoprocol	37-41	interleukin 13	Homo sapiens	158-163
18779659-6	2008	Both intraperitoneal and intravenous NDGA administration attenuated ovalbumin (OVA)-induced influx into the lungs of total leukocytes, as well as IL-4, IL-5, IL-13, and TNF-alpha levels.	Masoprocol	37-41	tumor necrosis factor	Homo sapiens	169-178
18794123-0	2008	Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.	Masoprocol	0-25	fibroblast growth factor receptor 3	Homo sapiens	48-83
18491370-0	2008	Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells.	Masoprocol	49-53	insulin like growth factor 1 receptor	Homo sapiens	62-76
18491370-1	2008	BACKGROUND: Nordihydroguaiaretic acid (NDGA) is an inhibitor of the IGF-1 receptor (IGF-1R) in breast and other cancers, and concomitantly inhibits tumor growth both in cultured cells and animals.	Masoprocol	12-37	insulin like growth factor 1 receptor	Homo sapiens	68-82
18491370-1	2008	BACKGROUND: Nordihydroguaiaretic acid (NDGA) is an inhibitor of the IGF-1 receptor (IGF-1R) in breast and other cancers, and concomitantly inhibits tumor growth both in cultured cells and animals.	Masoprocol	12-37	insulin like growth factor 1 receptor	Homo sapiens	84-90
18491370-1	2008	BACKGROUND: Nordihydroguaiaretic acid (NDGA) is an inhibitor of the IGF-1 receptor (IGF-1R) in breast and other cancers, and concomitantly inhibits tumor growth both in cultured cells and animals.	Masoprocol	39-43	insulin like growth factor 1 receptor	Homo sapiens	68-82
18491370-1	2008	BACKGROUND: Nordihydroguaiaretic acid (NDGA) is an inhibitor of the IGF-1 receptor (IGF-1R) in breast and other cancers, and concomitantly inhibits tumor growth both in cultured cells and animals.	Masoprocol	39-43	insulin like growth factor 1 receptor	Homo sapiens	84-90
18534796-12	2008	5-LOX IC(50) values were 25 microg/ml for EtOAc, 68 microg/ml for bacosides and 2 microg/ml for nordihydroguaiaretic acid (NDGA) where as COX-2 IC(50) values were 1.32 microg/ml for EtOAc, 1.19 microg/ml for bacoside fraction and 0.23 microg/ml for indomethacin.	Masoprocol	96-121	lysyl oxidase	Rattus norvegicus	2-5
18534796-12	2008	5-LOX IC(50) values were 25 microg/ml for EtOAc, 68 microg/ml for bacosides and 2 microg/ml for nordihydroguaiaretic acid (NDGA) where as COX-2 IC(50) values were 1.32 microg/ml for EtOAc, 1.19 microg/ml for bacoside fraction and 0.23 microg/ml for indomethacin.	Masoprocol	96-121	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	138-143
18541424-2	2008	All three regioisomers inhibited 5-lipoxygenase (5-LOX), where the relative potency order was 2-SO(2)NH(2) (IC(50)=10 microM) >3-SO(2)NH(2) (IC(50)=15 microM) >4-SO(2)NH(2) (IC(50)=68 microM) relative to the reference drug nordihydroguaiaretic acid (NDGA; IC(50)=35 microM).	Masoprocol	229-254	arachidonate 5-lipoxygenase	Homo sapiens	33-47
18541424-2	2008	All three regioisomers inhibited 5-lipoxygenase (5-LOX), where the relative potency order was 2-SO(2)NH(2) (IC(50)=10 microM) >3-SO(2)NH(2) (IC(50)=15 microM) >4-SO(2)NH(2) (IC(50)=68 microM) relative to the reference drug nordihydroguaiaretic acid (NDGA; IC(50)=35 microM).	Masoprocol	229-254	arachidonate 5-lipoxygenase	Homo sapiens	49-54
18645000-0	2008	Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer.	Masoprocol	0-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81
18645000-3	2008	In the current study, we show that the phenolic compound nordihydroguaiaretic acid (NDGA) promoted cell death of trastuzumab-naive and trastuzumab-refractory HER2-overexpressing breast cancer cells.	Masoprocol	57-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
18645000-0	2008	Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer.	Masoprocol	0-25	insulin like growth factor 1	Homo sapiens	39-67
18645000-3	2008	In the current study, we show that the phenolic compound nordihydroguaiaretic acid (NDGA) promoted cell death of trastuzumab-naive and trastuzumab-refractory HER2-overexpressing breast cancer cells.	Masoprocol	84-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
18645000-4	2008	NDGA induced DNA fragmentation, cleavage of poly(ADP-ribose) polymerase and caspase-3, and inhibition of colony formation.	Masoprocol	0-4	poly(ADP-ribose) polymerase 1	Homo sapiens	44-71
18645000-4	2008	NDGA induced DNA fragmentation, cleavage of poly(ADP-ribose) polymerase and caspase-3, and inhibition of colony formation.	Masoprocol	0-4	caspase 3	Homo sapiens	76-85
18083043-10	2008	Preincubation of RAGMs with NDGA (nordihydroguiaretic acid) (10(-5)M) completely abolished the production of LTB4 on RAGMSs challenged with A23187 in combination with RANTES or A23187 alone in the supernatants.	Masoprocol	28-32	C-C motif chemokine ligand 5	Rattus norvegicus	167-173
18418215-0	2008	Nordihydroguaiaretic acid restores expression of silenced E-cadherin gene in human breast cancer cell lines and xenografts.	Masoprocol	0-25	cadherin 1	Homo sapiens	58-68
17562544-0	2008	Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.	Masoprocol	0-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
17562544-0	2008	Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.	Masoprocol	0-25	insulin like growth factor 1 receptor	Homo sapiens	63-77
17562544-0	2008	Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.	Masoprocol	0-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
17562544-0	2008	Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.	Masoprocol	27-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
17562544-0	2008	Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.	Masoprocol	27-31	insulin like growth factor 1 receptor	Homo sapiens	63-77
17562544-0	2008	Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.	Masoprocol	27-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
17562544-1	2008	We have reported that nordihydroguaiaretic acid (NDGA) inhibits the tyrosine kinase activities of the IGF-1 receptor (IGF-1R) and the HER2 receptor in breast cancer cells.	Masoprocol	22-47	insulin like growth factor 1 receptor	Homo sapiens	102-116
17562544-1	2008	We have reported that nordihydroguaiaretic acid (NDGA) inhibits the tyrosine kinase activities of the IGF-1 receptor (IGF-1R) and the HER2 receptor in breast cancer cells.	Masoprocol	22-47	insulin like growth factor 1 receptor	Homo sapiens	118-124
17562544-1	2008	We have reported that nordihydroguaiaretic acid (NDGA) inhibits the tyrosine kinase activities of the IGF-1 receptor (IGF-1R) and the HER2 receptor in breast cancer cells.	Masoprocol	22-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-138
17562544-1	2008	We have reported that nordihydroguaiaretic acid (NDGA) inhibits the tyrosine kinase activities of the IGF-1 receptor (IGF-1R) and the HER2 receptor in breast cancer cells.	Masoprocol	49-53	insulin like growth factor 1 receptor	Homo sapiens	102-116
17562544-1	2008	We have reported that nordihydroguaiaretic acid (NDGA) inhibits the tyrosine kinase activities of the IGF-1 receptor (IGF-1R) and the HER2 receptor in breast cancer cells.	Masoprocol	49-53	insulin like growth factor 1 receptor	Homo sapiens	118-124
17562544-1	2008	We have reported that nordihydroguaiaretic acid (NDGA) inhibits the tyrosine kinase activities of the IGF-1 receptor (IGF-1R) and the HER2 receptor in breast cancer cells.	Masoprocol	49-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-138
18164318-0	2008	Reactivation of methylation-silenced tumor suppressor gene p16INK4a by nordihydroguaiaretic acid and its implication in G1 cell cycle arrest.	Masoprocol	71-96	cyclin dependent kinase inhibitor 2A	Homo sapiens	59-67
18610748-0	2008	Inhibitory effect of nordihydroguaiaretic acid and its tetra-acetylated derivative on respiration and growth of adenocarcinoma TA3 and its multiresistant variant TA3MTX-R.	Masoprocol	21-46	RIKEN cDNA 2700049A03 gene	Mus musculus	127-130
18083043-10	2008	Preincubation of RAGMs with NDGA (nordihydroguiaretic acid) (10(-5)M) completely abolished the production of LTB4 on RAGMSs challenged with A23187 in combination with RANTES or A23187 alone in the supernatants.	Masoprocol	34-58	C-C motif chemokine ligand 5	Rattus norvegicus	167-173
17997295-4	2007	Inhibition of PLA2 and LOX with prednisolone and nordihydroguaiaretic acid (NDGA) caused a semi-quantitative increase of utrophin and Bcl-2-, and a dose-dependent, quantitative increase of desmin expression, an effect that was augmented by hypo-osmotic treatment.	Masoprocol	49-74	phospholipase A2 group IB	Homo sapiens	14-18
17982097-2	2007	5-Lipoxygenase (5-LO) was the primary enzyme involved in ROS production by human mast cells (huMC) and mouse bone marrow-derived mast cells (mBMMC) following FcepsilonRI aggregation because incubation with 5-LO inhibitors (AA861, nordihydroguaiaretic acid, zileuton) but not a flavoenzyme inhibitor (diphenyleneiodonium) completely abrogated Ag-induced dichlorodihydrofluorescein (DCF) fluorescence.	Masoprocol	230-255	arachidonate 5-lipoxygenase	Homo sapiens	0-14
18923650-8	2008	The specific AP-1 inhibitor nordihydroguaiaretic acid suppresses the calcium-induced increase of PADI3 mRNA levels in keratinocytes.	Masoprocol	28-53	peptidyl arginine deiminase 3	Homo sapiens	97-102
17486636-6	2007	Nordihydroguaiaretic acid (NDGA), a phenolic compound isolated from the creosote bush (Larrea divaricata), has anti-tumor properties against a number of malignancies, has been shown to inhibit the phosphorylation and activation of the IGF-IR in breast cancer cells, and is currently in Phase I trials for prostate cancer.	Masoprocol	0-25	insulin like growth factor 1 receptor	Homo sapiens	235-241
17486636-6	2007	Nordihydroguaiaretic acid (NDGA), a phenolic compound isolated from the creosote bush (Larrea divaricata), has anti-tumor properties against a number of malignancies, has been shown to inhibit the phosphorylation and activation of the IGF-IR in breast cancer cells, and is currently in Phase I trials for prostate cancer.	Masoprocol	27-31	insulin like growth factor 1 receptor	Homo sapiens	235-241
17919072-0	2007	Nordihydroguaiaretic acid increases endothelial nitric oxide synthase expression via the transcription factor AP-1.	Masoprocol	0-25	nitric oxide synthase 3	Bos taurus	36-69
17919072-0	2007	Nordihydroguaiaretic acid increases endothelial nitric oxide synthase expression via the transcription factor AP-1.	Masoprocol	0-25	Jun proto-oncogene, AP-1 transcription factor subunit	Bos taurus	110-114
17919072-1	2007	It has been previously reported that the antioxidant compound nordihydroguaiaretic acid (NDGA) increases endothelial nitric oxide synthase (eNOS) expression in cultured bovine aortic endothelial cells.	Masoprocol	62-87	nitric oxide synthase 3	Bos taurus	105-138
17919072-1	2007	It has been previously reported that the antioxidant compound nordihydroguaiaretic acid (NDGA) increases endothelial nitric oxide synthase (eNOS) expression in cultured bovine aortic endothelial cells.	Masoprocol	62-87	nitric oxide synthase 3	Bos taurus	140-144
17919072-1	2007	It has been previously reported that the antioxidant compound nordihydroguaiaretic acid (NDGA) increases endothelial nitric oxide synthase (eNOS) expression in cultured bovine aortic endothelial cells.	Masoprocol	89-93	nitric oxide synthase 3	Bos taurus	105-138
17919072-1	2007	It has been previously reported that the antioxidant compound nordihydroguaiaretic acid (NDGA) increases endothelial nitric oxide synthase (eNOS) expression in cultured bovine aortic endothelial cells.	Masoprocol	89-93	nitric oxide synthase 3	Bos taurus	140-144
17997295-4	2007	Inhibition of PLA2 and LOX with prednisolone and nordihydroguaiaretic acid (NDGA) caused a semi-quantitative increase of utrophin and Bcl-2-, and a dose-dependent, quantitative increase of desmin expression, an effect that was augmented by hypo-osmotic treatment.	Masoprocol	49-74	utrophin	Homo sapiens	121-129
17997295-4	2007	Inhibition of PLA2 and LOX with prednisolone and nordihydroguaiaretic acid (NDGA) caused a semi-quantitative increase of utrophin and Bcl-2-, and a dose-dependent, quantitative increase of desmin expression, an effect that was augmented by hypo-osmotic treatment.	Masoprocol	49-74	BCL2 apoptosis regulator	Homo sapiens	134-139
17997295-4	2007	Inhibition of PLA2 and LOX with prednisolone and nordihydroguaiaretic acid (NDGA) caused a semi-quantitative increase of utrophin and Bcl-2-, and a dose-dependent, quantitative increase of desmin expression, an effect that was augmented by hypo-osmotic treatment.	Masoprocol	49-74	desmin	Homo sapiens	189-195
17997295-4	2007	Inhibition of PLA2 and LOX with prednisolone and nordihydroguaiaretic acid (NDGA) caused a semi-quantitative increase of utrophin and Bcl-2-, and a dose-dependent, quantitative increase of desmin expression, an effect that was augmented by hypo-osmotic treatment.	Masoprocol	76-80	phospholipase A2 group IB	Homo sapiens	14-18
17997295-4	2007	Inhibition of PLA2 and LOX with prednisolone and nordihydroguaiaretic acid (NDGA) caused a semi-quantitative increase of utrophin and Bcl-2-, and a dose-dependent, quantitative increase of desmin expression, an effect that was augmented by hypo-osmotic treatment.	Masoprocol	76-80	utrophin	Homo sapiens	121-129
17997295-4	2007	Inhibition of PLA2 and LOX with prednisolone and nordihydroguaiaretic acid (NDGA) caused a semi-quantitative increase of utrophin and Bcl-2-, and a dose-dependent, quantitative increase of desmin expression, an effect that was augmented by hypo-osmotic treatment.	Masoprocol	76-80	BCL2 apoptosis regulator	Homo sapiens	134-139
17997295-4	2007	Inhibition of PLA2 and LOX with prednisolone and nordihydroguaiaretic acid (NDGA) caused a semi-quantitative increase of utrophin and Bcl-2-, and a dose-dependent, quantitative increase of desmin expression, an effect that was augmented by hypo-osmotic treatment.	Masoprocol	76-80	desmin	Homo sapiens	189-195
17651887-8	2007	AP-1 inhibitor NDGA decreases NGF/p75 and expression of FasL and caspase 3 induced by (Ac)(5)GP, suggesting the importance of AP-1 in mediating NGF/p75 and their downstream apoptotic signals.	Masoprocol	15-19	PC4 and SFRS1 interacting protein 1	Homo sapiens	34-37
17651887-8	2007	AP-1 inhibitor NDGA decreases NGF/p75 and expression of FasL and caspase 3 induced by (Ac)(5)GP, suggesting the importance of AP-1 in mediating NGF/p75 and their downstream apoptotic signals.	Masoprocol	15-19	Fas ligand	Homo sapiens	56-60
17651887-8	2007	AP-1 inhibitor NDGA decreases NGF/p75 and expression of FasL and caspase 3 induced by (Ac)(5)GP, suggesting the importance of AP-1 in mediating NGF/p75 and their downstream apoptotic signals.	Masoprocol	15-19	caspase 3	Homo sapiens	65-74
17651887-8	2007	AP-1 inhibitor NDGA decreases NGF/p75 and expression of FasL and caspase 3 induced by (Ac)(5)GP, suggesting the importance of AP-1 in mediating NGF/p75 and their downstream apoptotic signals.	Masoprocol	15-19	PC4 and SFRS1 interacting protein 1	Homo sapiens	148-151
17395008-7	2007	Preincubation of chondrocytes with rotenone, an inhibitor of the mitochondrial electron transport chain, or nordihydroguaiaretic acid (NDGA), a selective 5-lipoxygenase inhibitor, partially prevented FN-f-stimulated MMP-13 production and decreased MAP kinase and NF-kappaB phosphorylation.	Masoprocol	108-133	arachidonate 5-lipoxygenase	Homo sapiens	154-168
17626122-7	2007	Whereas inhibition of cytochrome P-450 omega-hydroxylase and epoxygenases had no effect on this residual reactivity in ApoE and LDLR strains, inhibition of 12/15-lipoxygenase with nordihydroguaiaretic acid abolished the residual reactivity.	Masoprocol	180-205	arachidonate 15-lipoxygenase	Mus musculus	156-174
17502145-0	2007	Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs.	Masoprocol	41-66	insulin like growth factor 1 receptor	Homo sapiens	14-20
17502145-0	2007	Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs.	Masoprocol	68-72	insulin like growth factor 1 receptor	Homo sapiens	14-20
17502145-1	2007	Herein, we pursue the hypothesis that the structure of nordihydroguaiaretic acid (NDGA) can be refined for selective potency against the insulin-like growth factor 1 receptor (IGF-1R) as a potential therapeutic target for breast cancer while diminishing its action against other cellular targets.	Masoprocol	55-80	insulin like growth factor 1 receptor	Homo sapiens	137-174
17502145-1	2007	Herein, we pursue the hypothesis that the structure of nordihydroguaiaretic acid (NDGA) can be refined for selective potency against the insulin-like growth factor 1 receptor (IGF-1R) as a potential therapeutic target for breast cancer while diminishing its action against other cellular targets.	Masoprocol	55-80	insulin like growth factor 1 receptor	Homo sapiens	176-182
17502145-1	2007	Herein, we pursue the hypothesis that the structure of nordihydroguaiaretic acid (NDGA) can be refined for selective potency against the insulin-like growth factor 1 receptor (IGF-1R) as a potential therapeutic target for breast cancer while diminishing its action against other cellular targets.	Masoprocol	82-86	insulin like growth factor 1 receptor	Homo sapiens	137-174
17502145-1	2007	Herein, we pursue the hypothesis that the structure of nordihydroguaiaretic acid (NDGA) can be refined for selective potency against the insulin-like growth factor 1 receptor (IGF-1R) as a potential therapeutic target for breast cancer while diminishing its action against other cellular targets.	Masoprocol	82-86	insulin like growth factor 1 receptor	Homo sapiens	176-182
17395008-7	2007	Preincubation of chondrocytes with rotenone, an inhibitor of the mitochondrial electron transport chain, or nordihydroguaiaretic acid (NDGA), a selective 5-lipoxygenase inhibitor, partially prevented FN-f-stimulated MMP-13 production and decreased MAP kinase and NF-kappaB phosphorylation.	Masoprocol	108-133	matrix metallopeptidase 13	Homo sapiens	216-222
17395008-7	2007	Preincubation of chondrocytes with rotenone, an inhibitor of the mitochondrial electron transport chain, or nordihydroguaiaretic acid (NDGA), a selective 5-lipoxygenase inhibitor, partially prevented FN-f-stimulated MMP-13 production and decreased MAP kinase and NF-kappaB phosphorylation.	Masoprocol	135-139	arachidonate 5-lipoxygenase	Homo sapiens	154-168
17395008-7	2007	Preincubation of chondrocytes with rotenone, an inhibitor of the mitochondrial electron transport chain, or nordihydroguaiaretic acid (NDGA), a selective 5-lipoxygenase inhibitor, partially prevented FN-f-stimulated MMP-13 production and decreased MAP kinase and NF-kappaB phosphorylation.	Masoprocol	135-139	matrix metallopeptidase 13	Homo sapiens	216-222
17319946-7	2007	Nordihydroguaiaretic acid (NDGA), a non-selective lipoxygenase inhibitor, and MK886, a specific inhibitor of 5-lipoxygenase, induced MMP-3 expression synergistically with IL-1.	Masoprocol	0-25	matrix metallopeptidase 3	Homo sapiens	133-138
17319946-7	2007	Nordihydroguaiaretic acid (NDGA), a non-selective lipoxygenase inhibitor, and MK886, a specific inhibitor of 5-lipoxygenase, induced MMP-3 expression synergistically with IL-1.	Masoprocol	0-25	interleukin 1 alpha	Homo sapiens	171-175
17319946-7	2007	Nordihydroguaiaretic acid (NDGA), a non-selective lipoxygenase inhibitor, and MK886, a specific inhibitor of 5-lipoxygenase, induced MMP-3 expression synergistically with IL-1.	Masoprocol	27-31	matrix metallopeptidase 3	Homo sapiens	133-138
17319946-7	2007	Nordihydroguaiaretic acid (NDGA), a non-selective lipoxygenase inhibitor, and MK886, a specific inhibitor of 5-lipoxygenase, induced MMP-3 expression synergistically with IL-1.	Masoprocol	27-31	interleukin 1 alpha	Homo sapiens	171-175
17319946-8	2007	However IL-4 was still able to inhibit MMP-3 expression in the presence of NDGA or MK886 and IL-1.	Masoprocol	75-79	interleukin 4	Homo sapiens	8-12
17319946-8	2007	However IL-4 was still able to inhibit MMP-3 expression in the presence of NDGA or MK886 and IL-1.	Masoprocol	75-79	matrix metallopeptidase 3	Homo sapiens	39-44
16882662-10	2006	The AP-1 inhibitor, nordihydroguaiaretic acid, and a c-Fos small interfering RNA eliminated the effect of FN on MMP-9 expression.	Masoprocol	20-45	fibronectin 1	Homo sapiens	106-108
17175522-7	2007	The AP-1 beta-lactamase reporter was validated with inhibitors of kinases located upstream of AP-1 and with known natural product inhibitors of AP-1 (nordihydroguaiaretic acid and curcumin).	Masoprocol	150-175	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	4-8
17021030-3	2007	The beta2-subunit-dependent modulation by AA persisted in the presence of either superoxide dismutase or inhibitors of AA metabolism such as nordihydroguaiaretic acid and eicosatetraynoic acid, suggesting that AA acts directly rather than through its metabolites.	Masoprocol	141-166	hemoglobin, beta adult minor chain	Mus musculus	4-9
16904331-5	2006	Further in vivo studies employing a rat carrageenan-induced paw edema model showed that the oxime compounds (17a, 18a) were more potent anti-inflammatory agents than the 5-LOX inhibitor caffeic acid, and 15-LOX inhibitor nordihydroguaiaretic acid (NDGA), but less potent than the selective COX-2 inhibitor celecoxib.	Masoprocol	221-246	arachidonate 15-lipoxygenase	Rattus norvegicus	204-210
17069749-6	2007	NDGA and RIF inhibited the binding of Abeta to GM1 liposomes by competitively binding to the membranes and/or direct interaction with Abeta in solution, thus at least partly preventing fibrils from forming.	Masoprocol	0-4	amyloid beta precursor protein	Rattus norvegicus	38-43
17069749-6	2007	NDGA and RIF inhibited the binding of Abeta to GM1 liposomes by competitively binding to the membranes and/or direct interaction with Abeta in solution, thus at least partly preventing fibrils from forming.	Masoprocol	0-4	amyloid beta precursor protein	Rattus norvegicus	134-139
16882662-10	2006	The AP-1 inhibitor, nordihydroguaiaretic acid, and a c-Fos small interfering RNA eliminated the effect of FN on MMP-9 expression.	Masoprocol	20-45	matrix metallopeptidase 9	Homo sapiens	112-117
16409471-6	2006	The HCy effect on p38 MAPK phosphorylation was prevented by N-acetyl-L-cysteine and iloprost and was partially inhibited by nordihydroguaiaretic acid.	Masoprocol	124-149	mitogen-activated protein kinase 14	Homo sapiens	18-26
16788090-5	2006	Suppression of CYP1A1 mRNA expression in TCDD-treated Huh.8 cells was partially reversed after pretreatment with the antioxidants N-acetylcysteine and nordihydroguaiaretic acid, suggesting a role for oxidative stress.	Masoprocol	151-176	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	15-21
16473382-5	2006	Although pretreatment with ERK inhibitors (PD98059 or U0126) abolished ERK phosphorylation in response to NDGA, neither inhibitor had any effect on NDGA-induced apoptosis.	Masoprocol	106-110	mitogen-activated protein kinase 1	Mus musculus	27-30
16473382-5	2006	Although pretreatment with ERK inhibitors (PD98059 or U0126) abolished ERK phosphorylation in response to NDGA, neither inhibitor had any effect on NDGA-induced apoptosis.	Masoprocol	106-110	mitogen-activated protein kinase 1	Mus musculus	71-74
16638750-5	2006	Herein we report that nordihydroguaiaretic acid, a pan inhibitor of lipoxygenases and baicalein, a selective inhibitor of 12-lipoxygenase, reduced VEGF expression in human prostate cancer PC-3 cells.	Masoprocol	22-47	vascular endothelial growth factor A	Homo sapiens	147-151
16731771-7	2006	Docking of the known inhibitors curcumin and NDGA to P-12-LOX was used to optimize the docking protocol for the system in study.	Masoprocol	45-49	DNA polymerase epsilon 4, accessory subunit	Homo sapiens	53-61
16309466-5	2005	Inoculation of the parental bacteria into mice footpads led to an early increase in the infected limb volume that could be significantly reduced by inhibitors of both COX and lipoxygenase (ibuprofen and NDGA respectively).	Masoprocol	203-207	cytochrome c oxidase subunit 4I1	Mus musculus	167-187
16428296-2	2005	Here, using nordihydroguaiaretic acid (NDGA), with two phenyl rings connected by a four-carbon chain, as a representative, the structural basis for the inhibition of animal fatty acid synthase (FAS) by polyphenols was investigated.	Masoprocol	12-37	fatty acid synthase	Homo sapiens	173-192
16428296-2	2005	Here, using nordihydroguaiaretic acid (NDGA), with two phenyl rings connected by a four-carbon chain, as a representative, the structural basis for the inhibition of animal fatty acid synthase (FAS) by polyphenols was investigated.	Masoprocol	12-37	fatty acid synthase	Homo sapiens	194-197
16428296-2	2005	Here, using nordihydroguaiaretic acid (NDGA), with two phenyl rings connected by a four-carbon chain, as a representative, the structural basis for the inhibition of animal fatty acid synthase (FAS) by polyphenols was investigated.	Masoprocol	39-43	fatty acid synthase	Homo sapiens	173-192
16428296-2	2005	Here, using nordihydroguaiaretic acid (NDGA), with two phenyl rings connected by a four-carbon chain, as a representative, the structural basis for the inhibition of animal fatty acid synthase (FAS) by polyphenols was investigated.	Masoprocol	39-43	fatty acid synthase	Homo sapiens	194-197
16428296-3	2005	NDGA potently inhibits the overall reaction of FAS (IC(50) = 9.3 +/- 0.1 muM).	Masoprocol	0-4	fatty acid synthase	Homo sapiens	47-50
16428296-3	2005	NDGA potently inhibits the overall reaction of FAS (IC(50) = 9.3 +/- 0.1 muM).	Masoprocol	0-4	latexin	Homo sapiens	73-76
16428296-4	2005	The kinetic study indicated that NDGA inhibits FAS competitively with respect to acetyl-CoA, noncompetitively with respect to malonyl-CoA, and in a mixed manner with respect to NADPH.	Masoprocol	33-37	fatty acid synthase	Homo sapiens	47-50
16142439-0	2005	Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.	Masoprocol	0-25	insulin like growth factor 1	Homo sapiens	46-51
16325749-9	2005	Nordihydroguaiaretic acid, an inhibitor of the lipoxygenase pathway, blocked IL-8 and leukotriene B4 (LTB4) production induced by OxLA, whereas indomethacin, an inhibitor of the cyclooxygenase pathway, blocked IL-8, prostaglandin E2 (PGE2), and thromboxane B2 (TXB2) production.	Masoprocol	0-25	C-X-C motif chemokine ligand 8	Homo sapiens	77-81
16325749-9	2005	Nordihydroguaiaretic acid, an inhibitor of the lipoxygenase pathway, blocked IL-8 and leukotriene B4 (LTB4) production induced by OxLA, whereas indomethacin, an inhibitor of the cyclooxygenase pathway, blocked IL-8, prostaglandin E2 (PGE2), and thromboxane B2 (TXB2) production.	Masoprocol	0-25	C-X-C motif chemokine ligand 8	Homo sapiens	210-214
16358785-7	2005	The inhibitory effect of nordihydroguaretic acid is indirect and is conceivably caused by the accumulation of arachidonic acid due to suppression of its lipoxygenase-catalyzed oxidation at phospholipase A2 activation.	Masoprocol	25-48	phospholipase A2, group IB, pancreas	Mus musculus	189-205
16358785-12	2005	Nordihydroguaretic acid, quercetin, and dihydroquercetin, but not suramin, also interact with calmodulin, but this does not result in the complete closing of its hydrophobic site.	Masoprocol	0-23	calmodulin 2	Mus musculus	94-104
16142439-0	2005	Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.	Masoprocol	0-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-63
16142439-0	2005	Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.	Masoprocol	0-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-72
16142439-0	2005	Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.	Masoprocol	27-31	insulin like growth factor 1	Homo sapiens	46-51
16142439-0	2005	Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.	Masoprocol	27-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-63
16142439-0	2005	Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.	Masoprocol	27-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-72
16142439-6	2005	NDGA was also effective at inhibiting autophosphorylation of the isolated HER2/neu receptor at similar concentrations.	Masoprocol	0-4	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-82
15805544-6	2005	Nordihydroguaiaretic acid, AA-861, and baicalein, which are lipoxygenase inhibitors and also have antioxidant activity, blocked IGF-1R downregulation and apoptosis as well as reactive oxygen species (ROS) production.	Masoprocol	0-25	insulin like growth factor 1 receptor	Homo sapiens	128-134
16000313-7	2005	A LOX inhibitor, nordihydroguaiaretic acid, attenuated production of 15(S)-HETE and inhibited the phosphorylation of p38 MAPK following exposure to arachidonic acid.	Masoprocol	17-42	lysyl oxidase	Homo sapiens	2-5
16000313-7	2005	A LOX inhibitor, nordihydroguaiaretic acid, attenuated production of 15(S)-HETE and inhibited the phosphorylation of p38 MAPK following exposure to arachidonic acid.	Masoprocol	17-42	mitogen-activated protein kinase 14	Homo sapiens	117-125
16105230-9	2005	Both the ethanolic extract and nordihydroguaiaretic acid had cholestatic effects in the perfused liver, with an EC50 of 34 and 28 mg dL-1, respectively, when perfused for 10 min.	Masoprocol	31-56	l(1)L1	Drosophila melanogaster	133-137
15779087-4	2005	In addition, the inhibition of LO by nordihydroguaiaretic acid (NDGA; general LO inhibitor) or MK886 (5-LO inhibitor), but not baicalein (12-LO inhibitor), completely abrogated the LPS-induced iNOS expression.	Masoprocol	64-68	nitric oxide synthase 2	Homo sapiens	193-197
15943902-4	2005	The TNFR1 response was inhibited by D609, bromophenacyl bromide (BPB), nordihydroguararetic acid (NDGA), and by sodium salicylate, while TNFR2-mediated activation of NFkappaB and CMV promoter-enhancer was resistant to these compounds.	Masoprocol	98-102	TNF receptor superfamily member 1A	Homo sapiens	4-9
15781239-2	2005	We reported previously that nordihydroguaiaretic acid (NDGA) and wine-related polyphenol, myricetin (Myr), inhibit fAbeta formation from Abeta and destabilize preformed fAbeta in vitro.	Masoprocol	28-53	FA complementation group B	Homo sapiens	115-121
15781239-2	2005	We reported previously that nordihydroguaiaretic acid (NDGA) and wine-related polyphenol, myricetin (Myr), inhibit fAbeta formation from Abeta and destabilize preformed fAbeta in vitro.	Masoprocol	28-53	FA complementation group B	Homo sapiens	169-175
15781239-2	2005	We reported previously that nordihydroguaiaretic acid (NDGA) and wine-related polyphenol, myricetin (Myr), inhibit fAbeta formation from Abeta and destabilize preformed fAbeta in vitro.	Masoprocol	55-59	FA complementation group B	Homo sapiens	115-121
15781239-2	2005	We reported previously that nordihydroguaiaretic acid (NDGA) and wine-related polyphenol, myricetin (Myr), inhibit fAbeta formation from Abeta and destabilize preformed fAbeta in vitro.	Masoprocol	55-59	FA complementation group B	Homo sapiens	169-175
14557274-6	2004	Moreover, treatment of colon cells with certain diet-associated constituents, curcumin and nordihydroguaiaretic acid, reversibly targets UGTs causing inhibition without affecting protein levels; there is no direct inhibition of control UGT using curcumin as substrate in the in vitro assay.	Masoprocol	91-116	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	137-140
15695019-5	2005	On the other hand, inhibition of lipoxgenase (LPX) by 30 micromol/l nordihydroguaiaretic acid (NDGA) and the cytochrome P-450 (CYP) pathway by 100 micromol/l of metyrapone decreased TNF-alpha below normal levels as well.	Masoprocol	95-99	tumor necrosis factor	Rattus norvegicus	182-191
15389564-1	2005	Addition of nordihydroguaiaretic acid (NDGA) to the differentiation medium of C2C12 mouse myoblast cells caused severe inhibition of the formation of myotubes and suppressed differentiation-dependent elevation in the levels of the creatine kinase M isozyme (CKM).	Masoprocol	12-37	creatine kinase, muscle	Mus musculus	258-261
15389564-1	2005	Addition of nordihydroguaiaretic acid (NDGA) to the differentiation medium of C2C12 mouse myoblast cells caused severe inhibition of the formation of myotubes and suppressed differentiation-dependent elevation in the levels of the creatine kinase M isozyme (CKM).	Masoprocol	39-43	creatine kinase, muscle	Mus musculus	258-261
15522818-4	2004	In an attempt to identify a set of 12/15-LOX-regulated genes, the cDNA subtraction technique, followed by Northern blotting, was performed to screen particular clones, the expression of which was suppressed by the LOX inhibitor nordihydroguaiaretic acid (NDGA).	Masoprocol	228-253	lysyl oxidase	Rattus norvegicus	41-44
15522818-4	2004	In an attempt to identify a set of 12/15-LOX-regulated genes, the cDNA subtraction technique, followed by Northern blotting, was performed to screen particular clones, the expression of which was suppressed by the LOX inhibitor nordihydroguaiaretic acid (NDGA).	Masoprocol	228-253	lysyl oxidase	Rattus norvegicus	214-217
15522818-4	2004	In an attempt to identify a set of 12/15-LOX-regulated genes, the cDNA subtraction technique, followed by Northern blotting, was performed to screen particular clones, the expression of which was suppressed by the LOX inhibitor nordihydroguaiaretic acid (NDGA).	Masoprocol	255-259	lysyl oxidase	Rattus norvegicus	41-44
15522818-4	2004	In an attempt to identify a set of 12/15-LOX-regulated genes, the cDNA subtraction technique, followed by Northern blotting, was performed to screen particular clones, the expression of which was suppressed by the LOX inhibitor nordihydroguaiaretic acid (NDGA).	Masoprocol	255-259	lysyl oxidase	Rattus norvegicus	214-217
15379894-0	2004	The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice.	Masoprocol	46-71	tumor necrosis factor	Mus musculus	81-108
15379894-0	2004	The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice.	Masoprocol	46-71	superoxide dismutase 1, soluble	Mus musculus	162-166
15135918-7	2004	Quinacrine and nordihydroguaiaretic acid, a PLA(2) and an LO inhibitor, respectively, blocked the histamine-induced Ca(2+) influx in sensory neurons, while indomethacin (a cyclooxygenase inhibitor) did not.	Masoprocol	15-40	phospholipase A2 group IB	Rattus norvegicus	44-50
15132836-5	2004	RESULTS: 5-Lipoxygenase inhibitors nordihydroguaiaretic acid, AA861 and MK886, could suppress the expression of ICAM-1 protein as well as of its mRNA in a375 cells and reduce the adhesion of a375 to EC304.	Masoprocol	35-60	arachidonate 5-lipoxygenase	Homo sapiens	9-23
15132836-5	2004	RESULTS: 5-Lipoxygenase inhibitors nordihydroguaiaretic acid, AA861 and MK886, could suppress the expression of ICAM-1 protein as well as of its mRNA in a375 cells and reduce the adhesion of a375 to EC304.	Masoprocol	35-60	intercellular adhesion molecule 1	Homo sapiens	112-118
15694390-0	2005	Nordihydroguaiaretic acid inhibits IFN-gamma-induced STAT tyrosine phosphorylation in rat brain astrocytes.	Masoprocol	0-25	interferon gamma	Rattus norvegicus	35-44
15694390-3	2005	In this study, we found that nordihydroguaiaretic acid (NDGA), a well-known lipoxygenase (LO) inhibitor, suppressed IFN-gamma-induced inflammatory responses in brain astrocytes.	Masoprocol	29-54	interferon gamma	Rattus norvegicus	116-125
15694390-3	2005	In this study, we found that nordihydroguaiaretic acid (NDGA), a well-known lipoxygenase (LO) inhibitor, suppressed IFN-gamma-induced inflammatory responses in brain astrocytes.	Masoprocol	56-60	interferon gamma	Rattus norvegicus	116-125
15388505-6	2005	Indomethacin-resistant relaxations were further reduced by the lipoxygenase inhibitors cinnamyl-3,4-dihydroxy-cyanocinnamate (CDC; 1 muM), nordihydroguaiaretic acid (NDGA; 1 microM), and ebselen (1 microM).	Masoprocol	139-164	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	63-75
15388505-6	2005	Indomethacin-resistant relaxations were further reduced by the lipoxygenase inhibitors cinnamyl-3,4-dihydroxy-cyanocinnamate (CDC; 1 muM), nordihydroguaiaretic acid (NDGA; 1 microM), and ebselen (1 microM).	Masoprocol	166-170	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	63-75
15084746-9	2004	Furthermore, the arachidonate-induced up-regulation of PECAM-1 was abrogated by indomethacin [a cyclooxygenase (COX)-1 and -2 inhibitor] or N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide (a COX-2 inhibitor) but not nordihydroguaiaretic acid (a lipoxygenase inhibitor).	Masoprocol	223-248	platelet and endothelial cell adhesion molecule 1	Homo sapiens	55-62
14709335-6	2004	Antioxidants and activating protein-1 transcription factor inhibitors, nordihydroguaiaretic acid and N-acetyl-L-cysteine (NAC) suppressed MMP and ADAM-TS4 genes.	Masoprocol	71-96	ADAM metallopeptidase with thrombospondin type 1 motif 4	Bos taurus	146-154
15034932-11	2004	When the cells were treated with NDGA or SP600125 in the presence of antisense c-myc oligonucleotides, apoptosis was not observed and an increase of c-myc, p53, and bax proteins was not manifested.	Masoprocol	33-37	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	79-84
15034932-11	2004	When the cells were treated with NDGA or SP600125 in the presence of antisense c-myc oligonucleotides, apoptosis was not observed and an increase of c-myc, p53, and bax proteins was not manifested.	Masoprocol	33-37	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	149-154
15034932-11	2004	When the cells were treated with NDGA or SP600125 in the presence of antisense c-myc oligonucleotides, apoptosis was not observed and an increase of c-myc, p53, and bax proteins was not manifested.	Masoprocol	33-37	tumor protein p53	Homo sapiens	156-159
15034932-11	2004	When the cells were treated with NDGA or SP600125 in the presence of antisense c-myc oligonucleotides, apoptosis was not observed and an increase of c-myc, p53, and bax proteins was not manifested.	Masoprocol	33-37	BCL2 associated X, apoptosis regulator	Homo sapiens	165-168
12878172-6	2003	Inhibitors of the transcription factors AP-1 (nordihydroguaiaretic acid, NDGA) and NF-kappaB (curcumin, proteasome inhibitors, and Bay-11-7085) suppressed TNF-alpha-induced MMP-13 expression in primary chondrocytes and SW1353 cells.	Masoprocol	46-71	tumor necrosis factor	Homo sapiens	155-164
15165036-5	2004	NaBT-induced p21 (Cip/WAF 1) expression was enhanced by treatment with NDGA and 13-S-HODE reversed NaBT-induced p21 (Cip/WAF 1) expression in Caco-2 cells.	Masoprocol	71-75	cyclin dependent kinase inhibitor 1A	Homo sapiens	13-16
15165036-5	2004	NaBT-induced p21 (Cip/WAF 1) expression was enhanced by treatment with NDGA and 13-S-HODE reversed NaBT-induced p21 (Cip/WAF 1) expression in Caco-2 cells.	Masoprocol	71-75	muscular LMNA interacting protein	Homo sapiens	18-21
15165036-5	2004	NaBT-induced p21 (Cip/WAF 1) expression was enhanced by treatment with NDGA and 13-S-HODE reversed NaBT-induced p21 (Cip/WAF 1) expression in Caco-2 cells.	Masoprocol	71-75	cyclin dependent kinase inhibitor 1A	Homo sapiens	22-27
15165036-5	2004	NaBT-induced p21 (Cip/WAF 1) expression was enhanced by treatment with NDGA and 13-S-HODE reversed NaBT-induced p21 (Cip/WAF 1) expression in Caco-2 cells.	Masoprocol	71-75	cyclin dependent kinase inhibitor 1A	Homo sapiens	112-115
15165036-5	2004	NaBT-induced p21 (Cip/WAF 1) expression was enhanced by treatment with NDGA and 13-S-HODE reversed NaBT-induced p21 (Cip/WAF 1) expression in Caco-2 cells.	Masoprocol	71-75	muscular LMNA interacting protein	Homo sapiens	117-120
15165036-5	2004	NaBT-induced p21 (Cip/WAF 1) expression was enhanced by treatment with NDGA and 13-S-HODE reversed NaBT-induced p21 (Cip/WAF 1) expression in Caco-2 cells.	Masoprocol	71-75	cyclin dependent kinase inhibitor 1A	Homo sapiens	121-126
15034932-2	2004	The natural product, nordihydroguaiaretic acid (NDGA) shows an inhibitory effect on the binding of jun/AP-1 protein to the AP-1 site in 12-O-tetradecanoylphorbol-13-acetate (TPA)-stimulated HL60 cells.	Masoprocol	21-46	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	103-107
15034932-2	2004	The natural product, nordihydroguaiaretic acid (NDGA) shows an inhibitory effect on the binding of jun/AP-1 protein to the AP-1 site in 12-O-tetradecanoylphorbol-13-acetate (TPA)-stimulated HL60 cells.	Masoprocol	21-46	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	123-127
15034932-2	2004	The natural product, nordihydroguaiaretic acid (NDGA) shows an inhibitory effect on the binding of jun/AP-1 protein to the AP-1 site in 12-O-tetradecanoylphorbol-13-acetate (TPA)-stimulated HL60 cells.	Masoprocol	48-52	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	103-107
15034932-2	2004	The natural product, nordihydroguaiaretic acid (NDGA) shows an inhibitory effect on the binding of jun/AP-1 protein to the AP-1 site in 12-O-tetradecanoylphorbol-13-acetate (TPA)-stimulated HL60 cells.	Masoprocol	48-52	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	123-127
15199606-6	2004	Moreover, not even one of the drugs caused the specific cleavage of poly (ADP-ribose) polymerase to the 89-kDa fragment, however, a decrease in total amount of this protein was observed after treatment with NDGA and esculetin.	Masoprocol	207-211	poly (ADP-ribose) polymerase family, member 1	Mus musculus	68-96
18320708-5	2003	We show that adipocyte differentiation of 3T3-L1 preadipocytes is inhibited by the general LOX inhibitor NDGA (nordihydroguaiaretic acid) and the 12/15-LOX selective inhibitor baicalein.	Masoprocol	105-109	lysyl oxidase	Mus musculus	91-94
18320708-5	2003	We show that adipocyte differentiation of 3T3-L1 preadipocytes is inhibited by the general LOX inhibitor NDGA (nordihydroguaiaretic acid) and the 12/15-LOX selective inhibitor baicalein.	Masoprocol	111-136	lysyl oxidase	Mus musculus	91-94
14499634-0	2003	Nordihydroguaiaretic acid, an antioxidant, inhibits transforming growth factor-beta activity through the inhibition of Smad signaling pathway.	Masoprocol	0-25	transforming growth factor beta 1	Homo sapiens	52-83
14499634-5	2003	Among the examined compounds, we found nordihydroguaiaretic acid (NDGA) has a unique and strong inhibitory effect on various TGF-beta activities.	Masoprocol	39-64	transforming growth factor beta 1	Homo sapiens	125-133
14499634-5	2003	Among the examined compounds, we found nordihydroguaiaretic acid (NDGA) has a unique and strong inhibitory effect on various TGF-beta activities.	Masoprocol	66-70	transforming growth factor beta 1	Homo sapiens	125-133
12878172-6	2003	Inhibitors of the transcription factors AP-1 (nordihydroguaiaretic acid, NDGA) and NF-kappaB (curcumin, proteasome inhibitors, and Bay-11-7085) suppressed TNF-alpha-induced MMP-13 expression in primary chondrocytes and SW1353 cells.	Masoprocol	46-71	matrix metallopeptidase 13	Homo sapiens	173-179
12878172-6	2003	Inhibitors of the transcription factors AP-1 (nordihydroguaiaretic acid, NDGA) and NF-kappaB (curcumin, proteasome inhibitors, and Bay-11-7085) suppressed TNF-alpha-induced MMP-13 expression in primary chondrocytes and SW1353 cells.	Masoprocol	73-77	tumor necrosis factor	Homo sapiens	155-164
12517954-5	2003	Moreover, pretreatment of cells with nordihydroguaiaretic acid, a 15-lipoxygenase inhibitor, prevented PPARgamma activation and apoptosis.	Masoprocol	37-62	arachidonate 15-lipoxygenase	Homo sapiens	66-81
12565196-1	2003	MK886, an inhibitor of 5-lipoxygenase activating protein (FLAP), and the lipoxygenase (LOX) inhibitors baicalein and nordihydroguaiaretic acid (NDGA), induce apoptosis by mechanisms independent of both LOX and FLAP.	Masoprocol	117-142	arachidonate 5-lipoxygenase activating protein	Mus musculus	210-214
12565196-1	2003	MK886, an inhibitor of 5-lipoxygenase activating protein (FLAP), and the lipoxygenase (LOX) inhibitors baicalein and nordihydroguaiaretic acid (NDGA), induce apoptosis by mechanisms independent of both LOX and FLAP.	Masoprocol	144-148	arachidonate 5-lipoxygenase activating protein	Mus musculus	210-214
12565196-4	2003	MK886, baicalein, and NDGA significantly enhanced the release of [3H]-AA two to threefold within 2 h and induced apoptosis by 8 h. Neither MK886-induced AA release, nor apoptosis were affected by quinacrine, a phospholipase A2 inhibitor.	Masoprocol	22-26	phospholipase A2, group IB, pancreas	Mus musculus	210-226
12582831-2	2003	Epinephrine hyperalgesia and that induced by a selective activator of PKCepsilon, psiepsilonRACK, were inhibited by nordihydroguaretic acid (NDGA, non-selective lipoxygenase inhibitor), baicalein (BAIC, 12-lipoxygenase inhibitor) and 5, 6-dehydroarachidonic acid (5, 6-dhAA, 5-lipoxygenase inhibitor).	Masoprocol	116-139	protein kinase C, epsilon	Rattus norvegicus	70-80
12582831-2	2003	Epinephrine hyperalgesia and that induced by a selective activator of PKCepsilon, psiepsilonRACK, were inhibited by nordihydroguaretic acid (NDGA, non-selective lipoxygenase inhibitor), baicalein (BAIC, 12-lipoxygenase inhibitor) and 5, 6-dehydroarachidonic acid (5, 6-dhAA, 5-lipoxygenase inhibitor).	Masoprocol	116-139	arachidonate 5-lipoxygenase	Rattus norvegicus	275-289
12582831-2	2003	Epinephrine hyperalgesia and that induced by a selective activator of PKCepsilon, psiepsilonRACK, were inhibited by nordihydroguaretic acid (NDGA, non-selective lipoxygenase inhibitor), baicalein (BAIC, 12-lipoxygenase inhibitor) and 5, 6-dehydroarachidonic acid (5, 6-dhAA, 5-lipoxygenase inhibitor).	Masoprocol	141-145	protein kinase C, epsilon	Rattus norvegicus	70-80
12582831-2	2003	Epinephrine hyperalgesia and that induced by a selective activator of PKCepsilon, psiepsilonRACK, were inhibited by nordihydroguaretic acid (NDGA, non-selective lipoxygenase inhibitor), baicalein (BAIC, 12-lipoxygenase inhibitor) and 5, 6-dehydroarachidonic acid (5, 6-dhAA, 5-lipoxygenase inhibitor).	Masoprocol	141-145	arachidonate 5-lipoxygenase	Rattus norvegicus	275-289
12582831-3	2003	NDGA and 5, 6-dhAA inhibited the hyperalgesia associated with activation of the protein kinase A pathway, elicited by the direct-acting hyperalgesic agent prostaglandin E(2) or by the catalytic subunit of protein kinase A.	Masoprocol	0-4	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	80-96
12582831-3	2003	NDGA and 5, 6-dhAA inhibited the hyperalgesia associated with activation of the protein kinase A pathway, elicited by the direct-acting hyperalgesic agent prostaglandin E(2) or by the catalytic subunit of protein kinase A.	Masoprocol	0-4	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	205-221
12627879-5	2003	Nordihydroguaiaretic acid (NDGA, 1 to 10 micromol/l), the LOX inhibitor, also reduced IL-1beta (10 ng/ml)-stimulated nitrite production and iNOS expression in a dose-dependent manner.	Masoprocol	0-25	interleukin 1 beta	Homo sapiens	86-94
12627879-5	2003	Nordihydroguaiaretic acid (NDGA, 1 to 10 micromol/l), the LOX inhibitor, also reduced IL-1beta (10 ng/ml)-stimulated nitrite production and iNOS expression in a dose-dependent manner.	Masoprocol	0-25	nitric oxide synthase 2	Homo sapiens	140-144
12627879-5	2003	Nordihydroguaiaretic acid (NDGA, 1 to 10 micromol/l), the LOX inhibitor, also reduced IL-1beta (10 ng/ml)-stimulated nitrite production and iNOS expression in a dose-dependent manner.	Masoprocol	27-31	interleukin 1 beta	Homo sapiens	86-94
12627879-5	2003	Nordihydroguaiaretic acid (NDGA, 1 to 10 micromol/l), the LOX inhibitor, also reduced IL-1beta (10 ng/ml)-stimulated nitrite production and iNOS expression in a dose-dependent manner.	Masoprocol	27-31	nitric oxide synthase 2	Homo sapiens	140-144
12517954-5	2003	Moreover, pretreatment of cells with nordihydroguaiaretic acid, a 15-lipoxygenase inhibitor, prevented PPARgamma activation and apoptosis.	Masoprocol	37-62	peroxisome proliferator activated receptor gamma	Homo sapiens	103-112
12544727-4	2003	LPS-induced TF activity was inhibited by the lipoxygenase inhibitors nordihydroguaiaretic acid, CGS 23885 and ZM 230487, by 59, 32 and 88%, respectively.	Masoprocol	69-94	coagulation factor III, tissue factor	Homo sapiens	12-14
12531534-2	2002	Using primary cortical neurons, we show that nordihydroguaiaretic acid (NDGA) and brefeldin A (BFA), two ER stressors, induce early ER stress as shown by Western blotting of the eukaryotic initiation factor-2alpha (eIF2alpha), an ER stress marker.	Masoprocol	45-70	eukaryotic translation initiation factor 2A	Homo sapiens	215-224
12531534-2	2002	Using primary cortical neurons, we show that nordihydroguaiaretic acid (NDGA) and brefeldin A (BFA), two ER stressors, induce early ER stress as shown by Western blotting of the eukaryotic initiation factor-2alpha (eIF2alpha), an ER stress marker.	Masoprocol	72-76	eukaryotic translation initiation factor 2A	Homo sapiens	215-224
12384249-10	2002	The fall in TEER from bradykinin was blocked by HOE 140, U73122 and thapsigargin combined with La(3+), and also by aristolochic acid and NDGA, but not indomethacin, calphostin C or L-NAME.	Masoprocol	137-141	kininogen 1	Homo sapiens	22-32
12359096-0	2002	Effect of nordihydroguaiaretic acid on the secretion of lipoprotein lipase.	Masoprocol	10-35	lipoprotein lipase	Homo sapiens	56-74
12359096-2	2002	In this study, the effect of NDGA on lipoprotein lipase (LPL) secretion was investigated in 3T3-L1 adipocytes, and compared with those of brefeldin A (BFA), a well-known fungal metabolite that exhibits similar ER-Golgi redistribution.	Masoprocol	29-33	lipoprotein lipase	Homo sapiens	37-55
12359096-2	2002	In this study, the effect of NDGA on lipoprotein lipase (LPL) secretion was investigated in 3T3-L1 adipocytes, and compared with those of brefeldin A (BFA), a well-known fungal metabolite that exhibits similar ER-Golgi redistribution.	Masoprocol	29-33	lipoprotein lipase	Homo sapiens	57-60
11554738-3	2001	Similar effects were produced by conjugated nonadecadienoic acid (a 19-carbon CLA cognate that is more effective than CLA in reducing body fat gain in mice), the lipoxygenase inhibitor nordihydroguaiaretic acid (which is synergistic with CLA in reducing body fat gain in mice), and ciglitazone (TZD, a PPARgamma agonist).	Masoprocol	185-210	peroxisome proliferator activated receptor gamma	Mus musculus	302-311
12481414-4	2002	Apoptosis of pancreatic cancer cells induced by LOX inhibitors (including the nonselective LOX inhibitor nordihydroguaiaretic acid, the 5-LOX inhibitor Rev-5901, and the 12-LOX inhibitor baicalein) was confirmed by growth inhibition, annexin V binding, and terminal deoxynucleotidyl transferase-mediated nick end labeling assay in MiaPaCa-2 and AsPC-1 human pancreatic cancer cells.	Masoprocol	105-130	arachidonate 5-lipoxygenase	Homo sapiens	48-51
12079849-4	2002	Exposure of cardiomyocytes to esculetin or NDGA, two structurally different LO inhibitors, induced a complete inhibition of insulin-stimulated glucose uptake, whereas control cells showed a threefold stimulation by insulin.	Masoprocol	43-47	insulin	Homo sapiens	124-131
12079849-4	2002	Exposure of cardiomyocytes to esculetin or NDGA, two structurally different LO inhibitors, induced a complete inhibition of insulin-stimulated glucose uptake, whereas control cells showed a threefold stimulation by insulin.	Masoprocol	43-47	insulin	Homo sapiens	215-222
12065652-2	2002	We previously reported that nordihydroguaiaretic acid (NDGA) inhibited fAbeta formation from Abeta(1-40) and Abeta(1-42) dose-dependently in the range of 10-30 micromin vitro.	Masoprocol	28-53	FA complementation group B	Homo sapiens	71-77
12065652-2	2002	We previously reported that nordihydroguaiaretic acid (NDGA) inhibited fAbeta formation from Abeta(1-40) and Abeta(1-42) dose-dependently in the range of 10-30 micromin vitro.	Masoprocol	55-59	FA complementation group B	Homo sapiens	71-77
11747364-16	2001	The lipoxygenase inhibitor NDGA significantly reduced the number of migrating cells in cultures with no other supplements, or of those supplemented with either PMA or FGF-2.	Masoprocol	27-31	fibroblast growth factor 2	Bos taurus	167-172
12131928-3	2002	In addition, the basal levels of PRL secretion were decreased by the blockade of cyclooxygenase or lipoxygenase pathways, with indomethacin and nordihydroguaiaretic acid (NDGA), respectively.	Masoprocol	144-169	prolactin	Rattus norvegicus	33-36
12131928-3	2002	In addition, the basal levels of PRL secretion were decreased by the blockade of cyclooxygenase or lipoxygenase pathways, with indomethacin and nordihydroguaiaretic acid (NDGA), respectively.	Masoprocol	171-175	prolactin	Rattus norvegicus	33-36
12112316-9	2002	In addition, NDGA was found to inhibit activity of phosphatidylinositol 3-kinase (PI 3-kinase), a UVB-inducible enzyme that contributes to the induced expression of c-fos and AP-1.	Masoprocol	13-17	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	165-170
11953870-2	2002	Here we demonstrate that the 5-lipoxygenase inhibitor nordihydroguaiaretic acid potently inhibits anchorage-independent growth of human pancreatic and cervical cancer cells in soft agar and delays growth of pancreatic and cervical tumours established in athymic mice.	Masoprocol	54-79	arachidonate 5-lipoxygenase	Homo sapiens	29-43
11953870-6	2002	In addition, treatment with nordihydroguaiaretic acid lead to a disruption of the filamentous actin cytoskeleton in human pancreatic and cervical cancer cells which was accompanied by the activation of Jun-NH(2)-terminal kinase and p38(mapk).	Masoprocol	28-53	mitogen-activated protein kinase 14	Homo sapiens	232-235
11318430-1	2001	Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.	Masoprocol	0-25	arachidonate 5-lipoxygenase	Mus musculus	64-78
11470254-3	2001	Incubation of HL-60 cells with nordihydroguaiaretic acid resulted in apoptosis and it was characterised by mitochondria membrane depolarisation, release of cytochrome c from mitochondria into cytosol and activation of caspase-3.	Masoprocol	31-56	cytochrome c, somatic	Homo sapiens	156-168
11470254-3	2001	Incubation of HL-60 cells with nordihydroguaiaretic acid resulted in apoptosis and it was characterised by mitochondria membrane depolarisation, release of cytochrome c from mitochondria into cytosol and activation of caspase-3.	Masoprocol	31-56	caspase 3	Homo sapiens	218-227
11470254-4	2001	Indomethacin and nordihydroguaiaretic acid synergistically potentiated TNF-alpha-induced apoptosis, while arachidonic acid, AACOCF3 and MK-886 did not modulate its effects.	Masoprocol	17-42	tumor necrosis factor	Homo sapiens	71-80
11429387-8	2001	Antioxidants such as butylated hydroxytoluene (BHT), nordihydroguaiaretic acid (NDGA), or dimethylurea exhibited an only minimal inhibitory effect on 8-epi-PGF(2alpha) synthesis.	Masoprocol	53-78	placental growth factor	Rattus norvegicus	156-159
11429387-8	2001	Antioxidants such as butylated hydroxytoluene (BHT), nordihydroguaiaretic acid (NDGA), or dimethylurea exhibited an only minimal inhibitory effect on 8-epi-PGF(2alpha) synthesis.	Masoprocol	80-84	placental growth factor	Rattus norvegicus	156-159
11550224-7	2001	PrP106-126 neurotoxicity was mediated through the 5-lipoxygenase (5-LOX) pathway, as shown by abrogation of neuronal death with the 5-LOX inhibitors quinacrine, nordihydroguaiaretic acid, and caffeic acid.	Masoprocol	161-186	arachidonate 5-lipoxygenase	Homo sapiens	66-71
11605467-4	2001	Tests with inhibitors having different chemical structures revealed that the lipoxygenase activity from Mortierella cells was inhibited only by esculetin, ethanol and nordihydroguaiaretic acid (NDGA).	Masoprocol	167-192	linoleate 9S-lipoxygenase4	Zea mays	77-89
11605467-4	2001	Tests with inhibitors having different chemical structures revealed that the lipoxygenase activity from Mortierella cells was inhibited only by esculetin, ethanol and nordihydroguaiaretic acid (NDGA).	Masoprocol	194-198	linoleate 9S-lipoxygenase4	Zea mays	77-89
11318430-1	2001	Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.	Masoprocol	0-25	ornithine decarboxylase, structural 1	Mus musculus	83-106
11318430-1	2001	Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.	Masoprocol	27-31	arachidonate 5-lipoxygenase	Mus musculus	64-78
11318430-1	2001	Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.	Masoprocol	27-31	ornithine decarboxylase, structural 1	Mus musculus	83-106
11339632-11	2001	The blockade of cytochrome c release by NDGA was much more effective than that attained with cyclosporin A (CsA), a MPT inhibitor.	Masoprocol	40-44	cytochrome c, somatic	Homo sapiens	16-28
11388491-0	2001	Co-existing proteins interfere with the action of nordihydroguaiaretic acid on retrograde Golgi-to-ER protein trafficking in NRK cells and alpha-glucosidase reaction in vitro.	Masoprocol	50-75	sucrase-isomaltase	Homo sapiens	139-156
11388491-1	2001	Induction of retrograde trafficking of mannosidase II and TGN38 in NRK cells and inhibition of alpha-glucosidase in vitro by nordihydroguaiaretic acid (NDGA) were strongly interfered with by serum, serum albumin, or other unrelated proteins added to the medium or incubation mixture.	Masoprocol	125-150	sucrase-isomaltase	Homo sapiens	95-112
11388491-1	2001	Induction of retrograde trafficking of mannosidase II and TGN38 in NRK cells and inhibition of alpha-glucosidase in vitro by nordihydroguaiaretic acid (NDGA) were strongly interfered with by serum, serum albumin, or other unrelated proteins added to the medium or incubation mixture.	Masoprocol	152-156	sucrase-isomaltase	Homo sapiens	95-112
10841042-5	2000	Nordihydroguaiaretic acid, a lipoxygenase inhibitor, significantly amplified the arsenite-induced IL-6 synthesis.	Masoprocol	0-25	interleukin 6	Mus musculus	98-102
11168395-8	2001	Nordihydroguaiaretic acid (NDGA), momordin I, natural product inhibitors of the fos-jun/DNA complex formation, was applied to this jun-GST-fused fos system and it was found to decrease the apparent equilibrium binding of dimer and DNA.	Masoprocol	0-25	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	80-83
11168395-8	2001	Nordihydroguaiaretic acid (NDGA), momordin I, natural product inhibitors of the fos-jun/DNA complex formation, was applied to this jun-GST-fused fos system and it was found to decrease the apparent equilibrium binding of dimer and DNA.	Masoprocol	0-25	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	145-148
10950827-0	2000	Masoprocol decreases rat lipolytic activity by decreasing the phosphorylation of HSL.	Masoprocol	0-10	lipase E, hormone sensitive type	Rattus norvegicus	81-84
10950827-2	2000	The present study was initiated to test the hypothesis that the decrease in lipolytic activity by masoprocol resulted from modulation of adipose tissue hormone-sensitive lipase (HSL) activity.	Masoprocol	98-108	lipase E, hormone sensitive type	Rattus norvegicus	152-176
10950827-2	2000	The present study was initiated to test the hypothesis that the decrease in lipolytic activity by masoprocol resulted from modulation of adipose tissue hormone-sensitive lipase (HSL) activity.	Masoprocol	98-108	lipase E, hormone sensitive type	Rattus norvegicus	178-181
10950827-7	2000	The results of these in vitro and in vivo experiments suggest that the antilipolytic activity of masoprocol is secondary to its ability to inhibit HSL phosphorylation, possibly by increasing phosphatase activity.	Masoprocol	97-107	lipase E, hormone sensitive type	Rattus norvegicus	147-150
10873159-7	2000	Release of IL-6 elicited by TNF-alpha was significantly inhibited by dexamethasone, cycloheximide, and nordihydroguaiaretic acid (NDGA).	Masoprocol	103-128	interleukin 6	Homo sapiens	11-15
10873159-7	2000	Release of IL-6 elicited by TNF-alpha was significantly inhibited by dexamethasone, cycloheximide, and nordihydroguaiaretic acid (NDGA).	Masoprocol	103-128	tumor necrosis factor	Homo sapiens	28-37
10873159-7	2000	Release of IL-6 elicited by TNF-alpha was significantly inhibited by dexamethasone, cycloheximide, and nordihydroguaiaretic acid (NDGA).	Masoprocol	130-134	interleukin 6	Homo sapiens	11-15
10873159-7	2000	Release of IL-6 elicited by TNF-alpha was significantly inhibited by dexamethasone, cycloheximide, and nordihydroguaiaretic acid (NDGA).	Masoprocol	130-134	tumor necrosis factor	Homo sapiens	28-37
11035536-10	2000	NDGA selectively inhibited LOX activity without affecting COX activity.	Masoprocol	0-4	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	27-30
10826917-8	2000	Other MPO systems inactivating LADH were (a) MPO/H2O2/chlorpromazine; (b) MPO/H2O2/monophenolic systems, including L-tyrosine, serotonin and acetaminophen and (c) MPO/H2O2/di- and polyphenolic systems, including norepinephrine, catechol, nordihydroguaiaretic acid, caffeic acid, quercetin and catechin.	Masoprocol	238-263	myeloperoxidase	Sus scrofa	6-9
11139472-4	2001	The selective CYP 2C9 inhibitor sulfaphenazole and the superoxide anion (O(2-)) scavengers Tiron and nordihydroguaretic acid also induced a leftward shift in the NO-mediated concentration-relaxation curve to bradykinin.	Masoprocol	101-124	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	14-21
11139472-4	2001	The selective CYP 2C9 inhibitor sulfaphenazole and the superoxide anion (O(2-)) scavengers Tiron and nordihydroguaretic acid also induced a leftward shift in the NO-mediated concentration-relaxation curve to bradykinin.	Masoprocol	101-124	kininogen 1	Homo sapiens	208-218
11115572-8	2001	Kinase inhibitors, quercetin and NDGA were found to block signals for the perinuclear accumulation of Cdc42.	Masoprocol	33-37	cell division cycle 42	Homo sapiens	102-107
11016888-7	2000	In addition adipose tissue lipoprotein lipase (LPL) activity was increased in masoprocol-treated rats and adipose tissue hormone-sensitive lipase (HSL) activity was decreased.	Masoprocol	78-88	lipoprotein lipase	Rattus norvegicus	27-45
11016888-7	2000	In addition adipose tissue lipoprotein lipase (LPL) activity was increased in masoprocol-treated rats and adipose tissue hormone-sensitive lipase (HSL) activity was decreased.	Masoprocol	78-88	lipoprotein lipase	Rattus norvegicus	47-50
10923789-7	2000	LeHPL activity is reversibly inhibited by nordihydroguaiaretic acid, while salicylic acid irreversibly inhibited it.	Masoprocol	42-67	fatty acid hydroperoxide lyase, chloroplastic	Solanum lycopersicum	0-5
10692565-6	2000	AP-1 and NF-kappaB activation were blocked by the thiol antioxidant N-acetylcysteine and by nordihydroguaiaretic acid, an antioxidant and lipooxygenase inhibitor and an inhibitor of the epoxygenase activity of CYP1A1, and did not take place in c35, c37, or in Ah nuclear translator-deficient c4 cells.	Masoprocol	92-117	jun proto-oncogene	Mus musculus	0-4
10692565-6	2000	AP-1 and NF-kappaB activation were blocked by the thiol antioxidant N-acetylcysteine and by nordihydroguaiaretic acid, an antioxidant and lipooxygenase inhibitor and an inhibitor of the epoxygenase activity of CYP1A1, and did not take place in c35, c37, or in Ah nuclear translator-deficient c4 cells.	Masoprocol	92-117	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	210-216
10809172-12	2000	Pretreatment with 40 microM aristolochic acid to inhibit phospholipase A2 reduced 0.1 mM NDGA-induced Ca2+ release by 65%, but inhibiting phospholipase C with 2 microM U73122 had little effect.	Masoprocol	89-93	phospholipase A2 group IB	Canis lupus familiaris	57-73
10809172-13	2000	This suggests NDGA-induced Ca2+ release was independent of inositol 1,4,5-trisphosphate (IP3), but was modulated by phospholipase A2.	Masoprocol	14-18	phospholipase A2 group IB	Canis lupus familiaris	116-132
10698703-6	2000	Addition of 5-lipoxygenase products 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and leukotriene B(4), but not 5-hydroxyeicosatetraenoic acid (5-HETE) and leukotriene C(4), restored LPA-stimulated H(2)O(2) release in cells treated with the lipoxygenase inhibitors nordihydroguaiaretic acid and Zileuton.	Masoprocol	264-289	arachidonate 5-lipoxygenase	Homo sapiens	12-26
10803760-2	2000	Inhibitors of cyclooxygenase (indomethacin and diclofenac sodium) and lipoxygenase pathways (nordihydroguaiaretic acid, caffeic acid, and eicosapentaenoic acid) reduced H/R-induced LDH release in a dose-dependent manner, whereas an inhibitor of cytochrome P-450 monooxygenase pathway ethoxyresorufin was not effective.	Masoprocol	93-118	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	30-82
10653524-11	2000	Ac-DEVD-CHO (25 microM) and boc-asp-FMK (20 microM) both inhibited caspase-3 enzyme activity by 97% 8 h after NDGA treatment.	Masoprocol	110-114	caspase 3	Mus musculus	67-76
10692140-8	2000	In contrast, specific inhibition of the lipoxygenase system by nordihydroguaiaretic acid blocked IL-3 stimulated steroidogenesis while the effect of IL-6 was not affected.	Masoprocol	63-88	interleukin-3	Bos taurus	97-101
10680773-1	2000	Intrauterine administration of the 5-lipoxygenase inhibitor nordihydroguariaretic acid (NDGA; 5 mg, bid) on Days 9-14 of the ovine estrous cycle (estrus = Day 0) delayed luteolysis and extended the duration of the estrous cycle (20+/-1, SD, vs. 16+/-1 days; P < 0.01).	Masoprocol	88-92	arachidonate 5-lipoxygenase	Homo sapiens	35-49
10385691-0	1999	Modulation of expression of endothelial nitric oxide synthase by nordihydroguaiaretic acid, a phenolic antioxidant in cultured endothelial cells.	Masoprocol	65-90	nitric oxide synthase 3	Homo sapiens	28-61
10497175-8	1999	That 15(S)-lipoxygenase activity is of functional importance in garlic was shown by the inhibition of root growth by BW 755C, a dual cyclooxygenase/lipoxygenase inhibitor and nordihydroguaiaretic acid, a lipoxygenase inhibitor.	Masoprocol	175-200	arachidonate 15-lipoxygenase type B	Homo sapiens	5-23
10515420-4	1999	A high concentration of PLA2 (0.5 microg x mL(-1)) caused the muscle strips to contract, and this contractile response was significantly attenuated by pretreatment with indomethacin (IND; 10 microM), but not by nordihydroguaiaretic acid (NDGA; 10 microM).	Masoprocol	211-236	LOC104974671	Bos taurus	24-28
10515420-4	1999	A high concentration of PLA2 (0.5 microg x mL(-1)) caused the muscle strips to contract, and this contractile response was significantly attenuated by pretreatment with indomethacin (IND; 10 microM), but not by nordihydroguaiaretic acid (NDGA; 10 microM).	Masoprocol	238-242	LOC104974671	Bos taurus	24-28
11228745-7	1999	Attenuation of oxidase activation by inhibiting arachidonic acid metabolism with ETYA, NDGA, baicalein, or SKF-525A also inhibits angiotensin II-stimulated protein synthesis (74 +/- 2% and 34 +/- 1%, respectively).	Masoprocol	87-91	angiotensinogen	Homo sapiens	130-144
10385691-3	1999	We found that the antioxidants nordihydroguaiaretic acid (NDGA), catechol, glutaryl probucol, and N-acetylcysteine increased eNOS expression in cultured bovine aortic endothelial cells (BAECs).	Masoprocol	31-56	nitric oxide synthase 3	Bos taurus	125-129
10385691-3	1999	We found that the antioxidants nordihydroguaiaretic acid (NDGA), catechol, glutaryl probucol, and N-acetylcysteine increased eNOS expression in cultured bovine aortic endothelial cells (BAECs).	Masoprocol	58-62	nitric oxide synthase 3	Bos taurus	125-129
10385691-4	1999	NDGA seemed to be the most potent of the phenolic antioxidants, producing a 3-fold increase in eNOS mRNA.	Masoprocol	0-4	nitric oxide synthase 3	Homo sapiens	95-99
9675312-5	1998	Lipoxygenase inhibitors quercetin and nordihydroguiaretic acid inhibited GST-P-positive nodules but not cirrhosis or 8-OHdG.	Masoprocol	38-62	glutathione S-transferase pi 1	Rattus norvegicus	73-78
10667392-6	1999	Furthermore, combined treatment of aspirin and NDGA almost abolished the increase of alpha-naphthol-induced covalent binding, suggesting that PHS and LPO are both major pathways for xenobiotic activation in platelets.	Masoprocol	47-51	pterin-4 alpha-carbinolamine dehydratase 1	Homo sapiens	142-145
10208831-9	1999	These data confirm previous work using nordihydroguaiaretic acid and suggest that leukotrienes contribute to the angiotensin II-mediated potentiation of endothelin-1-evoked contractions.	Masoprocol	39-64	angiotensinogen	Homo sapiens	113-127
10208831-9	1999	These data confirm previous work using nordihydroguaiaretic acid and suggest that leukotrienes contribute to the angiotensin II-mediated potentiation of endothelin-1-evoked contractions.	Masoprocol	39-64	endothelin 1	Homo sapiens	153-165
9918822-0	1998	Dynamic recycling of ERGIC53 between the endoplasmic reticulum and the Golgi complex is disrupted by nordihydroguaiaretic acid.	Masoprocol	101-126	lectin, mannose binding 1	Homo sapiens	21-28
10203695-3	1998	Here, we report that caspase 8 and 3 activation, poly(ADP-ribose)polymerase cleavage and apoptosis are inhibited by the lipoxygenase inhibitor, nordihydroguaretic acid (NDGA), or ectopic expression of crm-A or bcl-2.	Masoprocol	144-167	caspase 8	Homo sapiens	21-30
10203695-3	1998	Here, we report that caspase 8 and 3 activation, poly(ADP-ribose)polymerase cleavage and apoptosis are inhibited by the lipoxygenase inhibitor, nordihydroguaretic acid (NDGA), or ectopic expression of crm-A or bcl-2.	Masoprocol	144-167	poly(ADP-ribose) polymerase 1	Homo sapiens	49-75
10203695-3	1998	Here, we report that caspase 8 and 3 activation, poly(ADP-ribose)polymerase cleavage and apoptosis are inhibited by the lipoxygenase inhibitor, nordihydroguaretic acid (NDGA), or ectopic expression of crm-A or bcl-2.	Masoprocol	144-167	BCL2 apoptosis regulator	Homo sapiens	210-215
10203695-3	1998	Here, we report that caspase 8 and 3 activation, poly(ADP-ribose)polymerase cleavage and apoptosis are inhibited by the lipoxygenase inhibitor, nordihydroguaretic acid (NDGA), or ectopic expression of crm-A or bcl-2.	Masoprocol	169-173	caspase 8	Homo sapiens	21-30
10203695-3	1998	Here, we report that caspase 8 and 3 activation, poly(ADP-ribose)polymerase cleavage and apoptosis are inhibited by the lipoxygenase inhibitor, nordihydroguaretic acid (NDGA), or ectopic expression of crm-A or bcl-2.	Masoprocol	169-173	poly(ADP-ribose) polymerase 1	Homo sapiens	49-75
10203695-3	1998	Here, we report that caspase 8 and 3 activation, poly(ADP-ribose)polymerase cleavage and apoptosis are inhibited by the lipoxygenase inhibitor, nordihydroguaretic acid (NDGA), or ectopic expression of crm-A or bcl-2.	Masoprocol	169-173	BCL2 apoptosis regulator	Homo sapiens	210-215
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	0-25	growth hormone 1	Homo sapiens	77-79
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	0-25	growth hormone secretagogue receptor	Homo sapiens	99-103
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	0-25	thyrotropin releasing hormone	Homo sapiens	105-108
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	0-25	growth hormone releasing hormone	Homo sapiens	110-114
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	0-25	thyrotropin releasing hormone	Homo sapiens	116-119
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	0-25	growth hormone releasing hormone	Homo sapiens	125-129
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	0-25	growth hormone secretagogue receptor	Homo sapiens	134-138
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	0-25	growth hormone releasing hormone	Homo sapiens	125-129
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	0-25	growth hormone 1	Homo sapiens	99-101
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	27-31	growth hormone 1	Homo sapiens	77-79
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	27-31	growth hormone secretagogue receptor	Homo sapiens	99-103
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	27-31	thyrotropin releasing hormone	Homo sapiens	105-108
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	27-31	growth hormone releasing hormone	Homo sapiens	110-114
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	27-31	thyrotropin releasing hormone	Homo sapiens	116-119
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	27-31	growth hormone releasing hormone	Homo sapiens	125-129
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	27-31	growth hormone secretagogue receptor	Homo sapiens	134-138
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	27-31	growth hormone releasing hormone	Homo sapiens	125-129
9768668-6	1998	Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion.	Masoprocol	27-31	growth hormone 1	Homo sapiens	99-101
9774254-6	1998	The hypoxia-elicited pressor response was prominently inhibited by (i) nordihydroguaiaretic acid (50-150 microM), an inhibitor of lipoxygenase and cyclooxygenase and (ii) methoxsalen (100 microM) and 1-aminobenzotriazole (1-10 mM), two inhibitors of cytochrome P450-derived metabolites.	Masoprocol	71-96	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	130-142
9699515-1	1998	We have examined the effects of three structurally distinct antioxidants (N-acetylcysteine [NAC], Trolox C [a water-soluble vitamin E derivative], and nordihydroguaiaretic acid [NGA]) on the expression of the c-fos gene over a 2-hour period.	Masoprocol	151-176	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	209-214
9699515-5	1998	Down regulation of protein kinase C (PKC) by pretreatment for 24 hours with 500 nm PMA prevents induction by subsequent stimulation with either PMA or NGA.	Masoprocol	151-154	protein kinase C alpha	Homo sapiens	37-40
9712826-6	1998	Among several inhibitors of superoxide-generating enzymes, only the lipoxygenase inhibitor, nordihydroguaiaretic acid reduced EGF-mediated ROS accumulation.	Masoprocol	92-117	epidermal growth factor like 1	Rattus norvegicus	126-129
9776484-2	1998	NDGA), an inhibitor of the enzyme 5-lipoxygenase, on days 10-14 of the oestrous cycle, maintained luteal function and delayed oestrus in the ewe.	Masoprocol	0-4	arachidonate 5-lipoxygenase	Homo sapiens	34-48
9797704-6	1998	2-CdA, CGP 52411, tyrphostin A48, staurosporine and NDGA were active as sensitisers against ara-C in HL-60 cells, CGP 52411 and tyrphostin A48 also in HL-60/ara-C cells, and 2-CdA, staurosporine and NDGA also in U937 cells.	Masoprocol	52-56	cytidine deaminase	Homo sapiens	176-179
9797704-6	1998	2-CdA, CGP 52411, tyrphostin A48, staurosporine and NDGA were active as sensitisers against ara-C in HL-60 cells, CGP 52411 and tyrphostin A48 also in HL-60/ara-C cells, and 2-CdA, staurosporine and NDGA also in U937 cells.	Masoprocol	199-203	cytidine deaminase	Homo sapiens	2-5
16793753-5	1998	The expression of CD62 was inhibited by the lipoxygenase (LOX) inhibitors quercetin and nordihydroguaiaretic acid but was not affected by the cyclooxygenase (COX) inhibitors aspirin and indomethacin.	Masoprocol	88-113	selectin P	Homo sapiens	18-22
9550546-7	1998	Nordihydroguaiaretic acid (NDGA; 10 pmol/L), an inhibitor of lipoxygenase (LOX), stimulated the ACM-induced increase in GPDH activity (ACM, 99 +/- 13; ACM + NDGA, 369 +/- 130).	Masoprocol	0-25	glycerol-3-phosphate dehydrogenase 1	Rattus norvegicus	120-124
9550546-7	1998	Nordihydroguaiaretic acid (NDGA; 10 pmol/L), an inhibitor of lipoxygenase (LOX), stimulated the ACM-induced increase in GPDH activity (ACM, 99 +/- 13; ACM + NDGA, 369 +/- 130).	Masoprocol	27-31	glycerol-3-phosphate dehydrogenase 1	Rattus norvegicus	120-124
9453306-10	1998	The LO inhibitor nordihydroguaiaretic acid (NDGA) decreased IL-stimulated NO and iNOS synthesis.	Masoprocol	17-42	nitric oxide synthase 2	Homo sapiens	81-85
9453306-10	1998	The LO inhibitor nordihydroguaiaretic acid (NDGA) decreased IL-stimulated NO and iNOS synthesis.	Masoprocol	44-48	nitric oxide synthase 2	Homo sapiens	81-85
9522277-5	1998	The reaction was significantly inhibited by nordihydroguaiaretic acid and gossypol, the classical inhibitors of lipoxygenase.	Masoprocol	44-69	linoleate 9S-lipoxygenase-4	Glycine max	112-124
9613612-5	1998	Similar to CD95L-induced apoptosis, APO2L-induced apoptosis is inhibited by ectopic expression of the caspase inhibitor, crm-A, or of bcl-2, or by coexposure to the corticosteroid, dexamethasone, or the lipoxygenase inhibitor, nordihydroguaretic acid.	Masoprocol	227-250	TNF superfamily member 10	Homo sapiens	36-41
9605420-9	1998	However, only the antioxidants, curcumin and nordihydroguaiaritic acid (NDGA) were found to inhibit IkappaBalpha degradation activated by tumour necrosis factor-alpha.	Masoprocol	72-76	NFKB inhibitor alpha	Homo sapiens	100-112
9541129-2	1998	METHODS: The effect of three antioxidants - butylated hydroxyanisol, tetrahydropapaveroline and nordihydroguaiaretic acid - on the production of tumour necrosis factor (TNF), interleukin (IL) 1, IL-6 and IL-8 (measured by enzyme-linked immunosorbent assay) by peripheral mononuclear cells and biopsies of inflamed colonic mucosa from inflammatory bowel disease patients were studied.	Masoprocol	96-121	tumor necrosis factor	Homo sapiens	145-167
9538194-6	1998	Increased NAD levels were found in both IFN gamma-treated and non-treated hepatocytes following the addition of PUFAs, but clofibrate, a peroxisome proliferator, bromophenacyl bromide (BPB), an inhibitor of phospholipase, nordihydroguaiaretic acid (NDGA), an inhibitor of lipoxygenase, and arachidonic acid, a metabolite of linoleic acid, did not inhibit IFN gamma-induced cellular injury.	Masoprocol	222-247	interferon gamma	Homo sapiens	40-49
9538194-6	1998	Increased NAD levels were found in both IFN gamma-treated and non-treated hepatocytes following the addition of PUFAs, but clofibrate, a peroxisome proliferator, bromophenacyl bromide (BPB), an inhibitor of phospholipase, nordihydroguaiaretic acid (NDGA), an inhibitor of lipoxygenase, and arachidonic acid, a metabolite of linoleic acid, did not inhibit IFN gamma-induced cellular injury.	Masoprocol	249-253	interferon gamma	Homo sapiens	40-49
9467967-5	1998	Indomethacin and nordihydroguaiaretic acid (NDGA), potent inhibitors of the cyclooxygenase (COX) and the lipoxygenase (LOX)/monooxygenase (MOX) pathways, respectively, had no effect on arachidonic acid activation of JNK1 suggesting that the observed phenomenon is independent of its metabolism through either pathway.	Masoprocol	44-48	monooxygenase DBH like 1	Homo sapiens	139-142
9467967-5	1998	Indomethacin and nordihydroguaiaretic acid (NDGA), potent inhibitors of the cyclooxygenase (COX) and the lipoxygenase (LOX)/monooxygenase (MOX) pathways, respectively, had no effect on arachidonic acid activation of JNK1 suggesting that the observed phenomenon is independent of its metabolism through either pathway.	Masoprocol	44-48	mitogen-activated protein kinase 8	Homo sapiens	216-220
9268696-2	1997	Bradykinin-induced actin breakdown and cortical actin formation were respectively prevented by indomethacin, a cyclooxygenase inhibitor, and nordihydroguaiaretic acid, a lipoxygenase inhibitor.	Masoprocol	141-166	kininogen 1	Homo sapiens	0-10
9400711-8	1997	However, nordihydroguaiaretic acid, a lipoxygenase inhibitor, decreased levels of NF-kappa B to background levels.	Masoprocol	9-34	nuclear factor kappa B subunit 1	Homo sapiens	82-92
9231737-5	1997	Pretreatment of cell cultures with the PLA2 inhibitors quinacrine and aristolochic acid resulted in a dose-dependent inhibition of melittin-stimulated PKC isozyme translocation as did the inhibitor of lipoxygenase, nordihydroguaiaretic acid, whereas the cyclooxygenase inhibitor indomethacin had no effect.	Masoprocol	215-240	phospholipase A2 group IB	Rattus norvegicus	39-43
9268230-5	1997	The lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA) selectively attenuated the angiotensin II-induced contractions in rabbit aortic rings from the control group only in the presence of the endothelium, whereas it had no effect on the responses to angiotensin II in the cholesterol group (with or without endothelium).	Masoprocol	27-52	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	4-16
9268230-5	1997	The lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA) selectively attenuated the angiotensin II-induced contractions in rabbit aortic rings from the control group only in the presence of the endothelium, whereas it had no effect on the responses to angiotensin II in the cholesterol group (with or without endothelium).	Masoprocol	54-58	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	4-16
9103531-4	1997	The data show that the dual inhibition of 5-lipoxygenase and HLE is unique to boswellic acids: other pentacyclic triterpenes with HLE inhibitory activities (e.g., ursolic acid and amyrin) do not inhibit 5-lipoxygenase, and leukotriene biosynthesis inhibitors from different chemical classes (e.g., NDGA, MK-886 and ZM-230,487) do not impair HLE activity.	Masoprocol	298-302	arachidonate 5-lipoxygenase	Homo sapiens	42-56
9112422-6	1997	In contrast, coincubation with nordihydroguaiaretic acid--a specific inhibitor of the lipoxygenase system--abolished IL-3 stimulated steroidogenesis but had no effect on IL-6 stimulated cortisol secretion.	Masoprocol	31-56	interleukin 3	Homo sapiens	117-121
9199495-4	1997	Formation of two AA metabolites generated during CD95-dependent apoptosis is attenuated by the lipoxygenase inhibitor, nordihydroguaretic acid (NDGA).	Masoprocol	119-142	Fas cell surface death receptor	Homo sapiens	49-53
9199495-4	1997	Formation of two AA metabolites generated during CD95-dependent apoptosis is attenuated by the lipoxygenase inhibitor, nordihydroguaretic acid (NDGA).	Masoprocol	144-148	Fas cell surface death receptor	Homo sapiens	49-53
9220356-9	1997	Exposure to 5 microM NDGA (nordihydroguaiaretic acid; which inhibits the 5-lipoxygenase pathway) or 10 microM ETYA (5,8,11,14-eicosatetrynoic acid: which inhibits the 12- and 15-lipoxygenase pathway) led to a reversible decrease in gj.	Masoprocol	21-25	arachidonate 5-lipoxygenase	Rattus norvegicus	73-87
9220356-9	1997	Exposure to 5 microM NDGA (nordihydroguaiaretic acid; which inhibits the 5-lipoxygenase pathway) or 10 microM ETYA (5,8,11,14-eicosatetrynoic acid: which inhibits the 12- and 15-lipoxygenase pathway) led to a reversible decrease in gj.	Masoprocol	27-52	arachidonate 5-lipoxygenase	Rattus norvegicus	73-87
9120300-4	1997	In this study, we examined the effects of 5-lipoxygenase inhibitors (nordihydroguaiaretic acid and AA861) on IL-1 beta-induced VCAM-1 gene expression in HUVECs.	Masoprocol	69-94	arachidonate 5-lipoxygenase	Homo sapiens	42-56
9120300-4	1997	In this study, we examined the effects of 5-lipoxygenase inhibitors (nordihydroguaiaretic acid and AA861) on IL-1 beta-induced VCAM-1 gene expression in HUVECs.	Masoprocol	69-94	interleukin 1 beta	Homo sapiens	109-118
9120300-4	1997	In this study, we examined the effects of 5-lipoxygenase inhibitors (nordihydroguaiaretic acid and AA861) on IL-1 beta-induced VCAM-1 gene expression in HUVECs.	Masoprocol	69-94	vascular cell adhesion molecule 1	Homo sapiens	127-133
9103531-4	1997	The data show that the dual inhibition of 5-lipoxygenase and HLE is unique to boswellic acids: other pentacyclic triterpenes with HLE inhibitory activities (e.g., ursolic acid and amyrin) do not inhibit 5-lipoxygenase, and leukotriene biosynthesis inhibitors from different chemical classes (e.g., NDGA, MK-886 and ZM-230,487) do not impair HLE activity.	Masoprocol	298-302	elastase, neutrophil expressed	Homo sapiens	61-64
9070230-3	1997	EGF and TGF alpha stimulated DNA synthesis in these cells which was attenuated by the addition of a lipoxygenase inhibitor, NDGA.	Masoprocol	124-128	epidermal growth factor	Homo sapiens	0-3
9066788-9	1997	When IL-3 is added in the presence of any of three lipoxygenase inhibitors tested (Piriprost, caffeic acid, nordihydroguiaretic acid) or FLAP inhibitor, MK-886, there is dose-dependent inhibition of the resumption of proliferation and of DNA synthesis.	Masoprocol	108-132	interleukin 3	Homo sapiens	5-9
9070230-3	1997	EGF and TGF alpha stimulated DNA synthesis in these cells which was attenuated by the addition of a lipoxygenase inhibitor, NDGA.	Masoprocol	124-128	transforming growth factor alpha	Homo sapiens	8-17
9013799-4	1997	However, treatment of the cultured HUVEC with alpha-tocopherol or nordihydroguaiaretic acid completely suppressed the 15-HPETE-induced change in t-PA and PAI-1 antigen release.	Masoprocol	66-91	plasminogen activator, tissue type	Homo sapiens	145-149
9032466-6	1997	Various antioxidants, such as pyrrolidine dithiocarbamate, p-bromophenacyl-bromide and nordihydroguaiaretic acid could strongly reduce NF-kappaB translocation, demonstrating the importance of oxidative species in the transduction mechanism.	Masoprocol	87-112	nuclear factor kappa B subunit 1	Homo sapiens	135-144
9013799-4	1997	However, treatment of the cultured HUVEC with alpha-tocopherol or nordihydroguaiaretic acid completely suppressed the 15-HPETE-induced change in t-PA and PAI-1 antigen release.	Masoprocol	66-91	serpin family E member 1	Homo sapiens	154-159
9201246-9	1997	The antioxidants N-acetylcysteine, nordihydroguaiaretic acid and mepacrine dose-dependently inhibited gamma-irradiation-mediated TNF alpha production.	Masoprocol	35-60	tumor necrosis factor	Homo sapiens	129-138
8961076-8	1996	Whereas the lipoxygenase inhibitor, nordihydroguaiaretic acid (5 x 10(-5) M), caused a slight increase in the contractions to norepinephrine in cholesterol-fed rabbits compared with normal rabbits, the cytochrome P450 epoxygenase inhibitor, metyrapone (10(-4) M), produced a greater enhancement of norepinephrine-induced contractions in cholesterol-fed rabbits but had no effect on responses in the normal rabbits.	Masoprocol	36-61	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	12-24
9061044-2	1997	It was shown that bFGF-induced incorporation of the radioactive precursors into GAGs was diminished by lipoxygenase inhibitors, nordihydroguaiaretic acid (NDGA) and esculetin, but not by a cyclooxygenase inhibitor indomethacin.	Masoprocol	128-153	fibroblast growth factor 2	Homo sapiens	18-22
9061044-2	1997	It was shown that bFGF-induced incorporation of the radioactive precursors into GAGs was diminished by lipoxygenase inhibitors, nordihydroguaiaretic acid (NDGA) and esculetin, but not by a cyclooxygenase inhibitor indomethacin.	Masoprocol	155-159	fibroblast growth factor 2	Homo sapiens	18-22
8944632-5	1996	Further-more, nordihydroguaiaretic acid inhibited Ca(2+)-dependent proliferation of mitogen-activated human peripheral blood mononuclear cells or Jurkat T cells and specifically blocked Ca(2+)-dependent interleukin 2 production by Jurkat T cells to a degree similar to the immunosuppressant drug cyclosporin A.	Masoprocol	14-39	interleukin 2	Homo sapiens	203-216
9014215-4	1996	A cyclooxygenase inhibitor indomethacin and lipoxygenase inhibitor nordehydroguaretic acid (NDGA) decreased PGE2- and LTC4-like activities, respectively, while allopurinol and superoxide dismutase (SOD) decreased both activities.	Masoprocol	92-96	superoxide dismutase 1	Homo sapiens	176-196
9014215-4	1996	A cyclooxygenase inhibitor indomethacin and lipoxygenase inhibitor nordehydroguaretic acid (NDGA) decreased PGE2- and LTC4-like activities, respectively, while allopurinol and superoxide dismutase (SOD) decreased both activities.	Masoprocol	92-96	superoxide dismutase 1	Homo sapiens	198-201
8983209-11	1996	The agent, nordihydroguaiaretic acid, blocks the monooxygenase pathway and blocks CYPIA1 activity increases.	Masoprocol	11-36	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	82-88
8931100-6	1996	The lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA, 20 nmol/l), significantly enhanced the 5-HT-induced pressor response in normal rings while significantly attenuating those responses in diabetic rings.	Masoprocol	28-53	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	4-16
8910370-6	1996	Nordihydroguaiaretic acid, an inhibitor of the lipoxygenase pathway, significantly inhibited both hydrogen peroxide and arachidonic acid-stimulated c-Fos and c-Jun protein expression and AP-1 activity.	Masoprocol	0-25	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	148-153
8910370-6	1996	Nordihydroguaiaretic acid, an inhibitor of the lipoxygenase pathway, significantly inhibited both hydrogen peroxide and arachidonic acid-stimulated c-Fos and c-Jun protein expression and AP-1 activity.	Masoprocol	0-25	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	158-163
8843902-12	1996	The inhibitory effect of AngII was abolished completely by losartan (0.1 microM), a specific antagonist of the AT1 receptor-subtype of AngII, and by nordihydroguaiaretic acid (50 microM), which at this concentration inhibits the lipoxygenase and cytochrome P-450-dependent pathways of arachidonic acid metabolism.	Masoprocol	149-174	angiotensinogen	Rattus norvegicus	25-30
8843902-12	1996	The inhibitory effect of AngII was abolished completely by losartan (0.1 microM), a specific antagonist of the AT1 receptor-subtype of AngII, and by nordihydroguaiaretic acid (50 microM), which at this concentration inhibits the lipoxygenase and cytochrome P-450-dependent pathways of arachidonic acid metabolism.	Masoprocol	149-174	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	246-262
8931100-6	1996	The lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA, 20 nmol/l), significantly enhanced the 5-HT-induced pressor response in normal rings while significantly attenuating those responses in diabetic rings.	Masoprocol	55-59	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	4-16
8881817-8	1996	SNP induced delta SCC was also significantly reduced by piroxicam (mean (SEM)) 10(-5)M (57.9 (11.9)%), nordihydroguaretic acid 10(-4)M (48.0 (12.9)%), tetrodotoxin (TTX 10(-6)M, 52.3 (9.1)%), and practically abolished by TTX and piroxicam together (96.8 (3.3)%).	Masoprocol	103-126	serpin family B member 3	Homo sapiens	18-21
8760145-3	1996	Pretreatment of human pulmonary adenocarcinoma cells H441 with the antioxidants N-acetyl-L-cysteine (NAC) and nordihydroguaiaretic acid (NDGA) blocked MnSOD induction by TNF-alpha, implicating ROS as a signaling agent in this pathway.	Masoprocol	110-135	superoxide dismutase 2	Homo sapiens	151-156
8760145-3	1996	Pretreatment of human pulmonary adenocarcinoma cells H441 with the antioxidants N-acetyl-L-cysteine (NAC) and nordihydroguaiaretic acid (NDGA) blocked MnSOD induction by TNF-alpha, implicating ROS as a signaling agent in this pathway.	Masoprocol	110-135	tumor necrosis factor	Homo sapiens	170-179
8760145-3	1996	Pretreatment of human pulmonary adenocarcinoma cells H441 with the antioxidants N-acetyl-L-cysteine (NAC) and nordihydroguaiaretic acid (NDGA) blocked MnSOD induction by TNF-alpha, implicating ROS as a signaling agent in this pathway.	Masoprocol	137-141	superoxide dismutase 2	Homo sapiens	151-156
8760145-3	1996	Pretreatment of human pulmonary adenocarcinoma cells H441 with the antioxidants N-acetyl-L-cysteine (NAC) and nordihydroguaiaretic acid (NDGA) blocked MnSOD induction by TNF-alpha, implicating ROS as a signaling agent in this pathway.	Masoprocol	137-141	tumor necrosis factor	Homo sapiens	170-179
8568469-8	1996	Furthermore, the gonadotrophin release by 1 nM GnRH was inhibited by nordihydroguaiaretic acid (a lipoxygenase inhibitor) with an IC50 of about 5 microM.	Masoprocol	69-94	gonadotropin releasing hormone 1	Homo sapiens	47-51
8836877-4	1996	Both indomethacin, an inhibitor of cyclooxygenase, and nordihydroguaiaretic acid, a lipoxygenase inhibitor, significantly enhanced the arsenite-induced accumulation of hsp27.	Masoprocol	55-80	heat shock protein 1	Mus musculus	168-173
8616873-6	1996	In contrast, the increase in adhesion to vitronectin induced by A23187 and AA was, at best, only partially inhibited by nordihydroguaiaretic acid treatment.	Masoprocol	120-145	vitronectin	Homo sapiens	41-52
8733110-5	1996	N-acetyl cysteine (NAC) induces c-fos transcription in both early and late passage cells, while nordihydroguaiaretic acid (NGA) induced c-fos transcription in early passage cells but fails to stimulate it in late passage cells.	Masoprocol	96-121	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	136-141
8733110-5	1996	N-acetyl cysteine (NAC) induces c-fos transcription in both early and late passage cells, while nordihydroguaiaretic acid (NGA) induced c-fos transcription in early passage cells but fails to stimulate it in late passage cells.	Masoprocol	123-126	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	136-141
11859379-8	1996	This inhibition of IL-6 expression by NDGA and indomethacin was dose responsive and also reversible with the addition of exogenous prostaglandin E(2) (PGE(2)) or leukotriene B(4) (LTB(4)).	Masoprocol	38-42	interleukin 6	Homo sapiens	19-23
8591993-6	1996	The expression of hsp70 to each stress was also enhanced in the presence of indomethacin, NDGA, or melittin.	Masoprocol	90-94	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	18-23
8633191-0	1996	Nordihydroguaiaretic acid blocks IL-2-independent lymphocyte proliferation and enhances responses to PPD.	Masoprocol	0-25	interleukin 2	Homo sapiens	33-37
8750525-4	1996	Esculetin and NDGA reduced the secretion of LTB, whereas piroxicam reduced the secretion of PGE.	Masoprocol	14-18	lymphotoxin beta	Homo sapiens	44-47
8591886-11	1996	The combined cyclooxygenase/lipoxygenase inhibitor BW 755C and the lipoxygenase inhibitor nordihydroguaiaretic acid completely blocked arachidonic acid-induced contractions in females.	Masoprocol	90-115	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	67-79
7585636-12	1995	The increased rate in NNK oxidation by arachidonic acid or lipoxygenase was inhibited completely by nordihydroguaiaretic acid.	Masoprocol	100-125	linoleate 9S-lipoxygenase-4	Glycine max	59-71
7674234-7	1995	Nordihydroguaiaretic acid (NDGA), an inhibitor of 5-lipoxygenase, was added to mixed cultures of splenocytes and macrophages containing low dose aspirin.	Masoprocol	0-25	arachidonate 5-lipoxygenase	Mus musculus	50-64
8774948-5	1995	However, nordihydroguaiaretic acid, which blocks cyclooxygenase and lipoxygenases, potentiated the effect of TPA on proenkephalin mRNA, when used at concentrations of 0.5-50 mumol/l.	Masoprocol	9-34	proenkephalin	Rattus norvegicus	116-129
7646440-4	1995	While indomethacin and nordihydroguaiaretic acid inhibited either the cyclo-oxygenase or lipoxygenase pathway of arachidonic acid metabolism, as measured by their products prostaglandin E2 and leukotriene B4, they did not influence PMA-mediated PLA2 activation or translocation of protein kinase C (PKC) from the soluble to the particulate fraction.	Masoprocol	23-48	ATPase, H+ transporting, lysosomal V1 subunit E1	Mus musculus	186-207
7646440-4	1995	While indomethacin and nordihydroguaiaretic acid inhibited either the cyclo-oxygenase or lipoxygenase pathway of arachidonic acid metabolism, as measured by their products prostaglandin E2 and leukotriene B4, they did not influence PMA-mediated PLA2 activation or translocation of protein kinase C (PKC) from the soluble to the particulate fraction.	Masoprocol	23-48	phospholipase A2, group IB, pancreas	Mus musculus	245-249
7561638-12	1995	Indomethacin, a cyclo-oxygenase inhibitor, completely inhibited, whereas nordihydroguaiaretic acid, a lipoxygenase inhibitor, slightly inhibited EGF action.	Masoprocol	73-98	epidermal growth factor	Homo sapiens	145-148
7674234-7	1995	Nordihydroguaiaretic acid (NDGA), an inhibitor of 5-lipoxygenase, was added to mixed cultures of splenocytes and macrophages containing low dose aspirin.	Masoprocol	27-31	arachidonate 5-lipoxygenase	Mus musculus	50-64
7603462-3	1995	The presence of the noninhibitory pentacyclic triterpenes both in intact cells and in the cell-free system caused a concentration-dependent reversal of the 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid, whereas the inhibitory actions of 5-lipoxygenase inhibitors from different chemical classes (MK-886, L-739,010, ZM-230,487, and nordihydroguaiaretic acid) were not modified.	Masoprocol	349-374	arachidonate 5-lipoxygenase	Rattus norvegicus	156-170
7733976-4	1995	Nordihydroguaiaretic acid (NDGA), an inhibitor of lipoxygenases, also inhibited APPs secretion.	Masoprocol	0-25	cathepsin B	Homo sapiens	80-84
7733976-4	1995	Nordihydroguaiaretic acid (NDGA), an inhibitor of lipoxygenases, also inhibited APPs secretion.	Masoprocol	27-31	cathepsin B	Homo sapiens	80-84
7695605-0	1995	Enhanced processing of APP induced by IL-1 beta can be reduced by indomethacin and nordihydroguaiaretic acid.	Masoprocol	83-108	interleukin 1 beta	Rattus norvegicus	38-47
7695605-6	1995	Indomethacin and NDGA, reported inhibitors of the cyclooxygenase and lipoxygenase pathways, respectively, block these effects, suggesting the involvement of prostaglandins and leukotrienes in IL-1 beta mediated APP processing.	Masoprocol	17-21	interleukin 1 beta	Rattus norvegicus	192-201
7878664-7	1995	Linoleic acid-dependent covalent binding of phenytoin was inhibited in a concentration-dependent fashion by the selective and nonselective LPO/PHS inhibitors indomethacin, nordihydroguaiaretic acid, quercetin, BW755C, and 5,8,11,14-eicosatetraynoic acid (ETYA) and by the hydroperoxidase inhibitor methimazole (p < 0.05).	Masoprocol	172-197	lactoperoxidase	Mus musculus	139-142
7878664-7	1995	Linoleic acid-dependent covalent binding of phenytoin was inhibited in a concentration-dependent fashion by the selective and nonselective LPO/PHS inhibitors indomethacin, nordihydroguaiaretic acid, quercetin, BW755C, and 5,8,11,14-eicosatetraynoic acid (ETYA) and by the hydroperoxidase inhibitor methimazole (p < 0.05).	Masoprocol	172-197	pterin 4 alpha carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 alpha (TCF1) 1	Mus musculus	143-146
7947991-9	1994	The plasma membrane vesicles also show a lipoxygenase, active in the alkaline (9.0-9.5) range, inhibited by NDGA, SHAM and propyl gallate, stimulated by H2O2, but with a lower Km value (60 microM) and less sensitive to calcium stimulation than the acidic one.	Masoprocol	108-112	linoleate 9S-lipoxygenase-4	Glycine max	41-53
18475674-3	1995	In the heart, the nonselective lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA, 1 muM) markedly suppressed the angiotensin II-induced decreases in coronary flow.	Masoprocol	54-79	angiotensinogen	Rattus norvegicus	118-132
18475674-3	1995	In the heart, the nonselective lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA, 1 muM) markedly suppressed the angiotensin II-induced decreases in coronary flow.	Masoprocol	81-85	angiotensinogen	Rattus norvegicus	118-132
18475674-4	1995	NDGA (10 muM) inhibited both angiotensin II- and methoxamine- (reference drug) induced contractions in aortic rings with (in the presence of L-NAME) and without endothelium.	Masoprocol	0-4	angiotensinogen	Rattus norvegicus	29-43
7972695-6	1994	We then determined that radiation-enhanced expression of alpha IIb beta 3 integrin and adhesion of B16 melanoma cells to fibronectin in vitro and metastasis in vivo were reduced by treatment of the cells with the lipoxygenase inhibitor NDGA prior to irradiation.	Masoprocol	236-240	fibronectin 1	Mus musculus	121-132
7986205-5	1994	Also, the presence of NDGA changed to redox state of NAD(P)+ to a more reduced level, and the redox states of ubiquinone, cytochrome b and cytochromes c + c1 changed to a more oxidized level.	Masoprocol	22-26	mitochondrially encoded cytochrome b	Homo sapiens	122-134
7886692-4	1994	wt PLA2 inhibitors such as p-bromophenacyl bromide, aristolochic acid, nordihydroguaiaretic acid, all trans-retinal and all trans-retinoic acid on the action of these enzymes.	Masoprocol	71-96	phospholipase A2, group IB, pancreas	Mus musculus	3-7
7523100-8	1994	Preexposure to NDGA suppressed by 43% the sustained response to 8-bromo-cAMP, which directly activates protein kinase-A; by 57% the sustained response to dioctanolglycerol, which directly activates protein kinase-C; and by 59% the spike-type response to ionomycin, which releases Cai2+ by an inositol 1,4,5-trisphosphate-independent mechanism.	Masoprocol	15-19	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	103-119
7943384-5	1994	Nordihydroguaiaretic acid, a lipoxygenase inhibitor, blocked these effects.	Masoprocol	0-25	linoleate 9S-lipoxygenase-4	Glycine max	29-41
7982093-2	1994	In the present study, the lipoxygenase inhibitor/antioxidant nordihydroguaiaretic acid (NDGA) protected cultured rat hippocampal neurons against the toxicity of A beta in a concentration-dependent manner.	Masoprocol	61-86	amyloid beta precursor protein	Rattus norvegicus	161-167
7982093-2	1994	In the present study, the lipoxygenase inhibitor/antioxidant nordihydroguaiaretic acid (NDGA) protected cultured rat hippocampal neurons against the toxicity of A beta in a concentration-dependent manner.	Masoprocol	88-92	amyloid beta precursor protein	Rattus norvegicus	161-167
7928003-3	1994	In initial support of this concept, we report that NDGA and Esculetin completely inhibited B-lymphocyte activation mediated by either membrane immunoglobulin (mIg), or the lipopolysaccharide (LPS) receptor.	Masoprocol	51-55	chemokine (C-X-C motif) ligand 9	Mus musculus	159-162
8021298-7	1994	In cells treated with nordihydroguaiaretic acid (NDGA), clotramizole, or econazole, compounds with lipoxygenase and cytochrome P-450 inhibitory actions, the thapsigargin-induced entry of calcium was decreased in a dose-dependent manner.	Masoprocol	22-47	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	116-132
8021298-7	1994	In cells treated with nordihydroguaiaretic acid (NDGA), clotramizole, or econazole, compounds with lipoxygenase and cytochrome P-450 inhibitory actions, the thapsigargin-induced entry of calcium was decreased in a dose-dependent manner.	Masoprocol	49-53	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	116-132
8035610-3	1994	NDGA inhibited A23187-induced c-fos mRNA expression by a similar magnitude as IL-4, whereas the effect of indomethacin was only minor.	Masoprocol	0-4	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	30-35
8004399-0	1994	Inhibitory effects of nordihydroguaiaretic acid on ETA-receptor-mediated contractions to endothelin-1 in rat trachea.	Masoprocol	22-47	endothelin receptor type A	Rattus norvegicus	51-54
8166228-8	1994	Dexamethasone (Dxm), indomethacin (Indo), and nordihydroguaiaretic acid, the respective inhibitors of PLA2-cyclooxygenase II, cyclooxygenase, and lipoxygenase, increased both constitutive and AVP- or ANG II-stimulated secretion of ET-1.	Masoprocol	46-71	phospholipase A2 group IIA	Homo sapiens	102-106
8004399-0	1994	Inhibitory effects of nordihydroguaiaretic acid on ETA-receptor-mediated contractions to endothelin-1 in rat trachea.	Masoprocol	22-47	endothelin 1	Rattus norvegicus	89-101
8004399-2	1994	It has been shown previously that nordihydroguaiaretic acid (NDGA) inhibits endothelin-1 (ET-1)-induced contractions in rat isolated tracheal smooth muscle.	Masoprocol	34-59	endothelin 1	Rattus norvegicus	76-88
8004399-2	1994	It has been shown previously that nordihydroguaiaretic acid (NDGA) inhibits endothelin-1 (ET-1)-induced contractions in rat isolated tracheal smooth muscle.	Masoprocol	34-59	endothelin 1	Rattus norvegicus	90-94
8004399-2	1994	It has been shown previously that nordihydroguaiaretic acid (NDGA) inhibits endothelin-1 (ET-1)-induced contractions in rat isolated tracheal smooth muscle.	Masoprocol	61-65	endothelin 1	Rattus norvegicus	76-88
8004399-2	1994	It has been shown previously that nordihydroguaiaretic acid (NDGA) inhibits endothelin-1 (ET-1)-induced contractions in rat isolated tracheal smooth muscle.	Masoprocol	61-65	endothelin 1	Rattus norvegicus	90-94
8004399-5	1994	NDGA inhibited contractions induced by each of the isoforms of ET (ET-1, ET-2 and ET-3) but not those induced by the ETB receptor-selective agonist, sarafotoxin S6c, the cholinoceptor agonist, carbachol or the depolarizing spasmogen, KCl.	Masoprocol	0-4	endothelin 1	Rattus norvegicus	67-71
8004399-5	1994	NDGA inhibited contractions induced by each of the isoforms of ET (ET-1, ET-2 and ET-3) but not those induced by the ETB receptor-selective agonist, sarafotoxin S6c, the cholinoceptor agonist, carbachol or the depolarizing spasmogen, KCl.	Masoprocol	0-4	endothelin 2	Rattus norvegicus	73-77
8004399-5	1994	NDGA inhibited contractions induced by each of the isoforms of ET (ET-1, ET-2 and ET-3) but not those induced by the ETB receptor-selective agonist, sarafotoxin S6c, the cholinoceptor agonist, carbachol or the depolarizing spasmogen, KCl.	Masoprocol	0-4	endothelin 3	Rattus norvegicus	82-86
8004399-9	1994	NDGA inhibited the ETA receptor-mediated, intracellular Ca(2+)-dependent contractions induced by 100 nM ET-1 in Ca(2+)-free solution (by 75%, P < 0.01).	Masoprocol	0-4	endothelin receptor type A	Rattus norvegicus	19-22
8004399-9	1994	NDGA inhibited the ETA receptor-mediated, intracellular Ca(2+)-dependent contractions induced by 100 nM ET-1 in Ca(2+)-free solution (by 75%, P < 0.01).	Masoprocol	0-4	endothelin 1	Rattus norvegicus	104-108
8004399-12	1994	Like NDGA, the sarcoplasmic reticulum Ca(2+)-ATPase inhibitors cyclopiazonic acid and thapsigargin inhibited contractions to ET-1, but not carbachol or KCl.	Masoprocol	5-9	endothelin 1	Rattus norvegicus	125-129
8004399-16	1994	However, in the presence of NDGA or the ETA receptor antagonist, BQ123, ET-1-induced contractions resembled the transient contractions induced by sarafotoxin S6c.	Masoprocol	28-32	endothelin 1	Rattus norvegicus	72-76
8004399-19	1994	In summary, NDGA selectively inhibited ET-1-induced contractions in rat tracheal smooth muscle via a lipoxygenase-independent mechanism involving inhibition of the ETA but not the ETB, receptor effector system.	Masoprocol	12-16	endothelin 1	Rattus norvegicus	39-43
8004399-19	1994	In summary, NDGA selectively inhibited ET-1-induced contractions in rat tracheal smooth muscle via a lipoxygenase-independent mechanism involving inhibition of the ETA but not the ETB, receptor effector system.	Masoprocol	12-16	endothelin receptor type A	Rattus norvegicus	164-167
8004399-21	1994	However, NDGA inhibited the intracellular Ca2+-dependent component of ET-1-induced contraction, possibly by inhibiting mobilisation of intracellular Ca2+.	Masoprocol	9-13	endothelin 1	Rattus norvegicus	70-74
8196475-5	1994	On the other hand, nordihydroguaiaretic acid (NDGA), an inhibitor of the lipoxygenase pathway of arachidonic acid metabolism, suppressed the spontaneous release of PAI-1:Ag by itself; in the presence of NDGA, bFGF failed to further suppress the PAI-1:Ag release.	Masoprocol	19-44	serpin family E member 1	Homo sapiens	164-169
7968258-5	1994	Stimulation of the [3H]thymidine incorporation by zinc disappeared in the presence of either cycloheximide or anti-bFGF IgG; in addition, a lipoxygenase inhibitor nordihydroguaiaretic acid diminished the zinc stimulation but a cyclooxygenase inhibitor indomethacin did not exhibit such an inhibitory effect.	Masoprocol	163-188	fibroblast growth factor 2	Bos taurus	115-119
8196475-5	1994	On the other hand, nordihydroguaiaretic acid (NDGA), an inhibitor of the lipoxygenase pathway of arachidonic acid metabolism, suppressed the spontaneous release of PAI-1:Ag by itself; in the presence of NDGA, bFGF failed to further suppress the PAI-1:Ag release.	Masoprocol	19-44	fibroblast growth factor 2	Homo sapiens	209-213
8196475-5	1994	On the other hand, nordihydroguaiaretic acid (NDGA), an inhibitor of the lipoxygenase pathway of arachidonic acid metabolism, suppressed the spontaneous release of PAI-1:Ag by itself; in the presence of NDGA, bFGF failed to further suppress the PAI-1:Ag release.	Masoprocol	19-44	serpin family E member 1	Homo sapiens	245-250
8196475-5	1994	On the other hand, nordihydroguaiaretic acid (NDGA), an inhibitor of the lipoxygenase pathway of arachidonic acid metabolism, suppressed the spontaneous release of PAI-1:Ag by itself; in the presence of NDGA, bFGF failed to further suppress the PAI-1:Ag release.	Masoprocol	46-50	serpin family E member 1	Homo sapiens	164-169
8196475-5	1994	On the other hand, nordihydroguaiaretic acid (NDGA), an inhibitor of the lipoxygenase pathway of arachidonic acid metabolism, suppressed the spontaneous release of PAI-1:Ag by itself; in the presence of NDGA, bFGF failed to further suppress the PAI-1:Ag release.	Masoprocol	46-50	fibroblast growth factor 2	Homo sapiens	209-213
8196475-5	1994	On the other hand, nordihydroguaiaretic acid (NDGA), an inhibitor of the lipoxygenase pathway of arachidonic acid metabolism, suppressed the spontaneous release of PAI-1:Ag by itself; in the presence of NDGA, bFGF failed to further suppress the PAI-1:Ag release.	Masoprocol	46-50	serpin family E member 1	Homo sapiens	245-250
8228253-4	1993	Additional studies demonstrate that MLD, SLD, and other less potent PLA2 inhibitors such as 4-bromophenacylbromide and nordihydroguiaretic acid inhibit the surface expression of MAC-1 (IC50: MLD, 0.33 microM; SLD, 0.23 microM; 4-bromophenacylbromide, 2.8 microM; NDGA, 3.5 microM) at concentrations similar to those at which they inhibit [3H]AA release.	Masoprocol	119-143	phospholipase A2 group IB	Homo sapiens	68-72
18472935-6	1994	Preincubation of the monocyte cultures with the lipoxygenase inhibitors nordihydroguaiaretic acid (10(-4) M) or diethylcarbamazine (10(-9) M) completely abolished the appearance of NCA and MCA.	Masoprocol	72-97	CEA cell adhesion molecule 4	Homo sapiens	181-184
18472956-7	1994	Pretreatment of SMC with NDGA, cycloheximide, and actinomycin not only inhibited IL-1 and TNT induced HETEs synthesis but also abolished LTB(4) production when co-incubated with macrophages.	Masoprocol	25-29	chromosome 16 open reading frame 82	Homo sapiens	90-93
8228253-4	1993	Additional studies demonstrate that MLD, SLD, and other less potent PLA2 inhibitors such as 4-bromophenacylbromide and nordihydroguiaretic acid inhibit the surface expression of MAC-1 (IC50: MLD, 0.33 microM; SLD, 0.23 microM; 4-bromophenacylbromide, 2.8 microM; NDGA, 3.5 microM) at concentrations similar to those at which they inhibit [3H]AA release.	Masoprocol	119-143	integrin subunit alpha M	Homo sapiens	178-183
7694796-2	1993	Nitrite production by peritoneal macrophages from mice receiving OK-432 treatment was significantly inhibited by phospholipase A2 inhibitors [dexamethasone and 4-bromophenacyl bromide (4-BPB)], lipoxygenase inhibitors [nordihydroguaiaretic acid (NDGA) and ketoconazole] and a glutathione S-transferase (leukotrienes LTA4-LTC4) inhibitor (ethacrynic acid).	Masoprocol	219-244	phospholipase A2, group IB, pancreas	Mus musculus	113-129
7694796-2	1993	Nitrite production by peritoneal macrophages from mice receiving OK-432 treatment was significantly inhibited by phospholipase A2 inhibitors [dexamethasone and 4-bromophenacyl bromide (4-BPB)], lipoxygenase inhibitors [nordihydroguaiaretic acid (NDGA) and ketoconazole] and a glutathione S-transferase (leukotrienes LTA4-LTC4) inhibitor (ethacrynic acid).	Masoprocol	246-250	phospholipase A2, group IB, pancreas	Mus musculus	113-129
8112503-4	1993	Platelet-activating factor (PAF) caused contraction of the rat stomach fundus in a concentration-dependent manner in the presence of atropine, guanethidine, chlorpheniramine, methylsergide, indomethacin, nordihydroguaiaretic acid and tetrodotoxin.	Masoprocol	204-229	PCNA clamp associated factor	Rattus norvegicus	0-26
8112503-4	1993	Platelet-activating factor (PAF) caused contraction of the rat stomach fundus in a concentration-dependent manner in the presence of atropine, guanethidine, chlorpheniramine, methylsergide, indomethacin, nordihydroguaiaretic acid and tetrodotoxin.	Masoprocol	204-229	PCNA clamp associated factor	Rattus norvegicus	28-31
8506987-5	1993	Both indomethacin and NDGA strongly inhibited IL-4-induced IgE production.	Masoprocol	22-26	interleukin 4	Homo sapiens	46-50
7509052-5	1993	Because NMDA receptor activation initiates the arachidonic acid cascade, we have recently looked at whether the phospholipase A2 and lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA) can reduce NMDA neurotoxicity in vitro.	Masoprocol	183-187	phospholipase A2 group IB	Homo sapiens	112-128
8281433-7	1993	On the other hand, DTLET decreased the release of both GnRH and PGE2 in the presence of nordihydroguaiaretic acid (NDGA), an inhibitor of the production of LTs.	Masoprocol	88-113	gonadotropin releasing hormone 1	Homo sapiens	55-59
8147272-5	1993	The addition of LTB4 at the time of PMA differentiation did not have effects on cell proliferation, but nordihydroguaiaretic acid (NDGA), a potent 5-lipoxygenase inhibitor, also inhibited HL-60 cell proliferation and did not have any effect on PMA-differentiated cell proliferation.	Masoprocol	104-129	arachidonate 5-lipoxygenase	Homo sapiens	147-161
8147272-5	1993	The addition of LTB4 at the time of PMA differentiation did not have effects on cell proliferation, but nordihydroguaiaretic acid (NDGA), a potent 5-lipoxygenase inhibitor, also inhibited HL-60 cell proliferation and did not have any effect on PMA-differentiated cell proliferation.	Masoprocol	131-135	arachidonate 5-lipoxygenase	Homo sapiens	147-161
8415814-3	1993	Nordihydroguaiaretic acid (NDGA) is known as the most potent inhibitor of 5-lipoxygenase in different tissues.	Masoprocol	0-25	arachidonate 5-lipoxygenase	Rattus norvegicus	74-88
8415814-3	1993	Nordihydroguaiaretic acid (NDGA) is known as the most potent inhibitor of 5-lipoxygenase in different tissues.	Masoprocol	27-31	arachidonate 5-lipoxygenase	Rattus norvegicus	74-88
8383025-8	1993	Macrophages treated with a non-selective 5-lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), used at 10 microM, added 15 min before LPS 100 ng/ml, produce a dose-dependent inhibition of LTB4.	Masoprocol	67-92	arachidonate 5-lipoxygenase	Homo sapiens	41-55
8464709-5	1993	Nordihydroguaiaretic acid (a lipoxygenase-cytochrome P450 monooxygenase inhibitor) significantly inhibited both hydrogen peroxide and arachidonic acid-induced c-fos mRNA expression, whereas indomethacin (a cyclooxygenase inhibitor) had no effect.	Masoprocol	0-25	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	159-164
8383025-8	1993	Macrophages treated with a non-selective 5-lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), used at 10 microM, added 15 min before LPS 100 ng/ml, produce a dose-dependent inhibition of LTB4.	Masoprocol	94-98	arachidonate 5-lipoxygenase	Homo sapiens	41-55
8490954-7	1993	However, the effects of IL-1 were also blocked by the lipoxygenase inhibitor nordihydroguaiaretic acid (2 x 10(-5) M) or by treating tissues with the leukotriene receptor blocker, ICI198615 (1 x 10(-8) M).	Masoprocol	77-102	interleukin 1 alpha	Homo sapiens	24-28
8473568-3	1993	Nordihydroguaiaretic acid protection is explained by its inhibition of lipoxygenase enzymes, and thus ultimately of TNF production in response to endotoxin.	Masoprocol	0-25	tumor necrosis factor	Mus musculus	116-119
8100381-3	1993	The anti-asthmatic/anti-allergic compounds azelastine, astemizole and oxatomide, and the 5-lipoxygenase inhibitor NDGA, were able to suppress the release of elastase from human leukocytes in concentrations between 10 and 100 microM.	Masoprocol	114-118	arachidonate 5-lipoxygenase	Homo sapiens	89-103
8380937-1	1993	Whereas we observed previously that concentrations of the lipoxygenase inhibitor nordihydroguaiaretic acid that inhibited leukotriene B4 release from lipopolysaccharide-stimulated human alveolar macrophages in vitro also inhibited subsequent interleukin-8 release, we hypothesized that leukotriene B4 release was required for the release of interleukin-8.	Masoprocol	81-106	C-X-C motif chemokine ligand 8	Homo sapiens	242-255
8380937-1	1993	Whereas we observed previously that concentrations of the lipoxygenase inhibitor nordihydroguaiaretic acid that inhibited leukotriene B4 release from lipopolysaccharide-stimulated human alveolar macrophages in vitro also inhibited subsequent interleukin-8 release, we hypothesized that leukotriene B4 release was required for the release of interleukin-8.	Masoprocol	81-106	C-X-C motif chemokine ligand 8	Homo sapiens	341-354
1279984-3	1992	Neurotensin produced a concentration-dependent inhibition of muscle contraction [mean inhibitory concentration (IC50): 2.8 x 10(-9) M], which was not blocked by phentolamine (10(-6) M), hexamethonium (10(-4) M), indomethacin (10(-6) M), nordihydroguaretic acid (10(-6) M), or tetrodotoxin (10(-6) M).	Masoprocol	237-260	neurotensin	Rattus norvegicus	0-11
1464738-7	1992	The lipoxygenase/cyclooxygenase inhibitors eicosatetraenoic acid and nordihydroguaiaretic acid and the calmodulin antagonist trifluoperazine were the only compounds tested that showed significant inhibition of phospholipase A2 activity.	Masoprocol	69-94	phospholipase A2 group IB	Homo sapiens	210-226
1643116-9	1992	The phospholipase A2 inhibitor nordihydroguaiaretic acid substantially prevented the zymosan-induced arachidonic acid release.	Masoprocol	31-56	phospholipase A2, group IB, pancreas	Mus musculus	4-20
1330924-8	1992	Further, the priming effects of PAF on adherence could be reversed by preincubation of neutrophils with the lipoxygenase inhibitors nordihydroguiaretic acid and 5,8,11,14-ETYA but not by preincubation with the cyclooxygenase inhibitor indomethacin.	Masoprocol	132-156	PCNA clamp associated factor	Homo sapiens	32-35
1526278-7	1992	Pretreatment of LAN-5 cells with nordihydroguaiaretic acid, a lipoxygenase inhibitor, or with indomethacin, a cyclooxygenase inhibitor, amplified the release of [3H]arachidonic acid and production of lysophosphatidylcholine induced by non-saturating concentrations of IFN-gamma.	Masoprocol	33-58	interferon gamma	Homo sapiens	268-277
1383617-5	1992	The ET-1-induced potentiation of the response to serotonin was prevented by nordihydroguaiaretic acid (3 x 10(-6) M), quinacrine (10(-6) M), and AA861 (10(-6) M), but not by indomethacin (10(-7) M) and baicalein (10(-6) M).	Masoprocol	76-101	endothelin 1	Rattus norvegicus	4-8
1619039-1	1992	The present work shows that the corticotropin-releasing factor (CRF)-releasing activity of interleukin-1 (IL-1) is partially inhibited by a phospholipase A2 (mepacrine) or a cyclooxygenase (indomethacin) inhibitor, but is not affected by inhibition of the lypoxygenase pathway with norhydroguaiaretic acid.	Masoprocol	282-305	corticotropin releasing hormone	Rattus norvegicus	32-62
1619039-1	1992	The present work shows that the corticotropin-releasing factor (CRF)-releasing activity of interleukin-1 (IL-1) is partially inhibited by a phospholipase A2 (mepacrine) or a cyclooxygenase (indomethacin) inhibitor, but is not affected by inhibition of the lypoxygenase pathway with norhydroguaiaretic acid.	Masoprocol	282-305	phospholipase A2 group IB	Rattus norvegicus	140-156
1540379-11	1992	A component of the signal transduction pathway for PAF effects was studied in cultured tracheal epithelial cells by coincubation of PAF with nordihydroguaiaretic acid (NDGA), a combined lipoxygenase and cyclooxygenase inhibitor, or p-bromophenacyl bromide (BPB), an inhibitor of cellular arachidonic acid release.	Masoprocol	141-166	PCNA clamp associated factor	Homo sapiens	51-54
1316134-3	1992	Indomethacin, the cyclooxygenase inhibitor, did not affect secretion stimulated by PAF, but nordihydroguiaretic acid (NDGA), a mixed cyclooxygenase and lipoxygenase inhibitor, attenuated secretion stimulated by PAF in a concentration-dependent manner.	Masoprocol	92-116	patchy fur	Mus musculus	211-214
1566862-7	1992	The release of NCA and MCA was inhibited by the lipoxygenase inhibitors, nordihydroguaiaretic acid and diethylcarbamazine.	Masoprocol	73-98	CEA cell adhesion molecule 4	Homo sapiens	15-18
1576704-4	1992	The reaction was completely inhibited by nordihydroguaiaretic acid (NDGA, 0.1 mM), a lipoxygenase inhibitor and an antioxidant, but not by indomethacin (0.1 mM), an inhibitor of prostaglandin H synthase (PHS), indicating that this reaction is associated with lipoxygenase activity, and/or is involved in a peroxyl radical process.	Masoprocol	41-66	linoleate 9S-lipoxygenase-4	Glycine max	85-97
1576704-4	1992	The reaction was completely inhibited by nordihydroguaiaretic acid (NDGA, 0.1 mM), a lipoxygenase inhibitor and an antioxidant, but not by indomethacin (0.1 mM), an inhibitor of prostaglandin H synthase (PHS), indicating that this reaction is associated with lipoxygenase activity, and/or is involved in a peroxyl radical process.	Masoprocol	41-66	linoleate 9S-lipoxygenase-4	Glycine max	259-271
1576704-4	1992	The reaction was completely inhibited by nordihydroguaiaretic acid (NDGA, 0.1 mM), a lipoxygenase inhibitor and an antioxidant, but not by indomethacin (0.1 mM), an inhibitor of prostaglandin H synthase (PHS), indicating that this reaction is associated with lipoxygenase activity, and/or is involved in a peroxyl radical process.	Masoprocol	68-72	linoleate 9S-lipoxygenase-4	Glycine max	85-97
1576704-4	1992	The reaction was completely inhibited by nordihydroguaiaretic acid (NDGA, 0.1 mM), a lipoxygenase inhibitor and an antioxidant, but not by indomethacin (0.1 mM), an inhibitor of prostaglandin H synthase (PHS), indicating that this reaction is associated with lipoxygenase activity, and/or is involved in a peroxyl radical process.	Masoprocol	68-72	linoleate 9S-lipoxygenase-4	Glycine max	259-271
1521562-1	1992	Using a perfused rat hindleg system, release of tissue-type plasminogen activator (t-PA) from endothelial cells could be induced by platelet-activating factor (PAF), bradykinin, substance P, thrombin, carbachol and A23187, while this release was inhibited by mepacrine and by nor-dihydroguaiaretic acid.	Masoprocol	276-302	plasminogen activator, tissue type	Rattus norvegicus	48-81
1521562-1	1992	Using a perfused rat hindleg system, release of tissue-type plasminogen activator (t-PA) from endothelial cells could be induced by platelet-activating factor (PAF), bradykinin, substance P, thrombin, carbachol and A23187, while this release was inhibited by mepacrine and by nor-dihydroguaiaretic acid.	Masoprocol	276-302	plasminogen activator, tissue type	Rattus norvegicus	83-87
1737059-6	1992	The anti-oxidants DES, NDGA and ferricyanide strongly inhibited the increase in ODC activity seen in response to either concanavalin A or PMA/ionomycin.	Masoprocol	23-27	ornithine decarboxylase, structural 1	Mus musculus	80-83
1540379-11	1992	A component of the signal transduction pathway for PAF effects was studied in cultured tracheal epithelial cells by coincubation of PAF with nordihydroguaiaretic acid (NDGA), a combined lipoxygenase and cyclooxygenase inhibitor, or p-bromophenacyl bromide (BPB), an inhibitor of cellular arachidonic acid release.	Masoprocol	168-172	PCNA clamp associated factor	Homo sapiens	51-54
1596675-18	1992	In contrast, NDGA (10 microM) inhibited ET-1- induced contractions (4.0 fold increase in mean EC50, P < 0.001, n = 5).	Masoprocol	13-17	endothelin 1	Rattus norvegicus	40-44
1309828-7	1992	The lipoxygenase inhibitor, nordihydroguaiaretic acid, blunted thrombin-induced calcium increase without affecting thrombin-induced increase in cAMP levels, suggesting different thrombin coupling mechanisms with these two second messenger pathways.	Masoprocol	28-53	coagulation factor II, thrombin	Homo sapiens	63-71
1521167-9	1992	Nordihydroguaiaretic acid (NDGA, anti-lipoxygenase) inhibited this induced ODC.	Masoprocol	0-25	ornithine decarboxylase, structural 1	Mus musculus	75-78
1521167-9	1992	Nordihydroguaiaretic acid (NDGA, anti-lipoxygenase) inhibited this induced ODC.	Masoprocol	27-31	ornithine decarboxylase, structural 1	Mus musculus	75-78
1640804-9	1992	The possible involvement of arachidonic acid derivatives in mediating ODC induction was further investigated by treatment with the cyclo-oxygenase inhibitor indomethacin and the lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA).	Masoprocol	201-226	ornithine decarboxylase 1	Homo sapiens	70-73
1684863-5	1991	Consistent with arachidonic acid or a lipoxygenase metabolite being a retrograde messenger, the phospholipase A2 and lipoxygenase inhibitor nordihydroguaiaretic acid blocked LTP in the guinea pig CA1 region in vitro.	Masoprocol	140-165	carbonic anhydrase 1	Cavia porcellus	196-199
1660902-4	1991	Nordihydroguaiaretic acid, an inhibitor of the lipoxygenase pathway of arachidonic acid metabolism, decreased the mitogenic effect of bFGF, whereas indomethacin, an inhibitor of the cyclooxygenase pathway, was ineffective.	Masoprocol	0-25	fibroblast growth factor 2	Bos taurus	134-138
1954875-13	1991	In contrast, the general lipoxygenase inhibitor nordihydroguaiaretic acid (10 microM) and the more specific 5-lipoxygenase inhibitors AA861 and RHC5901 (both 10 microM) reduced basal and blocked IL-1 beta-induced IL-6-release.	Masoprocol	48-73	interleukin 1 beta	Rattus norvegicus	195-204
1954875-13	1991	In contrast, the general lipoxygenase inhibitor nordihydroguaiaretic acid (10 microM) and the more specific 5-lipoxygenase inhibitors AA861 and RHC5901 (both 10 microM) reduced basal and blocked IL-1 beta-induced IL-6-release.	Masoprocol	48-73	interleukin 6	Rattus norvegicus	213-217
1951711-5	1991	Moreover, pretreatment of the cells with the lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA) abolished induction of NGF by cytokines; in contrast, the specific cyclooxygenase inhibitors indomethacin and diclofenac failed to modify NGF production.	Masoprocol	68-93	nerve growth factor	Rattus norvegicus	124-127
1951711-5	1991	Moreover, pretreatment of the cells with the lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA) abolished induction of NGF by cytokines; in contrast, the specific cyclooxygenase inhibitors indomethacin and diclofenac failed to modify NGF production.	Masoprocol	68-93	nerve growth factor	Rattus norvegicus	239-242
1951711-5	1991	Moreover, pretreatment of the cells with the lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA) abolished induction of NGF by cytokines; in contrast, the specific cyclooxygenase inhibitors indomethacin and diclofenac failed to modify NGF production.	Masoprocol	95-99	nerve growth factor	Rattus norvegicus	124-127
1951711-5	1991	Moreover, pretreatment of the cells with the lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA) abolished induction of NGF by cytokines; in contrast, the specific cyclooxygenase inhibitors indomethacin and diclofenac failed to modify NGF production.	Masoprocol	95-99	nerve growth factor	Rattus norvegicus	239-242
1804060-1	1991	Inhibition of 5-lipoxygenase by anthralin (1) and 41 derivatives is determined: the acids 38 and 39, the lactones 40-42 and 9-anthrone (8) are the most potent inhibitors, the lactone 41 reaching the efficacy of nordihydroguaiaretic acid (NDGA).	Masoprocol	211-236	arachidonate 5-lipoxygenase	Homo sapiens	14-28
1804060-1	1991	Inhibition of 5-lipoxygenase by anthralin (1) and 41 derivatives is determined: the acids 38 and 39, the lactones 40-42 and 9-anthrone (8) are the most potent inhibitors, the lactone 41 reaching the efficacy of nordihydroguaiaretic acid (NDGA).	Masoprocol	238-242	arachidonate 5-lipoxygenase	Homo sapiens	14-28
1719406-7	1991	The possible mechanism(s) of the antimutagenic and anti-tumorigenic activities may be due to the multiple effects of NDGA as inhibitor of the carcinogen metabolism and DNA-adduct formation, scavenger of carcinogen free radicals, and as inhibitor of TPA-induced ornithine decarboxylase activity.	Masoprocol	117-121	ornithine decarboxylase, structural 1	Mus musculus	261-284
1655977-4	1991	Whereas nordihydroguaiaretic acid was effective in suppressing both the alpha 1-adrenergic potentiation of VIP- or beta-adrenergic-stimulated cAMP and cGMP responses, indomethacin inhibited selectively the VIP-mediated cAMP and cGMP responses.	Masoprocol	8-33	vasoactive intestinal peptide	Rattus norvegicus	107-110
1665896-5	1991	Both CGRP- and ACh-induced relaxations of aorta were significantly inhibited by the EDRF blocking agents, hemoglobin (10 microM), methylene blue (10 microM), and nordihydroguaiaretic acid (NDGA, 10 microM).	Masoprocol	162-187	calcitonin-related polypeptide alpha	Rattus norvegicus	5-9
1933128-4	1991	Nordihydroguaiaretic acid (NDGA; 5 x 10(-6) M), an inhibitor of lipoxygenase and quinacrine (10(-5) M), which blocks the release of arachidonic acid from phospholipids by inhibiting the enzyme phospholipase A2, blocked hypoxia-induced contractions.	Masoprocol	0-25	phospholipase A2 group IB	Canis lupus familiaris	193-209
1933128-4	1991	Nordihydroguaiaretic acid (NDGA; 5 x 10(-6) M), an inhibitor of lipoxygenase and quinacrine (10(-5) M), which blocks the release of arachidonic acid from phospholipids by inhibiting the enzyme phospholipase A2, blocked hypoxia-induced contractions.	Masoprocol	27-31	phospholipase A2 group IB	Canis lupus familiaris	193-209
1680652-7	1991	Lipoxygenase inhibitors nordihydroguaiaretic acid, phenidone, 5,8,11-eicosatriynoic acid, and 5,8,11,14-eicosatetraynoic acid significantly inhibited epoxidation in a dose-dependent manner.	Masoprocol	24-49	linoleate 9S-lipoxygenase-4	Glycine max	0-12
1680628-0	1991	Nordihydroguaiaretic acid, an inhibitor of lipoxygenase, also inhibits cytochrome P-450-mediated monooxygenase activity in rat epidermal and hepatic microsomes.	Masoprocol	0-25	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	71-87
1680628-2	1991	In this study, we investigated the effect of NDGA on rat epidermal and hepatic monooxygenase activity and its interaction with rat hepatic microsomal cytochrome P-450.	Masoprocol	45-49	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	150-166
1782012-7	1991	A specific inhibitor of 5-lipoxygenase activity, 3 microM nordihydroguaiaretic acid, abolished excess CL activity.	Masoprocol	58-83	arachidonate 5-lipoxygenase	Homo sapiens	24-38
1665896-7	1991	Hemoglobin, methylene blue and NDGA also inhibited the CGRP-induced increases in both cyclic AMP and cyclic GMP levels.	Masoprocol	31-35	calcitonin-related polypeptide alpha	Rattus norvegicus	55-59
1716990-1	1991	The binding of the lignans, enterolactone, enterodiol, nordihydroguaiaretic acid (NDGA), and the isoflavonic phytoestrogen equol, to human and rat alpha-fetoprotein (AFP) was studied.	Masoprocol	82-86	alpha-fetoprotein	Rattus norvegicus	147-164
1716990-2	1991	They had differential inhibitory effects (NDGA greater than equol greater than enterolactone greater than enterodiol) on the binding of estrone and estradiol to rat AFP and the binding of unsaturated fatty acid to both rat and human AFP.	Masoprocol	42-46	alpha-fetoprotein	Rattus norvegicus	165-168
1716990-6	1991	NDGA also competitively inhibited estrone binding at low NDGA concentrations (increased Kd), but high concentrations induced conformational changes in rat AFP, as both Kd and the number of binding sites (n) were altered.	Masoprocol	0-4	alpha-fetoprotein	Rattus norvegicus	155-158
1665896-5	1991	Both CGRP- and ACh-induced relaxations of aorta were significantly inhibited by the EDRF blocking agents, hemoglobin (10 microM), methylene blue (10 microM), and nordihydroguaiaretic acid (NDGA, 10 microM).	Masoprocol	189-193	calcitonin-related polypeptide alpha	Rattus norvegicus	5-9
1904618-6	1991	Nordihydroguaiaretic acid and phenidone, the classical inhibitors of lipoxygenase, significantly blocked the sulfoxidation of thiobenzamide.	Masoprocol	0-25	linoleate 9S-lipoxygenase-4	Glycine max	69-81
2121330-11	1990	While the cyclooxygenase inhibitor indomethacin had no detectable effect, ketoconazole and nordihydroguaiaretic acid, inhibitors of lipoxygenase, also blocked the induction of TNF expression by TNF.	Masoprocol	91-116	tumor necrosis factor	Homo sapiens	176-179
1651573-1	1991	The effects of two catechols (1,2-benzenediol and nordihydroguaiaretic acid) on the myeloperoxidase-Cl(-)-H2O2 antimicrobial/cytotoxic system of the human neutrophil were investigated.	Masoprocol	50-75	myeloperoxidase	Homo sapiens	84-99
2174882-9	1990	Both percent open time and Na+ channel number induced by GTP gamma S, the exogenous alpha i-3 subunit, or arachidonic acid were inhibited by the addition of the 5-lipoxygenase inhibitor nordihydroguaiaretic acid.	Masoprocol	186-211	arachidonate 5-lipoxygenase	Homo sapiens	161-175
2121330-11	1990	While the cyclooxygenase inhibitor indomethacin had no detectable effect, ketoconazole and nordihydroguaiaretic acid, inhibitors of lipoxygenase, also blocked the induction of TNF expression by TNF.	Masoprocol	91-116	tumor necrosis factor	Homo sapiens	194-197
2122915-5	1990	PMA-induced u-PA synthesis was enhanced by eicosatetraynoic acid (ETYA), a competitive inhibitor of both the lipoxygenase and cyclooxygenase pathways and inhibited by nordihydroguaiaretic acid (NDGA), an inhibitor of the lipoxygenase pathway.	Masoprocol	167-192	plasminogen activator, urokinase	Sus scrofa	12-16
2122915-5	1990	PMA-induced u-PA synthesis was enhanced by eicosatetraynoic acid (ETYA), a competitive inhibitor of both the lipoxygenase and cyclooxygenase pathways and inhibited by nordihydroguaiaretic acid (NDGA), an inhibitor of the lipoxygenase pathway.	Masoprocol	194-198	plasminogen activator, urokinase	Sus scrofa	12-16
2122915-10	1990	These data suggest that NDGA inhibits PMA-stimulated PKC activity in intact cells leading to a decrease of u-PA mRNA level and u-PA biosynthesis in PMA-stimulated LLC-PK1 cells.	Masoprocol	24-28	plasminogen activator, urokinase	Sus scrofa	107-111
2122915-10	1990	These data suggest that NDGA inhibits PMA-stimulated PKC activity in intact cells leading to a decrease of u-PA mRNA level and u-PA biosynthesis in PMA-stimulated LLC-PK1 cells.	Masoprocol	24-28	plasminogen activator, urokinase	Sus scrofa	127-131
2172768-5	1990	NDGA inhibited Ca2+ channel currents in excised, outside-out patches, in the absence of intra- and extracellular Ca2+ (with Ba2+ as the charge carrier), and following preincubation of the cells with the phospholipase A2 inhibitor 4-bromophenacylbromide.	Masoprocol	0-4	phospholipase A2 group IB	Rattus norvegicus	203-219
2173722-8	1990	Preincubation of AM with nordihydroguiaretic acid (10(-4) M) completely abolished the appearance of NCA, LTB4, and NAP-1 in supernatants of AM challenged with LPS.	Masoprocol	25-49	C-X-C motif chemokine ligand 8	Homo sapiens	115-120
2233691-3	1990	Lipoxygenase inhibitors (nordihydroguaiaretic acid and 5,8,11,14-eicosatetraynoic acid) were previously shown to be very effective in blocking EGF-stimulated DNA synthesis; however, only low levels of lipoxygenase-derived arachidonate metabolites were detected.	Masoprocol	25-50	epidermal growth factor	Mus musculus	143-146
2282472-6	1990	Contractile responses to angiotensin II could be completely blocked by the combined action of the cyclo-oxygenase inhibitor, indomethacin (1 microM) and the lipoxygenase inhibitor, nordihydroguairetic acid (NDGA, 10 microM).	Masoprocol	207-211	angiotensinogen	Homo sapiens	25-39
1974733-3	1990	Oral pretreatment with either sulfasalazine, gossypol, or NDGA significantly decreased colonic MPO activity induced by acetic acid.	Masoprocol	58-62	myeloperoxidase	Rattus norvegicus	95-98
2161738-8	1990	Preincubation of hypothalamic explants with dexamethasone, indomethacin (1 microM), eicosatetraynoic acid (10 microM), or nordihydroguaiaretic acid (30 microM) resulted in inhibition of TNF alpha-stimulated CRH secretion (P less than 0.05).	Masoprocol	122-147	tumor necrosis factor	Rattus norvegicus	186-195
2161738-8	1990	Preincubation of hypothalamic explants with dexamethasone, indomethacin (1 microM), eicosatetraynoic acid (10 microM), or nordihydroguaiaretic acid (30 microM) resulted in inhibition of TNF alpha-stimulated CRH secretion (P less than 0.05).	Masoprocol	122-147	corticotropin releasing hormone	Rattus norvegicus	207-210
2315942-5	1990	In vitro, mouse liver cytosolic epoxide hydrolase activity was substantially inhibited by 4OH-DPT and dioH-DPT, and NDGA, but not by 2-amino-4-phenyl,5-(4"-hydroxyphenyl)-thiazole (5OH-DPT) or DPT itself.	Masoprocol	116-120	epoxide hydrolase 2	Rattus norvegicus	22-49
2157615-2	1990	Nordihydroguaiaretic acid (NDGA), an inhibitor of 5-lipoxygenase, abolished the effect of the enzyme on LH secretion.	Masoprocol	0-25	arachidonate 5-lipoxygenase	Rattus norvegicus	50-64
2157615-2	1990	Nordihydroguaiaretic acid (NDGA), an inhibitor of 5-lipoxygenase, abolished the effect of the enzyme on LH secretion.	Masoprocol	27-31	arachidonate 5-lipoxygenase	Rattus norvegicus	50-64
2126984-6	1990	Nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor, was found to suppress cytotoxicity in response to IFN gamma and GM-CSF in both cancer patient monocytes and normal monocytes.	Masoprocol	0-25	interferon gamma	Homo sapiens	110-119
2126984-6	1990	Nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor, was found to suppress cytotoxicity in response to IFN gamma and GM-CSF in both cancer patient monocytes and normal monocytes.	Masoprocol	0-25	colony stimulating factor 2	Homo sapiens	124-130
2126984-6	1990	Nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor, was found to suppress cytotoxicity in response to IFN gamma and GM-CSF in both cancer patient monocytes and normal monocytes.	Masoprocol	27-31	interferon gamma	Homo sapiens	110-119
2126984-6	1990	Nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor, was found to suppress cytotoxicity in response to IFN gamma and GM-CSF in both cancer patient monocytes and normal monocytes.	Masoprocol	27-31	colony stimulating factor 2	Homo sapiens	124-130
2104593-3	1990	The toxic effect of TNF/IFN-gamma (26.6 +/- 3.7%) was inhibited partially by both a cyclooxygenase inhibitor, indomethacin and a lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), and combination of maximally effective concentrations of Indo and NDGA (30 microM) produced further protection against TNF/IFN-gamma-induced lysis (3.5 +/- 0.9%).	Masoprocol	153-178	tumor necrosis factor-like	Rattus norvegicus	20-23
2104593-3	1990	The toxic effect of TNF/IFN-gamma (26.6 +/- 3.7%) was inhibited partially by both a cyclooxygenase inhibitor, indomethacin and a lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), and combination of maximally effective concentrations of Indo and NDGA (30 microM) produced further protection against TNF/IFN-gamma-induced lysis (3.5 +/- 0.9%).	Masoprocol	153-178	interferon gamma	Rattus norvegicus	24-33
2104593-3	1990	The toxic effect of TNF/IFN-gamma (26.6 +/- 3.7%) was inhibited partially by both a cyclooxygenase inhibitor, indomethacin and a lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), and combination of maximally effective concentrations of Indo and NDGA (30 microM) produced further protection against TNF/IFN-gamma-induced lysis (3.5 +/- 0.9%).	Masoprocol	153-178	tumor necrosis factor	Rattus norvegicus	20-33
2104593-3	1990	The toxic effect of TNF/IFN-gamma (26.6 +/- 3.7%) was inhibited partially by both a cyclooxygenase inhibitor, indomethacin and a lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), and combination of maximally effective concentrations of Indo and NDGA (30 microM) produced further protection against TNF/IFN-gamma-induced lysis (3.5 +/- 0.9%).	Masoprocol	180-184	tumor necrosis factor-like	Rattus norvegicus	20-23
2104593-3	1990	The toxic effect of TNF/IFN-gamma (26.6 +/- 3.7%) was inhibited partially by both a cyclooxygenase inhibitor, indomethacin and a lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), and combination of maximally effective concentrations of Indo and NDGA (30 microM) produced further protection against TNF/IFN-gamma-induced lysis (3.5 +/- 0.9%).	Masoprocol	180-184	interferon gamma	Rattus norvegicus	24-33
2104593-3	1990	The toxic effect of TNF/IFN-gamma (26.6 +/- 3.7%) was inhibited partially by both a cyclooxygenase inhibitor, indomethacin and a lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), and combination of maximally effective concentrations of Indo and NDGA (30 microM) produced further protection against TNF/IFN-gamma-induced lysis (3.5 +/- 0.9%).	Masoprocol	180-184	tumor necrosis factor	Rattus norvegicus	20-33
2104593-3	1990	The toxic effect of TNF/IFN-gamma (26.6 +/- 3.7%) was inhibited partially by both a cyclooxygenase inhibitor, indomethacin and a lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), and combination of maximally effective concentrations of Indo and NDGA (30 microM) produced further protection against TNF/IFN-gamma-induced lysis (3.5 +/- 0.9%).	Masoprocol	253-257	tumor necrosis factor-like	Rattus norvegicus	20-23
2104593-3	1990	The toxic effect of TNF/IFN-gamma (26.6 +/- 3.7%) was inhibited partially by both a cyclooxygenase inhibitor, indomethacin and a lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), and combination of maximally effective concentrations of Indo and NDGA (30 microM) produced further protection against TNF/IFN-gamma-induced lysis (3.5 +/- 0.9%).	Masoprocol	253-257	interferon gamma	Rattus norvegicus	24-33
2104593-3	1990	The toxic effect of TNF/IFN-gamma (26.6 +/- 3.7%) was inhibited partially by both a cyclooxygenase inhibitor, indomethacin and a lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), and combination of maximally effective concentrations of Indo and NDGA (30 microM) produced further protection against TNF/IFN-gamma-induced lysis (3.5 +/- 0.9%).	Masoprocol	253-257	tumor necrosis factor	Rattus norvegicus	20-33
1978718-2	1990	Nordihydroguaiaretic acid (a potent 5-lipoxygenase inhibitor) also exerted a strong and concentration-dependent inhibition of 5-HETE and leukotriene B4 and C4 formation with IC50 values of 0.15, 0.09, and 0.1 microM, respectively.	Masoprocol	0-25	arachidonate 5-lipoxygenase	Rattus norvegicus	36-50
2124313-3	1990	Inhibition of the general oxidative metabolism of arachidonate by 10(-5) M ETYA or of the arachidonate lipoxygenase metabolism by 10(-5) M NDGA decreased basal Prl release to 45 +/- 10% (n = 3) and 36 +/- 4% (n = 6) of the control release, respectively.	Masoprocol	139-143	prolactin	Rattus norvegicus	160-163
2124313-8	1990	However, the fraction of Prl release elicited by TRH, calculated as a percentage of the amount of Prl released prior to TRH application, was similar under control conditions, and in the presence of NDGA.	Masoprocol	198-202	prolactin	Rattus norvegicus	25-28
2124313-8	1990	However, the fraction of Prl release elicited by TRH, calculated as a percentage of the amount of Prl released prior to TRH application, was similar under control conditions, and in the presence of NDGA.	Masoprocol	198-202	thyrotropin releasing hormone	Rattus norvegicus	49-52
2106918-11	1990	The inhibition of acrosin release by NDGA can be eliminated by adding 15-HETE or 15-HPETE to the incubation medium.	Masoprocol	37-41	acrosin	Homo sapiens	18-25
2105952-10	1990	In contrast, indomethacin (10(-6) M) and nordihydroguaiaretic acid (10(-6) M) inhibited EGF-stimulated thymidine uptake and c-myc expression by approximately 50%.	Masoprocol	41-66	epidermal growth factor	Mus musculus	88-91
2242274-4	1990	Pretreatment of intact PMNs with 3-20 microM 15-HETE, A23187 and the 5-lipoxygenase inhibitor NDGA (or the dual cyclooxygenase/lipoxygenase inhibitor BW755C) followed by [14C]arachidonic acid addition resulted in an unexpected synergistic activation of the cryptic 15-lipoxygenase activity.	Masoprocol	94-98	arachidonate 5-lipoxygenase	Homo sapiens	69-83
2342774-7	1990	The phospholipase A2 inhibitor, quinacrine, and the lipoxygenase inhibitor, nordihydroguaiaretic acid, blocked the induction of SOD, while the cyclooxygenase inhibitor, indomethacin, did not.	Masoprocol	76-101	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	52-64